# eCTD Reuse Risk Research Work

**User:** Anonymous  
**Created:** 8/27/2026 22:59:18  
**Updated:** 9/8/2026 12:03:30  
**Exported:** 9/8/2026 12:04:50  
**Link:** [https://chatgpt.com/g/g-p-6a91076619988191a9fe13fcfa36a6fe/c/6a910779-f38c-83ea-8bff-5472bd42bf94](https://chatgpt.com/g/g-p-6a91076619988191a9fe13fcfa36a6fe/c/6a910779-f38c-83ea-8bff-5472bd42bf94)  

## Prompt:
8/27/2026, 10:59:19 PM

Give me the complete structure of an eCTD v3.2.2 application package, as well as a v4.0 one.

## Response:
8/27/2026, 10:59:20 PM

I’ll map both versions at two levels: the ICH common Modules 2–5 and the FDA-specific Module 1/package envelope, since Module 1 is regional rather than universal. I’ll also distinguish the logical dossier structure from the actual folders/XML files on disk—especially important because v4.0 is message-based and does not mirror v3.2.2’s directory tree exactly.

One important distinction is already clear from the current FDA specifications: v3.2.2 is a fixed, folder/DTD “backbone,” while v4.0 has one `submissionunit.xml` message whose coded Contexts of Use reconstruct the dossier. I’m checking the precise payload-folder layout now so the answer does not accidentally present v4.0 as merely a renamed v3 tree.

> **Searching 11 websites**
>
>
> **Searching 11 websites**
>
>
> **Searching 11 websites**
>
>
> **Searching 11 websites**
>
>
> **Planning retrieval of PDF headings**
>
> **Planning retrieval of PDF headings**
>
> **Planned PDF heading retrieval**
>
> 
>
> **Searching 11 websites**
>
>
> **Searched 11 websites**
>
> 
>
> **Downloading and Extracting FDA PDF Text**
>
>
> **Downloaded and inspected FDA eCTD guidance PDF contents**
>
> 
>
> **Searching www.fda.gov**
>
>
> **Searching www.fda.gov**
>
>
> **Outlining document section hierarchy**
>
> **Outlining document section hierarchy**
>
> **Outlined document section hierarchy**
>
> 
>
> **Searched 1 website**
>
> 
>
> **Extracting FDA PDF Text Content**
>
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Compared CTOC version differences between v3 and v4**
>
> 
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Planning detailed eCTD package structure**
>
> **Planning detailed eCTD package structure**
>
> **Compared CTOC versions and planned the detailed eCTD package structure**
>
> 
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Distinguishing v3 and v4 CTOC version differences**
>
> **Planning detailed eCTD package structure**
>
> **Planning detailed eCTD package structure**
>
> **Compared CTOC versions and planned detailed eCTD package structure**
>
> 
>
> **Extracted FDA PDF text and read CToc instructions**
>
> 
>
> Worked for 2m 4s

Below is the complete structural model for an FDA CDER/CBER eCTD application. Modules 2–5 are ICH-harmonized; Module 1 is FDA-specific. A submission package normally contains only applicable documents—not every possible heading or an empty folder for every heading.

A crucial distinction:

- eCTD v3.2.2: the XML backbone and physical directory structure closely mirror the CTD hierarchy.
- eCTD v4.0: the physical package is flatter; `submissionunit.xml`, Contexts of Use, keywords, and document references construct the logical CTD hierarchy.

FDA currently accepts new CDER/CBER applications in eCTD v4.0. Existing v3.2.2 applications are subject to FDA’s staged forward-compatibility implementation. [FDA eCTD v4.0 standards](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v40-and-regional-m1)

# 1. eCTD v3.2.2 physical package

An application consists of a top-level application folder containing numbered sequences:

```text
application-root/
├── 0000/                         Initial sequence
├── 0001/                         Amendment, supplement, report, etc.
├── 0002/
└── nnnn/
```

Each sequence has this general structure:

```text
0000/
├── index.xml                     ICH backbone for Modules 2–5
├── index-md5.txt                 MD5 checksum of index.xml
│
├── m1/
│   └── us/
│       ├── us-regional.xml       FDA Module 1 backbone
│       ├── 11-forms/
│       ├── 12-cover-letters/
│       ├── 13-admin-info/
│       ├── ...
│       └── 120-gen-invest-plan/
│
├── m2/
│   ├── 22-intro/
│   ├── 23-qos/
│   ├── 24-nonclin-over/
│   ├── 25-clin-over/
│   ├── 26-nonclin-sum/
│   └── 27-clin-sum/
│
├── m3/
│   ├── 32-body-data/
│   │   ├── s/
│   │   ├── p/
│   │   ├── a/
│   │   └── r/
│   └── 33-lit-ref/
│
├── m4/
│   ├── 42-stud-rep/
│   │   ├── 421-pharmacol/
│   │   ├── 422-pharmaco-kin/
│   │   └── 423-tox/
│   └── 43-lit-ref/
│
├── m5/
│   ├── 52-tab-list/
│   ├── 53-clin-stud-rep/
│   │   ├── 531-biopharm/
│   │   ├── 532-human-biomaterials/
│   │   ├── 533-human-pk/
│   │   ├── 534-human-pd/
│   │   ├── 535-efficacy-safety/
│   │   ├── 536-postmarket/
│   │   └── 537-crf/
│   └── 54-lit-ref/
│
└── util/
    ├── dtd/
    │   ├── ich-ectd-3-2.dtd
    │   └── us-regional-v3-3.dtd
    └── style/
        ├── ectd-2-0.xsl
        └── us-regional.xsl
```

FDA’s current v3.2.2 standard uses:

- ICH eCTD backbone: v3.2.2
- FDA Module 1 backbone specification: currently supported FDA specification
- US regional DTD: v3.3
- `index.xml` plus `index-md5.txt`
- `us-regional.xml` for FDA Module 1
- Study Tagging Files, where applicable, for Modules 4 and 5

The ICH specification confirms that every sequence contains `index.xml`, `index-md5.txt`, the regional Module 1 XML, applicable content, and the supporting DTD files. [ICH/FDA eCTD v3.2.2 backbone specification](https://www.fda.gov/media/159380/download)

## Study folders in v3.2.2

For a tagged nonclinical or clinical study:

```text
study-folder/
├── stf.xml
├── study-report.pdf
├── synopsis.pdf
├── protocol.pdf
├── statistical-analysis-plan.pdf
├── datasets/
│   ├── tabulations/
│   └── analysis/
├── programs/
├── define.xml
├── define.pdf
├── reviewers-guide.pdf
└── other-study-files.*
```

`stf.xml` supplies study metadata and associates the files with the relevant study.

# 2. eCTD v4.0 physical package

FDA’s v4.0 package uses a sequence-number folder containing:

```text
sequence-number/
├── submissionunit.xml
├── sha256.txt
├── m1/
│   └── submitted-module-1-files.*
├── m2/
│   └── submitted-module-2-files.*
├── m3/
│   └── submitted-module-3-files.*
├── m4/
│   └── submitted-module-4-files.*
└── m5/
    └── submitted-module-5-files.*
```

For example:

```text
1/
├── submissionunit.xml
├── sha256.txt
├── m1/
│   ├── cover-letter.pdf
│   └── form-fda-356h.pdf
├── m2/
│   └── clinical-overview.pdf
├── m3/
│   ├── drug-substance-specification.pdf
│   └── drug-product-stability.pdf
├── m4/
│   └── toxicology-study-001.pdf
└── m5/
    ├── study-abc-csr.pdf
    ├── study-abc-protocol.pdf
    └── study-abc-sdtm.zip
```

Important v4.0 rules:

- FDA does not use an extra region folder such as `us/`.
- `submissionunit.xml` replaces both `index.xml` and `us-regional.xml`.
- `sha256.txt` replaces the v3.2.2 MD5 backbone checksum file.
- DTD and stylesheet folders are no longer submitted.
- The module folders hold payload files; they do not need to reproduce the full CTD hierarchy physically.
- Module 1 normally uses a single folder.
- Subfolders are added only when needed for organization or another FDA technical requirement.
- The logical placement of every document is declared in `submissionunit.xml`.

This precise physical layout appears in FDA’s current Module 1 implementation guide. [FDA eCTD v4.0 Module 1 Implementation Guide](https://www.fda.gov/media/194432/download)

## Logical anatomy of `submissionunit.xml`

Conceptually, the message contains:

```text
submissionUnit
├── Submission-unit identification
│   ├── UUID
│   ├── sequence number
│   ├── submission-unit type
│   ├── status
│   ├── title
│   └── effective time
│
├── Application
│   ├── application type
│   ├── application number
│   ├── applicant
│   ├── application references
│   └── application metadata
│
├── Submission
│   ├── submission UUID
│   ├── submission type
│   ├── submission identifier
│   └── submission relationships
│
├── Keywords
│   ├── substance
│   ├── manufacturer
│   ├── product
│   ├── dosage form
│   ├── indication
│   ├── study ID/title
│   ├── document type
│   ├── site
│   └── regional keywords
│
├── Contexts of Use
│   ├── CTD heading code
│   ├── associated keywords
│   ├── document reference
│   ├── priority/order
│   ├── lifecycle status
│   └── replacement/reuse relationships
│
├── Documents
│   ├── document UUID
│   ├── document title
│   ├── file reference
│   ├── integrity checksum
│   └── lifecycle/reuse metadata
│
└── Contacts and parties
    ├── sender
    ├── applicant
    └── regulatory contact
```

Thus, the physical location:

```text
m3/drug-substance-specification.pdf
```

does not, by itself, determine its regulatory location. A Context of Use connects that document to:

```text
3.2.S.4.1 Specification
```

and links the appropriate drug-substance and manufacturer keywords.

# 3. Logical CTD dossier structure

The following is the regulatory table of contents represented by both versions, subject to the FDA Module 1 differences identified later.

## Module 1 — FDA regional administrative information

```text
1.1  Forms

1.2  Cover letters

1.3  Administrative information
     1.3.1  Contact/sponsor/applicant information
            1.3.1.1  Change of address or corporate name
            1.3.1.2  Change in contact/agent
            1.3.1.3  Change in sponsor
            1.3.1.4  Transfer of obligation
            1.3.1.5  Change in ownership/reissuance of license
     1.3.2  Field copy certification
     1.3.3  Debarment certification
     1.3.4  Financial certification and disclosure
     1.3.5  Patent and exclusivity
            1.3.5.1  Patent information
            1.3.5.2  Patent certification
            1.3.5.3  Exclusivity claim
     1.3.6  Tropical disease priority review voucher

1.4  References
     1.4.1  Letter of authorization
     1.4.2  Statement of right of reference
     1.4.3  Authorized persons to incorporate by reference
     1.4.4  Cross-reference to previously submitted information

1.5  Application status
     1.5.1  Withdrawal of IND
     1.5.2  Inactivation request
     1.5.3  Reactivation request
     1.5.4  Reinstatement request
     1.5.5  Withdrawal of unapproved BLA/NDA/ANDA/supplement
     1.5.6  Withdrawal of listed drug
     1.5.7  Withdrawal of approval/revocation of license

1.6  Meetings
     1.6.1  Meeting request
     1.6.2  Meeting background materials
     1.6.3  Correspondence regarding meetings

1.7  Fast Track
     1.7.1  Fast Track designation request
     1.7.2  Fast Track designation withdrawal
     1.7.3  Rolling review request
     1.7.4  Related correspondence

1.8  Special protocol assessment request
     1.8.1  Clinical study
     1.8.2  Carcinogenicity study
     1.8.3  Stability study
     1.8.4  Animal efficacy study

1.9  Pediatric administrative information
     1.9.1  Waiver request
     1.9.2  Deferral request
     1.9.3  Pediatric exclusivity determination
     1.9.4  Proposed pediatric study request/amendments
     1.9.5  Proposal for written agreement — v3.2.2 legacy
     1.9.6  Other pediatric correspondence

1.10 Dispute resolution
     1.10.1 Request
     1.10.2 Related correspondence

1.11 Information amendments not covered by Modules 2–5
     1.11.1 Quality
     1.11.2 Nonclinical
     1.11.3 Clinical
     1.11.4 Multiple-module

1.12 Other correspondence
     1.12.1–1.12.17 FDA-defined correspondence categories
     1.12.18 RMAT designation — v4.0

1.13 Annual report
     1.13.1–1.13.15 Annual-report components

1.14 Labeling
     1.14.1 Draft labeling
     1.14.2 Final labeling
     1.14.3 Listed-drug labeling
     1.14.4 Investigational-drug labeling
     1.14.5 Foreign labeling
     1.14.6 Product labeling for §2253 submissions

1.15 Promotional material
     1.15.1 Correspondence
     1.15.2 Materials
            1.15.2.1.1 Clean version
            1.15.2.1.2 Annotated version
            1.15.2.1.3 Annotated-labeling version
            1.15.2.1.4 Annotated references

1.16 Risk management
     1.16.1 Non-REMS risk management
     1.16.2 REMS
            1.16.2.1–1.16.2.6 REMS components

1.17 Postmarketing studies
     1.17.1 Postmarketing commitments
     1.17.2 Postmarketing requirements

1.18 Naming
     1.18.1 Proprietary names
     1.18.2 Biological Proper Name Suffix — v4.0

1.19 Pre-EUA and EUA

1.20 General investigational plan for initial IND
```

## Module 2 — Summaries

```text
2.2  Introduction

2.3  Quality Overall Summary
     2.3.I  Introduction
     2.3.S  Drug substance
     2.3.P  Drug product
     2.3.A  Appendices
     2.3.R  Regional information

2.4  Nonclinical overview

2.5  Clinical overview

2.6  Nonclinical written and tabulated summaries
     2.6.1  Introduction
     2.6.2  Pharmacology written summary
     2.6.3  Pharmacology tabulated summary
     2.6.4  Pharmacokinetics written summary
     2.6.5  Pharmacokinetics tabulated summary
     2.6.6  Toxicology written summary
     2.6.7  Toxicology tabulated summary

2.7  Clinical summary
     2.7.1  Biopharmaceutic studies and analytical methods
     2.7.2  Clinical pharmacology studies
     2.7.3  Clinical efficacy
     2.7.4  Clinical safety
     2.7.5  References
     2.7.6  Synopses of individual studies
```

## Module 3 — Quality

```text
3.2  Body of data

     3.2.S  Drug substance
            3.2.S.1 General information
                    S.1.1 Nomenclature
                    S.1.2 Structure
                    S.1.3 General properties
            3.2.S.2 Manufacture
                    S.2.1–S.2.6
            3.2.S.3 Characterization
                    S.3.1–S.3.2
            3.2.S.4 Control of drug substance
                    S.4.1–S.4.5
            3.2.S.5 Reference standards/materials
            3.2.S.6 Container-closure system
            3.2.S.7 Stability
                    S.7.1–S.7.3

     3.2.P  Drug product
            3.2.P.1 Description and composition
            3.2.P.2 Pharmaceutical development
            3.2.P.3 Manufacture
                    P.3.1–P.3.5
            3.2.P.4 Control of excipients
                    P.4.1–P.4.6
            3.2.P.5 Control of drug product
                    P.5.1–P.5.6
            3.2.P.6 Reference standards/materials
            3.2.P.7 Container-closure system
            3.2.P.8 Stability
                    P.8.1–P.8.3

     3.2.A  Appendices
            3.2.A.1 Facilities and equipment
            3.2.A.2 Adventitious-agents safety evaluation
            3.2.A.3 Novel excipients

     3.2.R  Regional information

3.3  Literature references
```

## Module 4 — Nonclinical study reports

```text
4.2  Study reports

     4.2.1 Pharmacology
           4.2.1.1 Primary pharmacodynamics
           4.2.1.2 Secondary pharmacodynamics
           4.2.1.3 Safety pharmacology
           4.2.1.4 Pharmacodynamic drug interactions

     4.2.2 Pharmacokinetics
           4.2.2.1 Analytical methods and validation
           4.2.2.2 Absorption
           4.2.2.3 Distribution
           4.2.2.4 Metabolism
           4.2.2.5 Excretion
           4.2.2.6 Pharmacokinetic drug interactions
           4.2.2.7 Other pharmacokinetic studies

     4.2.3 Toxicology
           4.2.3.1 Single-dose toxicity
           4.2.3.2 Repeat-dose toxicity
           4.2.3.3 Genotoxicity
                   4.2.3.3.1 In vitro
                   4.2.3.3.2 In vivo
           4.2.3.4 Carcinogenicity
                   4.2.3.4.1 Long-term
                   4.2.3.4.2 Short/medium-term
                   4.2.3.4.3 Other
           4.2.3.5 Reproductive/developmental toxicity
                   4.2.3.5.1–4.2.3.5.4
           4.2.3.6 Local tolerance
           4.2.3.7 Other toxicity
                   4.2.3.7.1 Antigenicity
                   4.2.3.7.2 Immunotoxicity
                   4.2.3.7.3 Mechanistic studies
                   4.2.3.7.4 Dependence
                   4.2.3.7.5 Metabolites
                   4.2.3.7.6 Impurities
                   4.2.3.7.7 Other

4.3  Literature references
```

## Module 5 — Clinical study reports

```text
5.2  Tabular listing of all clinical studies

5.3  Clinical study reports and related information

     5.3.1 Biopharmaceutic studies
           5.3.1.1 Bioavailability
           5.3.1.2 Comparative BA and BE
           5.3.1.3 In vitro–in vivo correlation
           5.3.1.4 Bioanalytical/analytical methods

     5.3.2 Studies using human biomaterials
           5.3.2.1 Plasma-protein binding
           5.3.2.2 Hepatic metabolism/drug interaction
           5.3.2.3 Other human biomaterials

     5.3.3 Human pharmacokinetic studies
           5.3.3.1 Healthy-subject PK/tolerability
           5.3.3.2 Patient PK/tolerability
           5.3.3.3 Intrinsic-factor PK
           5.3.3.4 Extrinsic-factor PK
           5.3.3.5 Population PK

     5.3.4 Human pharmacodynamic studies
           5.3.4.1 Healthy-subject PD and PK/PD
           5.3.4.2 Patient PD and PK/PD

     5.3.5 Efficacy and safety studies
           5.3.5.1 Controlled clinical studies
           5.3.5.2 Uncontrolled clinical studies
           5.3.5.3 Analyses of data from multiple studies
           5.3.5.4 Other clinical studies

     5.3.6 Postmarketing experience

     5.3.7 Case-report forms and individual-patient listings

5.4  Literature references
```

The official FDA comprehensive tables contain additional study-document types beneath Modules 4 and 5—CSR body, synopsis, protocol, SAP, CRFs, SDTM/SEND/ADaM datasets, programs, data definitions, reviewer guides and specialty reports. [v3.2.2 comprehensive table of contents](https://www.fda.gov/media/181848/download), [v4.0 comprehensive table of contents](https://www.fda.gov/media/179699/download)

# 4. Principal structural differences

| Feature | eCTD v3.2.2 | eCTD v4.0 |
|---|---|---|
| Main XML | `index.xml` | `submissionunit.xml` |
| FDA Module 1 XML | Separate `us-regional.xml` | Incorporated into the single message |
| XML technology | DTD-based | HL7 RPS-derived XML Schema |
| Backbone checksum | `index-md5.txt` | `sha256.txt` |
| Supporting schemas | DTDs/stylesheets shipped in `util/` | Schemas/stylesheets not shipped with each sequence |
| Physical hierarchy | Closely resembles CTD hierarchy | Module payload folders; logical hierarchy resides in XML |
| Document identity | Leaf ID | Persistent document UUID |
| Placement | Leaf under a hard-coded XML heading | Context of Use with coded CTD heading |
| Metadata | Mainly DTD attributes | Controlled vocabularies and keywords |
| Lifecycle | `new`, `replace`, `delete`, `append` | Context/document status and replacement relationships |
| Document reuse | Leaf references | Persistent document IDs and reuse references |
| Study metadata | Separate `stf.xml` | Study ID/title and document-type keywords |
| Ordering | Mostly fixed backbone order | Explicit priority/order metadata |
| One-to-many lifecycle | Limited | Native support for one-to-one, one-to-many and many-to-one relationships |
| Grouped submissions | Regional workaround | Represented within the submission-unit message |
| Future two-way communication | Not supported | Included in the broader v4 design, subject to regional implementation |

The CTD scientific organization remains recognizable across both versions. The largest change in v4.0 is not the scientific dossier—it is how documents, metadata, lifecycle relationships and regulatory context are represented electronically.

## Prompt:
8/27/2026, 11:57:44 PM

I am interested in coming up with some research and a solution for the AAAI 2027 demonstration track in this domain. Basically, with this, I am assuming applicants wanting their submissions to be regulatory compliant and accepted might have a pain point I am trying to build on:

1. Documents in older version submissions (e.g., v3.2.2) that they want to reuse in a newer version submission (e.g., v4.0).
2. "Artifacts" (e.g., wording) that are in such documents in point 1 that might no longer be accepted by the FDA standard, according to "child standards" of the specific version standard, if there are some available.

I want you to do a web/research and tell me if these pain points are warranted. And, let me know if a solution is worth a submission at AAAI 2027 demonstration

## Response:
8/27/2026, 11:57:43 PM

I’ll test the two pain points separately against current FDA/ICH rules, then assess the research gap against existing regulatory-publishing tools and the likely AAAI demo criteria. The key question is whether this is merely format conversion—or whether there is a defensible AI problem involving version-aware evidence, traceable compliance decisions, and human review.

The first pain point is strongly supported, but it is already partly addressed by publishing vendors. The more defensible gap is appearing in the second point: not generic “old wording detection,” but deciding which legacy content can be safely reused under a new, time-stamped FDA standards stack—and explaining when lifecycle continuity must be preserved versus deliberately broken.

> **Clarifying AAAI 2027 demo track status**
>
> **Clarifying AAAI 2027 demo track status**
>
> **Clarified AAAI 2027 demo track status**
>
> 
>
> **Searching 7 websites**
>
>
> **Searching 7 websites**
>
>
> **Searched 7 websites**
>
> 
>
> **Extracting AAAI-27 Demonstration Call Content**
>
>
> **Extracted and converted AAAI-27 demonstration call content to plain text**
>
> 
>
> **Searching 18 websites**
>
>
> **Searching 28 websites**
>
>
> **Analyzing eCTD hierarchy and child standards**
>
> **Analyzing eCTD hierarchy and child standards**
>
> **Analyzed eCTD hierarchy and child standards**
>
> 
>
> **Searching 28 websites**
>
>
> **Assessing standard catalog and metadata changes**
>
> **Assessing standard catalog and metadata changes**
>
> **Planning document reuse and content validation criteria**
>
> **Planning document reuse and content validation criteria**
>
> **Assessed catalog and metadata changes and planned document reuse validation**
>
> 
>
> **Assessing standard catalog and metadata changes**
>
> **Assessing standard catalog and metadata changes**
>
> **Planning document reuse and content validation criteria**
>
> **Planning document reuse and content validation criteria**
>
> **Assessed catalog changes and planned document reuse validation**
>
> 
>
> **Searched 28 websites**
>
> 
>
> **Searching 9 websites**
>
>
> **Planning synthetic FDA benchmark creation**
>
> **Planning synthetic FDA benchmark creation**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Planned synthetic FDA benchmark creation and evaluation demo**
>
> 
>
> **Planning synthetic FDA benchmark creation**
>
> **Planning synthetic FDA benchmark creation**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Planned synthetic FDA benchmark creation and evaluation demo**
>
> 
>
> **Planning synthetic FDA benchmark creation**
>
> **Planning synthetic FDA benchmark creation**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Outlining detailed project evaluation and demo plan**
>
> **Designing hybrid legacy document reuse system**
>
> **Designing hybrid legacy document reuse system**
>
> **Planned synthetic FDA benchmark, evaluation demo, and hybrid document reuse system**
>
> 
>
> **Searched 9 websites**
>
> 
>
> Worked for 2m 22s

## Bottom line

Yes, the underlying pain point is real and timely—but the strongest AAAI contribution is not simply “convert eCTD v3.2.2 documents into v4.0.”

Commercial publishing systems already perform much of the structural conversion and forward-compatibility work. A stronger research problem is:

> Given a legacy eCTD dossier and a target FDA standards snapshot, determine which content can be reused safely, which requires new metadata or relocation, which must break lifecycle and be resubmitted, and which needs human regulatory review—with traceable evidence for every decision.

That version-aware, evidence-grounded reuse decision problem is technically interesting, demonstrable, and not obviously solved by existing eCTD publishing software.

# 1. Pain point 1: reusing v3.2.2 documents in v4.0

## Verdict: strongly warranted

FDA and ICH formally call this **Forward Compatibility**. It exists specifically to allow a v4.0 submission to reference or lifecycle content originally submitted under v3.2.2.

The current FDA Technical Conformance Guide states that:

- A v4.0 submission can reference a v3.2.2 document through its legacy leaf reference.
- Previously submitted files do not need to be uploaded again.
- Reuse can occur within or across applications, subject to repository restrictions.
- Only active v3.2.2 leaves can be lifecycled.
- Relevant headings and metadata values must match when maintaining lifecycle continuity.
- Study ID, study title, manufacturer and other legacy attributes may need to become v4.0 keyword definitions.
- Once an application transitions to v4.0, later v3.2.2 sequences will be rejected. [FDA eCTD v4.0 Technical Conformance Guide](https://www.fda.gov/media/179700/download)

FDA has also defined high-severity validations specifically for forward compatibility. For example:

- The referenced v3.2.2 leaf must exist and be active.
- The v4.0 Context of Use and related legacy leaf must have matching headings and keywords.
- A reused document must resolve successfully.
- A v4.0 keyword-definition display name must exactly match the corresponding v3.2.2 value. [FDA eCTD v4.0 Validation Criteria](https://www.fda.gov/media/194434/download)

This is therefore a genuine operational problem—not a hypothetical one.

## Why the problem remains difficult

Forward compatibility is not just file conversion:

| Legacy condition | Required decision |
|---|---|
| Active v3.2.2 leaf under a still-valid heading | Reference and maintain lifecycle |
| Suspended/deleted legacy leaf | Cannot normally be lifecycled as active content |
| Same document needed under a different v4.0 heading | Reuse document, but create a new Context of Use and potentially break the previous lifecycle chain |
| Legacy attribute still permitted | Create matching v4.0 keyword |
| Legacy attribute allowed but no longer recommended | Choose between preserving lifecycle or breaking lifecycle to clean up metadata |
| Legacy heading removed in v4.0 | Relocate content and break lifecycle |
| Links inside the reused PDF point to an obsolete context | Repair or resubmit rather than blindly reuse |
| Document resides in the other FDA center’s repository | Cannot reuse across the CDER/CBER repository boundary |

FDA explicitly warns that hyperlinks within a reused document must remain relevant to its new Context of Use.

## The pain point is especially timely

As of August 28, 2026, FDA accepts v4.0 for new applications, but production forward compatibility for existing v3.2.2 applications is still not generally available. FDA’s 2025 annual assessment says Phase 2 required further software revisions and was expected to be followed by an industry technical pilot. [FDA CBER–CDER Data Standards Annual Assessment](https://www.fda.gov/media/193422/download)

FDA has nevertheless already published:

- Forward-compatibility rules
- Validation criteria
- Transition mappings
- Regional controlled vocabularies
- Forward-compatibility XML samples

So this is an unusually good moment for a research prototype: the rules and examples exist, while operational practices and tools are still maturing.

# 2. Pain point 2: obsolete “artifacts” or wording

## Verdict: partially warranted, but it needs reframing

Your intuition is right that legacy documents may contain elements inconsistent with the target submission environment. However, **“wording no longer accepted by the eCTD version” is too broad and somewhat technically inaccurate**.

eCTD principally defines:

- Package structure
- XML/message structure
- Document placement
- Metadata
- Controlled vocabularies
- Lifecycle relationships
- File formats
- Checksums
- Study-data associations
- Technical validation rules

It does not generally inspect every PDF sentence and determine whether the scientific prose is acceptable.

You should distinguish three different outcomes:

| Level | Meaning | Typical checks |
|---|---|---|
| Technical acceptance | FDA systems can receive and process the sequence | XML, file paths, checksums, IDs, keywords, leaf references |
| Filing/administrative adequacy | The regulatory activity contains required information | Forms, signatures, required sections, application-specific requirements |
| Scientific acceptability | The evidence and explanations satisfy reviewers | Study design, analyses, benefit-risk arguments, CMC justification |

A system may pass eCTD technical validation and still receive information requests, refuse-to-file issues or substantive review deficiencies.

Therefore, your system should not claim to predict that a submission will be “accepted by FDA.” It should claim something narrower, such as:

> Detecting technical, structural, metadata and guidance-related risks affecting the reuse of legacy dossier content.

## What kinds of legacy artifacts are genuinely checkable?

### A. Removed or changed CTD headings

ICH confirmed that some v3.2.2 headings are no longer available in v4.0. For example, the legacy headings:

- 3.2.S.1.1 Nomenclature
- 3.2.S.1.2 Structure
- 3.2.S.1.3 General properties

are not separately represented in the cited v4.0 Context-of-Use hierarchy. Legacy content under those headings may need to be placed at 3.2.S.1 or higher, breaking the previous lifecycle relationship. [ICH M8 vendor questions and answers](https://admin.ich.org/sites/default/files/2025-03/M8%20Vendor%20Group%20Questions_2025_0314.pdf)

That is an excellent concrete demonstration case.

### B. Legacy metadata that is now discouraged

ICH discusses legacy manufacturer values such as:

- `all`
- `applicant`
- `not specified`

To preserve lifecycle, a v4.0 keyword may need to reproduce the legacy attribute. Alternatively, the applicant can break lifecycle and establish better metadata. This creates a genuine decision trade-off rather than a simple validation check.

### C. Exact-value mismatches

For forward compatibility, a v4.0 keyword display name may need to match the legacy v3.2.2 value exactly. Differences in spacing, capitalization, abbreviations or normalized company names could produce a high-severity error.

### D. Obsolete forms or structured content

Examples include:

- Superseded FDA form editions
- Outdated Structured Product Labeling requirements
- Unsupported dataset standards
- Obsolete controlled-vocabulary terms
- Older PDF or file-format characteristics
- Missing current reviewer guides
- Study data inconsistent with the applicable FDA Data Standards Catalog

These are real “child-standard” dependencies, although I would call them a **regulatory standards stack**, not child standards.

### E. Stale cross-references and hyperlinks

A technically reusable PDF may contain:

- Links to files unavailable in the new application context
- References to an old sequence or section
- Statements such as “see Module 3.2.S.1.1,” where the target heading has changed
- Old applicant/manufacturer names
- References to withdrawn protocols or superseded analyses

FDA specifically instructs applicants to ensure that hyperlinks remain relevant when reusing documents.

### F. Guidance-sensitive prose

Some prose can be flagged where a current guidance introduces clearly identifiable requirements, such as:

- Required statements
- Updated labeling terminology
- New safety-reporting language
- Required descriptions of analytical methods
- Changed benefit-risk report organization

But these findings should be classified as:

```text
Potential guidance inconsistency — human confirmation required
```

They should not be represented as deterministic FDA rejection predictions. FDA guidances are often nonbinding and highly dependent on product, application type, study date and regulatory context.

# 3. Is the basic migration solution novel?

## No—not by itself

Existing commercial systems already advertise forward-compatibility support:

- LORENZ docuBridge allows users to continue v3.2 dossiers in v4.0 by changing the submission format. [LORENZ release information](https://www.lorenz.cc/services/software-releases/whats-new-docuBridge/index.cfm?version=24.2.0.0)
- EXTEDO describes preserving lifecycle by referencing legacy leaf IDs, matching metadata and avoiding a full baseline resubmission. [EXTEDO forward-compatibility overview](https://www.extedo.com/blog/forward-compatibility-in-ectd-v4-how-to-carry-your-current-ectd-v3-application-history-into-the-future)
- Veeva supports document reuse, Context-of-Use ordering and metadata updates in its publishing platform. [Veeva publishing documentation](https://regulatory.veevavault.help/en/gr/48611/)

The AAAI call explicitly says demonstrations must present ideas not already established in mainstream products or services. Therefore, a demo whose main contribution is:

> Upload v3.2.2 → generate v4.0 XML

would be weak.

# 4. The stronger research gap

A defensible gap is the absence of a transparent decision-support layer between legacy content and the publishing system.

## Proposed research question

> Can a hybrid version-aware standards graph, deterministic rule engine and evidence-grounded language model improve the safety and explainability of legacy eCTD document-reuse decisions compared with rule-only migration tools and conventional RAG?

## Proposed system: “RegBridge”

The system would ingest:

1. A v3.2.2 dossier or selected sequences.
2. A target jurisdiction and date—for example, FDA CDER, August 2026.
3. The target eCTD version and regulatory activity.
4. The applicable ICH/FDA standards packages.

It would produce a decision for every candidate document:

```text
REUSE_AS_LEGACY_REFERENCE
REUSE_WITH_NEW_CONTEXT
REUSE_AFTER_METADATA_REPAIR
BREAK_LIFECYCLE_AND_RESUBMIT
DO_NOT_REUSE
HUMAN_REGULATORY_REVIEW
```

Each decision would include:

- Legacy leaf ID and lifecycle state
- Original CTD heading
- Proposed v4.0 Context of Use
- Required keyword definitions
- Applicable standards versions
- Exact supporting rule or guidance
- Detected document-level risks
- Confidence and uncertainty
- Proposed minimal repair
- Human approval requirement

## Suggested architecture

```mermaid
flowchart TD
    A["v3.2.2 dossier"] --> B["Lifecycle and metadata graph"]
    C["Versioned FDA/ICH standards"] --> D["Applicability and rule graph"]
    B --> E["Hybrid reuse decision engine"]
    D --> E
    E --> F["Evidence-backed migration report"]
    E --> G["Draft v4.0 submission unit"]
```

Use:

- Deterministic parsing for `index.xml`, `us-regional.xml` and `stf.xml`
- Symbolic rules for schema, lifecycle, heading and controlled-vocabulary constraints
- Versioned retrieval for guidances and technical specifications
- NLP/LLM analysis only for document content, cross-references and ambiguous guidance applicability
- Mandatory evidence citations and abstention
- Human approval before applying lifecycle-breaking changes

This division is important: an LLM should not be responsible for generating IDs, checksums, lifecycle references or exact controlled-vocabulary values without deterministic verification.

# 5. A compelling five-minute demonstration

A strong demo could show three legacy documents:

### Case 1: Removed heading

A document originally under `3.2.S.1.1`.

The system explains:

- The exact lower-level heading is unavailable in the target v4.0 hierarchy.
- Direct lifecycle continuation is unsafe.
- The document can be placed under `3.2.S.1`.
- The old lifecycle relationship must be broken.
- New Context-of-Use metadata is generated.

### Case 2: Discouraged manufacturer attribute

A legacy leaf uses manufacturer value `all`.

The system presents two alternatives:

1. Preserve lifecycle by creating a matching keyword, with a warning that the value is no longer recommended.
2. Break lifecycle and introduce a cleaner manufacturer keyword.

This is an excellent human-AI decision point.

### Case 3: Semantically stale reusable PDF

A technically reusable document contains:

- A hyperlink to an obsolete sequence
- A reference to a removed heading
- An outdated applicant name

The structural converter says “reusable,” but RegBridge says:

```text
Technically referenceable; not safe for reuse without document revision.
```

That distinction is your most persuasive contribution.

# 6. Evaluation needed for credibility

Build a benchmark of migration cases from:

- FDA forward-compatibility XML samples
- FDA Module 1 samples
- ICH mappings and Q&A cases
- FDA validation criteria
- Synthetic mutations of compliant samples
- Publicly available approval documents where appropriate

FDA currently permits technical sample testing for new v4.0 applications, but its sample-submission page says forward-compatibility testing is not yet generally available. [FDA sample-submission process](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/submit-ectd-v40-or-standardized-data-sample-fda)

Suggested baselines:

- Deterministic mapping only
- General-purpose LLM
- Flat RAG
- Rule engine plus flat RAG
- Your temporal standards-graph hybrid

Suggested metrics:

| Dimension | Metric |
|---|---|
| Reuse decision | Macro-F1 and exact-match accuracy |
| Unsafe decisions | False-negative rate—most important |
| Heading mapping | Mapping accuracy |
| Metadata generation | Exact-match accuracy |
| Evidence | Citation precision and evidence recall |
| Generated package | XSD and published validation-rule pass rate |
| Uncertainty | Selective accuracy/calibration |
| Human usefulness | Review time and correction rate |
| Explanation quality | Regulatory-expert rating |

The system should be optimized to avoid unsafe false negatives: failing to warn about a problematic reuse is worse than sending an extra case to human review.

Related work already shows that RAG-based compliance checking and regulatory question answering are active research areas, so “we used RAG” will not be novel by itself. Relevant examples include the [COLING 2025 compliance-checking framework](https://aclanthology.org/2025.coling-main.178/) and the [RegNLP regulatory retrieval work](https://aclanthology.org/2025.regnlp-1.1.pdf). Your novelty should come from temporal applicability, lifecycle reasoning, hybrid validation and actionable repair.

# 7. Fit for the AAAI 2027 Demonstration Program

## Verdict: yes, conditionally

The official program welcomes:

- Decision-making systems
- Human-AI interaction
- Intelligent collaborative systems
- NLP systems
- Software and testing tools
- Systems integrating multiple AI methods

Demonstrations are judged on clarity, significance, AI relevance and audience engagement. The required submission is:

- Two-page paper
- One additional page for references
- Video up to five minutes
- Deadline: **September 18, 2026, 11:59 PM AoE**
- In-person demonstration in Montréal, February 18–21, 2027

See the [official AAAI-27 Demonstrations Call](https://aaai.org/conference/aaai/aaai-27/demonstration-call/).

Given today’s date, you have approximately three weeks. Therefore:

| Proposed scope | AAAI prospects |
|---|---|
| Concept or architecture only | Weak |
| Basic v3-to-v4 converter | Weak; established commercially |
| RAG chatbot over FDA standards | Weak; limited novelty |
| Working hybrid reuse-risk analyzer with three compelling cases | Good |
| Analyzer plus benchmark, baselines and expert review | Strong |

## My recommendation

Proceed, but frame it as:

> **RegBridge: Evidence-Grounded, Version-Aware Decision Support for Safe Reuse of Legacy Regulatory Dossier Content**

The paper’s principal claim should be:

> Existing forward-compatibility mechanisms establish whether legacy documents can be technically referenced; RegBridge determines whether they should be reused in a target regulatory context, identifies necessary lifecycle and content repairs, and provides auditable evidence for human approval.

That is much stronger than claiming an autonomous “FDA-compliant submission generator,” and it fits AAAI’s interest in human-AI collaboration, decision support, NLP and trustworthy AI.

## Prompt:
8/28/2026, 6:50:53 PM

I am interested and fully vested in this direction. I am not very knowledgeable about knowledge graphs, but I do have some ideas with constraint-schema formation. For implementation work, I want Codex to do the implementation work. The goal is to have the risk analyzer ready (and the three compelling cases), and baselines (a simple agent with the documents ingested as context), with the paper. I have attached a paper on a knowledge graph formation method, their GitHub i [screemix/Wikontic: $$EACL 26$$ $$AAAI DEMO 26$$ Build ontology-aware Knowledge Graphs](https://github.com/screemix/Wikontic)  

I want you to tell me from a plan perspective if my plan is feasible and makes sense for a successful demo. Then, look into the graph implementation and let me know if that a solution we can base on with the graph formulation.

## Response:
8/28/2026, 6:50:54 PM

I’m treating this as a continuation of the RegBridge direction, so I’ll first preserve the earlier scope and constraints, then inspect Wikontic’s paper, ontology model, extraction pipeline, dependencies, and license. I’ll judge feasibility against the actual AAAI-27 demo deadline and separate what Wikontic can supply from what still needs a regulatory-specific constraint layer.

The personal-context check is only to keep the previously agreed research framing intact—especially the distinction between structural migration and evidence-backed reuse-risk decisions. I’m now verifying whether any unseen project constraints materially change the plan before evaluating Wikontic.

> **Searching 13 websites**
>
>
> **Searching 13 websites**
>
>
> **Searched 13 websites**
>
> 
>
> **Cloning and Inspecting Wikontic Source**
>
>
> **Outlining regulatory knowledge graph schema**
>
> **Outlining regulatory knowledge graph schema**
>
> **Outlined a regulatory knowledge graph schema**
>
> 
>
> **Inspecting Evidence and Qualifier Handling**
>
>
> **Formulating 21-day implementation plan**
>
> **Formulating 21-day implementation plan**
>
> **Evaluating graph storage and reuse options**
>
> **Evaluating graph storage and reuse options**
>
> **Formulated 21-day implementation plan and evaluated graph storage options**
>
> 
>
> **Formulating 21-day implementation plan**
>
> **Formulating 21-day implementation plan**
>
> **Evaluating graph storage and reuse options**
>
> **Evaluating graph storage and reuse options**
>
> **Formulated 21-day implementation plan and evaluated graph storage options**
>
> 
>
> **Formulating 21-day implementation plan**
>
> **Formulating 21-day implementation plan**
>
> **Evaluating graph storage and reuse options**
>
> **Evaluating graph storage and reuse options**
>
> **Designing hybrid graph and constraint schema**
>
> **Designing hybrid graph and constraint schema**
>
> **Designed a 21-day hybrid graph and constraint implementation plan**
>
> 
>
> **Formulating 21-day implementation plan**
>
> **Formulating 21-day implementation plan**
>
> **Evaluating graph storage and reuse options**
>
> **Evaluating graph storage and reuse options**
>
> **Designing hybrid graph and constraint schema**
>
> **Designing hybrid graph and constraint schema**
>
> **Detailing example triples and project milestones**
>
> **Detailing example triples and project milestones**
>
> **Formulated a 21-day hybrid graph implementation plan with schemas and milestones**
>
> 
>
> **Inspected Wikontic source, configuration, architecture, utilities, and evidence handling**
>
> 
>
> Worked for 1m 49s

## Overall verdict

Your plan is feasible for the AAAI-27 Demonstration Track, provided we freeze the scope to:

- A working reuse-risk analyzer
- Three compelling forward-compatibility cases
- Three lightweight baselines
- A small evidence-grounded evaluation set
- A polished interactive demonstration
- The required two-page paper and five-minute video

It is not feasible in the remaining three weeks to build a production-grade system covering every FDA application type, CTD section, guidance and document-content requirement.

The right target is a convincing research prototype that demonstrates a new decision-support capability.

## Wikontic verdict

Wikontic is useful as a methodological inspiration and possibly as a source of selected implementation patterns. I would not directly use its complete architecture as the foundation of RegBridge.

The best choice is:

> Adapt Wikontic’s ontology-constrained extraction idea, but build a smaller, regulatory-specific, version-aware graph and constraint engine.

# 1. Why your plan makes sense

The proposed demonstration has a strong and understandable contrast:

### Existing publishing-tool decision

```text
Can this legacy document technically be referenced?
```

### RegBridge decision

```text
Should this legacy document be reused in this target regulatory context,
and what must change before reuse?
```

That distinction gives the demonstration a clear “before versus after” story.

The system can show that an ordinary agent or conventional publishing check might conclude:

```text
Document exists.
Legacy leaf is active.
Therefore: reusable.
```

RegBridge can instead conclude:

```text
Technically referenceable, but unsafe to reuse as-is because:

1. Its original heading was removed in v4.0.
2. Its legacy manufacturer metadata is discouraged.
3. Its internal hyperlink points to an obsolete dossier context.

Recommended action: break lifecycle, relocate, repair and resubmit.
```

That is compelling, interactive and directly relevant to human-AI decision support.

# 2. What Wikontic actually does

Wikontic is an ontology-aware knowledge-graph construction pipeline. It performs:

1. LLM extraction of subject–relation–object triplets.
2. Extraction of contextual qualifiers such as dates and conditions.
3. Semantic alignment of extracted entity types and relations.
4. Validation against Wikidata domain and range constraints.
5. Entity normalization and deduplication.
6. Graph storage, visualization and multi-hop question answering.

For example:

```text
Christopher Nolan ──directed──> Inception
```

with:

```text
subject type: human
object type: film
qualifier: point in time = 2010
```

Wikontic checks whether the `directed` relation is valid between those entity types and normalizes variants such as “Nolan” and “Christopher Nolan.” Its EACL paper reports ontology-consistent, compact graphs and competitive multi-hop QA performance. [Wikontic EACL paper](https://aclanthology.org/2026.eacl-long.388/)

Its code is:

- Python-based
- MIT-licensed
- Compatible with OpenAI-style APIs
- Equipped with Streamlit
- Able to use MongoDB or Qdrant
- Structured around ontology mappings, triplet extraction and refinement

See the [Wikontic GitHub repository](https://github.com/screemix/Wikontic).

# 3. Where Wikontic fits RegBridge

These Wikontic ideas transfer well:

| Wikontic capability | RegBridge adaptation |
|---|---|
| Candidate triplet extraction | Extract candidate regulatory obligations and applicability conditions |
| Entity typing | Identify Rule, Heading, Version, Document, Authority and Keyword |
| Relation alignment | Normalize “supersedes,” “requires,” “maps to,” “not permitted in” |
| Qualifiers | Capture effective date, jurisdiction, application type and exception |
| Ontology validation | Reject relationships not allowed by our regulatory schema |
| Entity deduplication | Merge alternate names for the same standard, heading or validation rule |
| Filtered-triplet storage | Preserve rejected or uncertain regulatory facts for review |
| Graph visualization | Show why a reuse decision was made |

For example, an extracted statement could become:

```text
Rule eCTD4-078
    ──requires──>
Exact legacy keyword-value match
```

with qualifiers:

```json
{
  "authority": "FDA",
  "jurisdiction": "US",
  "target_version": "eCTD 4.0",
  "severity": "high",
  "effective_from": "2024-09-16",
  "source_section": "Validation rule eCTD4-078"
}
```

That is directly inspired by Wikontic’s typed triplets with qualifiers.

# 4. Why we should not fork Wikontic unchanged

## A. Its ontology is Wikidata-centered

Wikontic’s ontology contains Wikidata entity types and properties. Regulatory concepts such as these are not naturally captured by that ontology:

- Validation rule
- Lifecycle operation
- CTD heading
- Submission sequence
- Regulatory authority
- Binding requirement
- Nonbinding recommendation
- Effective version
- Application type
- Exception
- Reuse decision
- Evidence span

Wikontic permits an alternative mappings directory, but its structured aligner still expects Wikidata-style mapping files, property IDs, type hierarchies and subject/object constraints. Converting the entire regulatory model into that format would introduce unnecessary work.

## B. Regulatory reasoning is temporal and conditional

A Wikidata-style fact might be:

```text
FDA ──published──> Technical Conformance Guide
```

Our required representation is closer to:

```text
Rule R applies when:
    authority = FDA
    center = CDER
    target eCTD version = 4.0
    legacy leaf status = active
    keyword is allowed
    submission date >= effective date
    no repository-boundary exception exists
```

This is more than graph connectivity. It needs executable constraints.

## C. Wikontic does not provide sufficient provenance

Wikontic stores a `source_text_id`, but the inspected implementation does not natively provide everything our system needs:

- Exact supporting evidence span
- Page and section
- Standards version
- Effective interval
- Binding versus recommended status
- Extraction confidence
- Human verification status
- Conflicting-rule resolution
- Rule applicability explanation

For regulatory decision support, provenance is not optional.

## D. It does not provide a regulatory rule engine

Ontology validation tells us whether a relationship is structurally meaningful. It does not necessarily execute rules such as:

```text
IF legacy leaf is inactive
THEN it cannot be reused through forward compatibility.
```

or:

```text
IF target heading does not exist in v4.0
THEN break lifecycle and create a new Context of Use.
```

We need our own deterministic decision layer.

## E. It was already an AAAI-26 demonstration

Wikontic itself appeared in the AAAI-26 Demonstration Track. [Wikontic AAAI demo paper](https://ojs.aaai.org/index.php/AAAI/article/view/42341)

A submission framed as “Wikontic applied to eCTD” could be perceived as a domain adaptation of last year’s demo. Our technical contribution must therefore go beyond Wikontic:

> Version-aware regulatory applicability, executable constraints, lifecycle reasoning, evidence-backed risk decisions and minimal repair recommendations.

# 5. Recommended graph formulation

You do not need to become deeply knowledgeable about knowledge graphs to build this. At its core, our graph will consist of typed objects and permitted relationships.

## Principal node types

```text
StandardDocument
StandardVersion
Rule
EvidenceSpan
RegulatoryAuthority
ApplicationContext
CTDHeading
KeywordDefinition
ValidationCriterion
LegacyLeaf
DossierDocument
ReuseDecision
RepairAction
```

## Principal relationships

```text
VERSION_OF
SUPERSEDES
APPLIES_TO
DEFINED_BY
SUPPORTED_BY
LOCATED_UNDER
AVAILABLE_IN
REMOVED_IN
MAPS_TO
HAS_KEYWORD
REFERENCES_DOCUMENT
REPLACES
CONFLICTS_WITH
REQUIRES
PROHIBITS
RECOMMENDS
TRIGGERS_DECISION
REQUIRES_REPAIR
```

## Attributes or qualifiers

Every important rule edge should carry:

```json
{
  "authority": "FDA",
  "jurisdiction": "US",
  "center": "CDER",
  "application_types": ["NDA", "IND", "BLA"],
  "valid_from": "2024-09-16",
  "valid_to": null,
  "source_document": "eCTD v4.0 Technical Conformance Guide",
  "source_version": "1.5",
  "source_section": "2.1",
  "bindingness": "technical requirement",
  "severity": "high",
  "extraction_method": "manual|structured|llm",
  "review_status": "verified",
  "confidence": 1.0
}
```

# 6. Your constraint-schema idea should be central

I believe your constraint-schema formation idea is more important than the choice of graph database.

The graph represents the connected regulatory knowledge. The constraint schemas define what relationships and decisions are permitted.

## Schema-level constraints

```text
LOCATED_UNDER:
    subject must be LegacyLeaf or DossierDocument
    object must be CTDHeading

SUPERSEDES:
    subject must be StandardVersion
    object must be StandardVersion

SUPPORTED_BY:
    subject must be Rule or ReuseDecision
    object must be EvidenceSpan
```

## Decision constraints

```text
C1:
IF legacy_leaf.status != active
THEN decision = DO_NOT_REUSE

C2:
IF original_heading is unavailable in target_version
THEN decision = BREAK_LIFECYCLE_AND_RESUBMIT

C3:
IF legacy_keyword != target_keyword_display_name
AND lifecycle continuity is requested
THEN risk = HIGH

C4:
IF repository_center(source) != repository_center(target)
THEN decision = DO_NOT_REUSE

C5:
IF internal hyperlink is irrelevant to target context
THEN decision = HUMAN_REVIEW or REPAIR_AND_RESUBMIT
```

I recommend implementing these as:

- Pydantic models for node and edge schemas
- JSON Schema for portable validation
- A small deterministic Python rule engine
- A graph representation using NetworkX or a similarly lightweight library
- JSON/SQLite persistence
- LLM extraction only for ambiguous prose and document-level content risks

We do not need Neo4j, MongoDB Atlas or a large semantic-web stack for the AAAI prototype.

# 7. Recommended implementation architecture

## Layer 1: deterministic dossier parser

Parse:

- `index.xml`
- `us-regional.xml`
- `stf.xml`
- Leaf IDs
- Operations
- Modified-file references
- CTD locations
- Metadata attributes
- File paths

This constructs the legacy dossier graph without using an LLM.

## Layer 2: standards registry

Ingest selected official sources:

- FDA v4.0 Technical Conformance Guide
- FDA v4.0 Validation Criteria
- FDA Module 1 Implementation Guide
- FDA/ICH controlled vocabularies
- ICH forward-compatibility mappings
- Selected ICH Q&A

Structured tables and XML should be parsed deterministically. LLM extraction should only propose rules from prose.

## Layer 3: constraint graph

Validate every proposed rule against the regulatory schema:

```text
Candidate extraction
→ entity/relation normalization
→ schema validation
→ evidence verification
→ approved rule graph
```

This is the portion conceptually based on Wikontic.

## Layer 4: reuse analyzer

For each legacy leaf:

1. Verify lifecycle status.
2. Determine original heading and metadata.
3. Find the target-version heading.
4. Check keyword continuity.
5. check repository and application restrictions.
6. Run deterministic validation rules.
7. Analyze document content and links where required.
8. Produce a risk and recommended action.

## Layer 5: explanation interface

The UI should show:

- Legacy document
- Original heading and metadata
- Applicable target rules
- Detected incompatibilities
- Reuse decision
- Recommended repair
- Supporting evidence
- Graph path leading to the decision

# 8. Baselines

Your proposed simple agent is appropriate, but one baseline is not enough to isolate the graph’s value.

Use:

| System | Description |
|---|---|
| B0: Long-context agent | Receives the dossier information and standards documents directly |
| B1: Flat RAG agent | Retrieves relevant standards passages without graph or constraints |
| B2: Rule-only analyzer | Uses deterministic rules without semantic document analysis |
| RegBridge | Versioned graph + constraints + evidence-grounded LLM |

This gives us useful comparisons:

- B0 tests raw model reasoning.
- B1 tests whether retrieval alone solves the problem.
- B2 tests whether deterministic rules alone are sufficient.
- RegBridge demonstrates the value of combining them.

# 9. Evaluation scope

For the demo, create a small benchmark around the three cases:

1. Removed heading
2. Discouraged or mismatched metadata
3. Semantically stale document or hyperlink

Generate approximately ten controlled variants of each:

```text
30 total cases
```

Measure:

- Reuse-decision accuracy
- High-risk recall
- Unsafe false-negative rate
- Heading-mapping accuracy
- Evidence citation accuracy
- Correct repair recommendation
- Abstention accuracy
- End-to-end runtime

The most important metric is:

> How often does the system incorrectly approve unsafe reuse?

# 10. Feasible schedule

The AAAI-27 deadline is September 18, 2026. The following schedule is tight but realistic.

| Dates | Work |
|---|---|
| Aug 28–30 | Freeze scope, schemas, decision labels and three cases |
| Aug 31–Sep 3 | Implement v3 parser, standards registry and graph models |
| Sep 4–7 | Implement constraint engine and three end-to-end cases |
| Sep 8–10 | Implement baselines and 30-case evaluation |
| Sep 11–12 | Complete Streamlit demonstration |
| Sep 13–14 | Run experiments and produce result table |
| Sep 15 | Complete two-page paper draft |
| Sep 16 | Record five-minute demonstration |
| Sep 17 | Final QA and submission preparation |
| Sep 18 | Submit |

## Scope that must be excluded

Do not attempt before the deadline:

- Full automatic v4.0 package generation
- Every FDA application type
- Every CTD heading
- Complete scientific-content compliance
- Automatic rewriting of regulatory documents
- FDA acceptance prediction
- Production security or enterprise RIM integration
- Fully automatic ontology construction without review

# Final recommendation

Proceed with the demo.

Base the graph-construction methodology partly on Wikontic’s pattern:

```text
LLM candidate extraction
→ type/relation alignment
→ ontology validation
→ normalization
```

But implement a new regulatory-specific contribution:

```text
temporal standards graph
→ executable constraint schemas
→ lifecycle-aware reuse decisions
→ evidence-backed repair recommendations
```

The strongest framing is:

> **RegBridge is not another eCTD converter. It is a version-aware, constraint-guided decision-support system that determines whether legacy regulatory content should be reused and explains the safest migration action.**

That is feasible, clearly different from Wikontic, and strong enough for an AAAI demonstration if the prototype is completed on schedule.

## Prompt:
8/28/2026, 7:10:38 PM

I like this. I want your other product, OpenAI Codex, to handle the implementation. It should first understand the research topic and goal (baselines to test against after implementation, etc), the implementation idea we have, and what it should build. Can you come up with an AGENTS.md that will house it? A separate IMPLEMENTATION.md will talk about implementation (a link from AGENTS.md will reference it). Before you do that, For any logical gaps/jumps that needs my input, please ask me before you create the files. Please think through properly and take into consideration everything this will need. I will come up with some steering and testing it once implementation is done.

## Response:
8/28/2026, 7:10:40 PM

I’m using the continuity check to preserve the RegBridge research decisions, the ask-user-input skill to resolve only choices that materially affect the repository instructions, and the Library workflow because the final `AGENTS.md` and `IMPLEMENTATION.md` will be reusable project artifacts. I will not create either file until you answer the scope questions.

I found three decisions that genuinely change what Codex should be instructed to build. My recommendations are intentionally deadline-oriented: FDA/CDER first, a modular Python backend with a fast demo UI, and provider-neutral model access with an offline fixture mode.

> **Planning clarification before creation**
>
> **Planning clarification before creation**
>
> **Planning key technical and scope questions**
>
> **Planning key technical and scope questions**
>
> **Planned clarification and key technical scope questions**
>
> 
>
> **Planning clarification before creation**
>
> **Planning clarification before creation**
>
> **Planning key technical and scope questions**
>
> **Planning key technical and scope questions**
>
> **Planned clarification and key technical scope questions**
>
> 
>
> **Defining multi-regulator options**
>
> **Defining multi-regulator options**
>
> **Outlining architecture and model options**
>
> **Outlining architecture and model options**
>
> **Defined multi-regulator options and outlined architecture models**
>
> 
>
> **Asked ⁨3⁩ questions**
>
> 
>
> Worked for 4s

Before I create the files, please choose:

1. Regulatory scope:

   - FDA/CDER first (recommended)
   - CDER and CBER
   - Multi-regulator framework

2. Application stack:

   - FastAPI + Streamlit (recommended)
   - Streamlit only
   - FastAPI + React

3. Runtime model setup:

   - Provider-neutral OpenAI-compatible adapter with offline fixtures (recommended)
   - OpenAI API only
   - Fully local models

You can simply reply: **“Use all recommended options.”**

## Prompt:
8/28/2026, 7:14:37 PM

1. Use recommended options
2. Fast API + React (iconoir/Tailwind)
3. Use recommended options

## Response:
8/28/2026, 7:14:38 PM

Got it: FDA/CDER-first scope, FastAPI plus React using Tailwind and Iconoir, and a provider-neutral OpenAI-compatible model layer with deterministic offline fixtures. I’ll now turn the research design into two repository-governing documents, with `AGENTS.md` defining Codex’s operating contract and `IMPLEMENTATION.md` defining the build architecture, milestones, baselines, tests, and acceptance gates.

Those choices close the material gaps: FDA/CDER-first scope, FastAPI + React with Tailwind/Iconoir, and a provider-neutral OpenAI-compatible model adapter with offline fixtures. I’m now turning the research plan into two Codex-facing contracts: a concise operating guide and a build specification with architecture, evaluation controls, milestones, and completion gates.

The drafts now encode the project as a research system, not a generic regulatory chatbot. I’ve made the scientific controls explicit—same-corpus baselines, frozen evidence snapshots, no hard-coded case outcomes, model abstention, and unsafe false negatives as the primary metric—and separated those from the application architecture. I’m doing a consistency pass now, especially around decision precedence, graph authority, and the offline/live model boundary.

The consistency review is clean. The operating guide stays concise enough to govern Codex, while the implementation file carries the detailed graph schema, rule precedence, APIs, UI journey, security boundaries, 30-case benchmark design, four-system evaluation, and deadline-oriented milestones. Saving files to Library.

> **Planning AGENTS.md and IMPLEMENTATION.md contents**
>
> **Planning AGENTS.md and IMPLEMENTATION.md contents**
>
> **Planned AGENTS.md and IMPLEMENTATION.md contents**
>
> 
>
> **Inspecting repository status and guidance files**
>
>
> **Planning implementation with official sources**
>
> **Planning implementation with official sources**
>
> **Planned implementation using official sources**
>
> 
>
> **Applying a patch to files**
>
>
> **Inspected repository guidance, sorted files, and applied a patch**
>
> 
>
> **Inspecting project guidance and implementation docs**
>
>
> **Planning code fence validation**
>
> **Planning code fence validation**
>
> **Planned code fence validation**
>
> 
>
> **Planning full script retrieval strategy**
>
> **Planning full script retrieval strategy**
>
> **Planned full script retrieval strategy**
>
> 
>
> **Planning script copying method**
>
> **Planning script copying method**
>
> **Designing secure script execution flow**
>
> **Designing secure script execution flow**
>
> **Planned secure script copying and execution flow**
>
> 
>
> **Planning script copying method**
>
> **Planning script copying method**
>
> **Designing secure script execution flow**
>
> **Designing secure script execution flow**
>
> **Planned a secure script copying and execution workflow**
>
> 
>
> **Inspected project guidance and implementation documentation**
>
> 
>
> **Creating temporary upload directory**
>
>
> **Planning temp directory cleanup and markdown checks**
>
> **Planning temp directory cleanup and markdown checks**
>
> **Planned temp directory cleanup and markdown checks**
>
> 
>
> **Validating documentation files and checksums**
>
>
> **Summarizing final deliverables and automation options**
>
> **Summarizing final deliverables and automation options**
>
> **Summarized final deliverables and automation options**
>
> 
>
> **Uploaded and validated documentation files with checksums**
>
> 
>
> Worked for 6m 18s

Created both files with your recommended choices incorporated:

- [AGENTS.md](sandbox:/workspace/scratch/cbdce6a09de8/AGENTS.md) — research mission, scope, reasoning rules, scientific controls, Codex behavior, and definition of done.
- [IMPLEMENTATION.md](sandbox:/workspace/scratch/cbdce6a09de8/IMPLEMENTATION.md) — graph model, constraints, FastAPI/React architecture, APIs, UI, three cases, baselines, evaluation, security, testing, milestones, and demo flow.

No unresolved decision blocks M0 implementation. Larger choices—additional regulators, graph databases, embeddings, deployment, and automatic package generation—are explicitly deferred.

The plan treats Wikontic as methodological inspiration rather than a direct architectural fork, preserving RegBridge’s distinct contribution around version-aware applicability, executable constraints, provenance, and regulatory decision traces.

If helpful, I can set up “Review RegBridge milestone progress” so the AAAI submission schedule stays visible.

## Prompt:
8/28/2026, 9:30:55 PM

I do see in the implementation document, every node and edge has a stable identifier and type. One question: who may mark an evidence span or rule `authoritative_for_demo`  the tag means? then your answer, so I can think through it

## Response:
8/28/2026, 9:30:54 PM

> **Defining governance roles and status tags**
>
> **Defining governance roles and status tags**
>
> **Defined governance roles and status tags**
>
> 
>
> Worked for 11s

`authoritative_for_demo` means:

> This item has been human-approved as sufficiently reliable to drive RegBridge’s deterministic conclusions within the frozen research demonstration.

It does **not** mean FDA has endorsed it, that it is legally authoritative, or that it applies outside the explicitly encoded FDA/CDER context.

Who should assign it?

- Codex or an LLM: **never**.
- Automated extraction pipeline: **never**.
- You as project owner: may approve the engineering representation, but ideally not the regulatory interpretation alone.
- Designated human regulatory reviewer: should approve the regulatory meaning, applicability, and rule formulation.
- Ideally, a second reviewer adjudicates unclear or disputed rules.

The approval means different things for each object:

- For an `EvidenceSpan`: the reviewer confirms that the text was copied accurately from the pinned official source, its locator is correct, and its version/context metadata is accurate.
- For a `Rule`: the reviewer confirms that the formal constraint faithfully represents the evidence, has the correct applicability conditions, and supports the specified severity, decision, and repair.

A sensible workflow is:

```text
candidate
   ↓ extraction and schema validation
reviewed
   ↓ human checks source and interpretation
approved_for_demo_execution
   ↓ may drive deterministic demo decisions
rejected
```

I recommend renaming `authoritative_for_demo` to `approved_for_demo_execution`. The latter is less likely to imply FDA authority.

For the strongest paper, a regulatory professional with eCTD experience should approve the three principal rules. If that is unavailable before submission, you can perform documented author verification, but the paper should call it **author-reviewed formalization**, acknowledge the absence of expert validation, and avoid using “authoritative.”

Each approval record should capture:

- reviewer identity or anonymized reviewer ID;
- reviewer role and relevant expertise;
- approval date;
- source version and SHA-256 digest;
- evidence locator;
- approved rule version;
- comments or interpretation assumptions;
- whether approval was independent;
- any unresolved disagreement.

My recommended governance is therefore: Codex constructs candidates, you verify implementation fidelity, and a regulatory-domain reviewer approves regulatory interpretation. Until that final approval, the rule should remain `reviewed` and produce `HUMAN_REGULATORY_REVIEW` rather than a hard compliance conclusion.

## Prompt:
8/28/2026, 9:33:50 PM

I don't think we will have access to a regulatory professional with eCTD experience

## Response:
8/28/2026, 9:33:49 PM

> **Revising governance terminology and rule classification**
>
> **Revising governance terminology and rule classification**
>
> **Documenting verification and framing limitations**
>
> **Documenting verification and framing limitations**
>
> **Revised governance terminology and documented verification limitations**
>
> 
>
> Worked for 15s

That is not fatal to the project. We should remove expert review as a dependency and make the governance transparent.

I would replace `authoritative_for_demo` with:

- `candidate` — automatically extracted or newly drafted.
- `source_verified` — checked against an exact passage, table, schema, or controlled terminology from a pinned official source.
- `author_adjudicated_for_demo` — the research team has approved its operationalization for the benchmark.
- `rejected` — unsupported, incorrect, or outside scope.

`author_adjudicated_for_demo` would mean:

> The research team has verified the source and accepted this particular formalization for executing the controlled demonstration. It is not expert-validated regulatory guidance.

You or another project author may assign it through a documented review protocol. Codex and the LLM may propose candidates but cannot approve them.

I would also classify rules by interpretation risk:

| Rule basis | Example | System treatment |
|---|---|---|
| Direct encoding | Heading exists/does not exist in the target specification | May be a hard rule |
| Mechanical derivation | Exact metadata value conflicts with a controlled list | May be a hard rule if fully evidenced |
| Interpretive guidance | Guidance discourages a practice but allows context | Advisory finding or human review |
| Semantic inference | PDF wording or hyperlink appears stale | Risk signal; never an automatic compliance verdict |

Each rule should therefore record:

```yaml
review_status: author_adjudicated_for_demo
verification_basis: direct_standard_encoding
expert_validated: false
enforcement_mode: hard
```

For ambiguous rules:

```yaml
review_status: author_adjudicated_for_demo
verification_basis: author_interpretation
expert_validated: false
enforcement_mode: advisory
```

This changes the paper’s claims slightly. The benchmark labels should be described as **author-adjudicated labels grounded in official sources**, not regulatory ground truth. The evaluation would demonstrate internal correctness, evidence traceability, and risk-detection performance—not FDA compliance accuracy.

For the three cases:

- The removed-heading case can probably remain deterministic because it relies on direct structural evidence.
- The metadata case may combine deterministic checks with an advisory interpretation.
- The stale-wording case should produce a risk warning or `HUMAN_REGULATORY_REVIEW`, not a definitive noncompliance ruling.

This is still a credible AAAI demo. In fact, the explicit boundary between machine-verifiable rules and interpretations requiring escalation strengthens the responsible-AI story. We should disclose “no regulatory expert validation” as a limitation and design the system so later expert review can be added without changing the architecture.

## Prompt:
8/28/2026, 9:41:17 PM

Okay, I already have the IMPLEMENTATION.md, you can do the necessary modification to it, so I get the new one

## Response:
8/28/2026, 9:41:16 PM

I’ll revise only `IMPLEMENTATION.md` to remove expert review as a dependency. The new version will use author-adjudicated, source-grounded governance; separate hard rules from advisory interpretations; and explicitly state that the benchmark is not regulatory ground truth. I’m using the file-management workflow so this replaces the existing document version rather than creating an unrelated duplicate.

The key adjustment is methodological rather than architectural: the system can still execute direct, machine-verifiable standards facts as hard constraints, while author interpretations remain advisory and can only escalate to review. I’m also replacing “gold” terminology with “author-adjudicated reference labels” so the evaluation does not imply expert regulatory ground truth.

The revised governance is internally consistent: no expert is assumed, only direct/mechanical rules may be hard constraints, interpretations are advisory, semantic findings escalate rather than declare noncompliance, and all benchmark labels carry author-adjudication metadata. Saving file to Library.

> **Preparing to update existing library implementation**
>
> **Preparing to update existing library implementation**
>
> **Prepared to update existing library implementation**
>
> 
>
> **Searching documentation for authority markers**
>
>
> **Revising governance and status criteria**
>
> **Revising governance and status criteria**
>
> **Revised governance and status criteria**
>
> 
>
> **Reviewing implementation documentation sections**
>
>
> **Searched documentation for authority markers and implementation details**
>
> 
>
> **Applying a code patch**
>
>
> **Identifying AGENTS and Implementation conflicts**
>
> **Identifying AGENTS and Implementation conflicts**
>
> **Adding supersede note in Implementation**
>
> **Adding supersede note in Implementation**
>
> **Added a supersede note to resolve Implementation conflicts**
>
> 
>
> **Identifying AGENTS and Implementation conflicts**
>
> **Identifying AGENTS and Implementation conflicts**
>
> **Adding supersede note in Implementation**
>
> **Adding supersede note in Implementation**
>
> **Identified AGENTS conflicts and added an Implementation supersede note**
>
> 
>
> **Validating implementation documentation consistency**
>
>
> **Applied code patches and validated implementation documentation consistency**
>
> 
>
> **Replaced expert governance with source-verified adjudication**
>
> 
>
> **Applying Library File Metadata**
>
>
> **Noting AGENTS markdown update reminder**
>
> **Noting AGENTS markdown update reminder**
>
> **Noted the AGENTS markdown update reminder**
>
> 
>
> **Searching AGENTS.md for authority terms**
>
>
> **Noting enum inconsistency in terminology**
>
> **Noting enum inconsistency in terminology**
>
> **Noted enum terminology inconsistency**
>
> 
>
> **Applied library file metadata and searched AGENTS.md for authority terms**
>
> 
>
> Worked for 2m 28s

Updated [`IMPLEMENTATION.md`](sandbox:/workspace/scratch/cbdce6a09de8/`IMPLEMENTATION.md`).

Main changes:

- Removed `authoritative_for_demo`.
- Added `source_verified` and `author_adjudicated_for_demo`.
- Made `expert_validated: false` the default.
- Added a two-pass author-review protocol.
- Distinguished `hard`, `advisory`, `semantic_signal`, and `disabled` rules.
- Restricted hard decisions to directly encoded or mechanically derived official requirements.
- Replaced “gold labels” with “author-adjudicated reference labels.”
- Added explicit disclosure that the prototype lacks regulatory-expert validation.
- Updated benchmark records, integrity checks, milestones, and release criteria accordingly.

One later consistency cleanup will be needed in `AGENTS.md`, where older generic `reviewed` terminology remains.

## Prompt:
8/28/2026, 9:44:50 PM

Okay, you said an AGENTS.md consistency cleanup will be needed? If so, do it

## Response:
8/28/2026, 9:44:49 PM

Yes. I’ll synchronize `AGENTS.md` with the revised governance vocabulary and enforcement boundary so Codex receives one consistent instruction set: source verification, author adjudication, no assumed expert validation, and no hard conclusions from interpretive or semantic rules.

The two documents now agree on every governance-critical term and boundary. `AGENTS.md` also tells Codex that author adjudication is internal research approval, forbids models from promoting review status, and prevents advisory or semantic findings from producing definitive regulatory decisions. Saving file to Library.

> **Reviewing project guidance and compliance rules**
>
>
> **Defining ontology validation rules**
>
> **Defining ontology validation rules**
>
> **Defined ontology validation rules**
>
> 
>
> **Applying a patch to files**
>
>
> **Applied file patches and validated documentation compliance**
>
> 
>
> **Synchronized evidence governance documentation**
>
> 
>
> **Applying library file metadata attributes**
>
>
> **Applied library file metadata attributes**
>
> 
>
> Worked for 1m 3s

Updated [`AGENTS.md`](sandbox:/workspace/scratch/cbdce6a09de8/`AGENTS.md`).

It is now consistent with `IMPLEMENTATION.md` on:

- Review-status vocabulary.
- Author adjudication versus expert validation.
- Hard, advisory, and semantic enforcement modes.
- Reference labels instead of regulatory ground truth.
- Model promotion restrictions.
- Required disclaimers and completion gates.

Codex can now read both documents without encountering conflicting governance instructions.

## Prompt:
8/28/2026, 10:05:04 PM

![ff08d324-79ce-4d84-a5cb-311c5a89684c.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000ffc081f79a42f9059673c202&fn=ff08d324-79ce-4d84-a5cb-311c5a89684c.png&cd=attachment&ts=496913&p=fs&cid=1&sig=51246ae38af3b30e16b5d957e1ef69a0f9d7f35e4e5bed5ede1c0d0c69d98b95&v=0)

Here is my latest exchange with Codex. I believe approving it is the right decision. What do you think?

## Response:
8/28/2026, 10:05:05 PM

Your instinct is broadly right, but I would approve it conditionally—not with the exact wording shown. The prospective scenario is defensible; the important question is whether the implementation cleanly separates “hard within the controlled future scenario” from “currently operational FDA behavior.” I’m checking the current FDA materials before recommending the precise approval text.

> **Planning to verify FDA eCTD v4.0 details**
>
> **Planning to verify FDA eCTD v4.0 details**
>
> **Analyzing FDA eCTD v4.0 compatibility rules**
>
> **Analyzing FDA eCTD v4.0 compatibility rules**
>
> **Analyzed FDA eCTD v4.0 details and compatibility rules**
>
> 
>
> **Planning to verify FDA eCTD v4.0 details**
>
> **Planning to verify FDA eCTD v4.0 details**
>
> **Analyzing FDA eCTD v4.0 compatibility rules**
>
> **Analyzing FDA eCTD v4.0 compatibility rules**
>
> **Verified FDA eCTD v4.0 compatibility details**
>
> 
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Clarified lifecycle break/resubmit and reclassified it as context reuse**
>
> 
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Clarified lifecycle break resubmission and reclassified it as context reuse**
>
> 
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Clarifying lifecycle break and resubmit meaning**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Reclassifying lifecycle action as context reuse**
>
> **Verifying source and operational limitations**
>
> **Verifying source and operational limitations**
>
> **Clarified lifecycle resubmission, reclassified context reuse, and verified limitations**
>
> 
>
> **Searched 2 websites**
>
> 
>
> Worked for 1m 14s

I would approve the prospective research scenario, but I would **not approve the proposed rule exactly as written**.

The sources support a slightly different decision.

FDA currently says only new applications may start in v4.0 and forward compatibility for existing v3.2.2 applications is not yet available. FDA’s June 2026 assessment also says additional software revisions are required before a technical pilot. Therefore, clearly labeling Case A as prospective is correct. [FDA eCTD status](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd), [FDA 2025 Annual Assessment](https://www.fda.gov/media/193422/download).

However, the Technical Conformance Guide says that when the heading or keywords must change:

- the original context group should be suspended;
- a new context group should be created;
- the existing document may be referenced using its unique identifier;
- resubmission of the file and document element is unnecessary.

That is closer to `REUSE_WITH_NEW_CONTEXT` than `BREAK_LIFECYCLE_AND_RESUBMIT`. [FDA Technical Conformance Guide, §§1.5.4–1.5.5](https://www.fda.gov/media/179700/download).

The CTOC evidence is sound: v4.0 retains `3.2.S.1` while removing `3.2.S.1.1–3.2.S.1.3`. [FDA CTOC v2.2, pp. 7 and 38–39](https://www.fda.gov/media/179699/download).

I recommend replying to Codex with:

> I approve treating M1 as a clearly labeled prospective forward-compatibility research scenario. Current FDA operational availability must remain recorded as `not_operational`, displayed in the API/UI, and disclosed in the paper and demonstration.
>
> I will act as `author-01`, with `expert_validated: false`. I approve the two source-verification records after confirming that the stated SHA-256 digests correspond to the pinned local PDFs.
>
> I do not approve the proposed rule action exactly as written. Please revise it as follows:
>
> - Decision: `REUSE_WITH_NEW_CONTEXT`
> - Repair action: `CREATE_NEW_CONTEXT_GROUP_AND_SUSPEND_OLD`
> - For the controlled Case A mapping, relocate content from `3.2.S.1.1`, `3.2.S.1.2`, or `3.2.S.1.3` to the explicitly mapped v4.0 heading `3.2.S.1`.
> - Reference the existing document through its unique identifier; do not state that the physical file or document element must be resubmitted.
> - Record that the new context group does not retain the old context-group lifecycle relationship, although document reuse remains possible.
> - Basis: `mechanical_derivation`
> - Enforcement: `hard`, but only inside the controlled prospective FDA/CDER demonstration scenario.
>
> Do not implement “nearest available parent” as a general algorithm. Use an explicit, source-supported heading mapping for this case. In current-operational mode, the analyzer should report that v3.2.2-to-v4.0 forward compatibility is unavailable rather than execute the prospective rule.

One more point: do not approve the SHA-256 statements solely because Codex generated them. Open the pinned PDFs, confirm the cited pages, and ensure those hashes belong to the files you inspected. That is the author-verification step.

This revised case is actually more compelling: a baseline may incorrectly say “replace or resubmit the document,” while RegBridge distinguishes document reuse from context-group lifecycle continuity.

## Prompt:
8/28/2026, 10:09:26 PM

These are the PDFs. They were fetched from FDA's website

[Attachment: fda-ectd-v4-technical-conformance-guide-v1.5.pdf]

[Attachment: fda-ectd-v4-ctoc-headings-v2.2.pdf]

## Response:
8/28/2026, 10:09:26 PM

Good—these let me verify the exact pinned artifacts rather than relying on Codex’s summary. I’ll check their SHA-256 digests and inspect the cited pages directly, including the wording that determines whether the correct action is “resubmit” or “reuse under a new context.”

The digests match Codex’s records exactly. I found one provenance detail worth correcting before approval: the CTOC’s page references should distinguish PDF page numbers from the printed page numbers, and the “3.2.S.1 remains” entry appears on the following PDF page rather than the page stated in the exchange. I’m pinning the exact locator now.

> **Verifying and Extracting FDA eCTD Guidance**
>
>
> **Planning PDF page rendering for visual inspection**
>
> **Planning PDF page rendering for visual inspection**
>
> **Planned PDF page rendering for visual inspection**
>
> 
>
> **Rendering Selected PDF Pages as Images**
>
>
> **Confirming PDF hashes and citations**
>
> **Confirming PDF hashes and citations**
>
> **Clarifying PDF versus printed page numbering**
>
> **Clarifying PDF versus printed page numbering**
>
> **Confirmed PDF hashes and clarified page numbering citations**
>
> 
>
> **Confirming PDF hashes and citations**
>
> **Confirming PDF hashes and citations**
>
> **Clarifying PDF versus printed page numbering**
>
> **Clarifying PDF versus printed page numbering**
>
> **Confirmed PDF hashes and clarified page numbering citations**
>
> 
>
> **Verified FDA eCTD guidance and rendered selected PDF pages as images**
>
> 
>
> **Extracting and Rendering PDF Page Eight**
>
>
> **Confirming exact source verification hashes**
>
> **Confirming exact source verification hashes**
>
> **Confirmed exact source verification hashes**
>
> 
>
> **Rendering PDF Page 11 as PNG**
>
>
> **Preparing final verification summary**
>
> **Preparing final verification summary**
>
> **Confirming source verification details**
>
> **Confirming source verification details**
>
> **Prepared final verification summary and confirmed source details**
>
> 
>
> **Preparing final verification summary**
>
> **Preparing final verification summary**
>
> **Confirming source verification details**
>
> **Confirming source verification details**
>
> **Confirmed source verification details and prepared final summary**
>
> 
>
> **Rendered PDF pages eight and eleven as PNG images**
>
> 
>
> Worked for 1m 31s

The PDFs verify Codex’s hashes exactly, so you can now approve the source records—but with one corrected page locator and the revised decision action.

Verified files:

- [Technical Conformance Guide v1.5](sandbox:/workspace/scratch/cbdce6a09de8/upload/fda-ectd-v4-technical-conformance-guide-v1.5.pdf)  
  SHA-256: `dccd247940cdf5bc7cbf6a5e31b8f2547ad7f61650ae1a138113feb315f8002e`
- [CTOC Headings v2.2](sandbox:/workspace/scratch/cbdce6a09de8/upload/fda-ectd-v4-ctoc-headings-v2.2.pdf)  
  SHA-256: `382ec5e00b44d179abe7d3e1d9cebecef939938218c36badbde1689f54bfc3e6`

The precise CTOC locators are:

- `3.2.S.1 General information` remains: **PDF page 8, printed page 5**.
- `3.2.S.1.1–3.2.S.1.3` were removed: **PDF page 39, printed page 36**.

Therefore, Codex’s “pages 7 and 39” should be corrected to “PDF pages 8 and 39.”

The Technical Conformance Guide confirms:

- Section 2.1, page 13: replacement requires the same headings and attributes.
- Section 1.5.4, page 11: when the context changes, replacement is not allowed; create a new context group, suspend the old content, and reference the existing document. The physical file and document element do not need to be resubmitted.

You can send Codex:

> I approve treating M1 as a clearly labeled prospective forward-compatibility research scenario. Current FDA operational availability must remain recorded as `not_operational` and displayed in the API/UI, paper, and demonstration.
>
> I confirm that I am acting as `author-01`, with `expert_validated: false`.
>
> I approve these source-verification records:
>
> 1. CTOC v2.2, SHA-256 `382ec5e00b44d179abe7d3e1d9cebecef939938218c36badbde1689f54bfc3e6`:
>    - PDF page 8/printed page 5 shows that `3.2.S.1 General information` remains.
>    - PDF page 39/printed page 36 identifies `3.2.S.1.1–3.2.S.1.3` as removed subheadings.
> 2. Technical Conformance Guide v1.5, SHA-256 `dccd247940cdf5bc7cbf6a5e31b8f2547ad7f61650ae1a138113feb315f8002e`:
>    - Section 2.1/PDF page 13 requires headings and attributes to remain the same when replacing v3.2.2 content.
>    - Section 1.5.4/PDF page 11 requires a new context group when heading placement changes and states that the existing document may be referenced without resubmitting its file or document element.
>
> I approve the rule with the following corrected adjudication:
>
> - Decision: `REUSE_WITH_NEW_CONTEXT`
> - Repair: `CREATE_NEW_CONTEXT_GROUP_AND_SUSPEND_LEGACY_CONTENT`
> - Explicit mapping: `3.2.S.1.1`, `3.2.S.1.2`, and `3.2.S.1.3` → `3.2.S.1`
> - Reuse the existing document through its identifier; do not resubmit the physical file or document element.
> - Basis: `mechanical_derivation`
> - Enforcement: `hard`
> - Scope: controlled prospective FDA/CDER demonstration only
> - Expert validation: `false`
>
> Do not implement “nearest available parent” as a generic mapping algorithm. This rule should use the explicit source-supported mapping above. In current-operational mode, report that forward compatibility is unavailable instead of executing the prospective rule.

That is the approval I recommend.

## Prompt:
8/29/2026, 8:46:23 PM

![c74ed71c-fa01-41cc-b8e9-2e2678f2fe3d.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000212481fd8e297b496c992244&fn=c74ed71c-fa01-41cc-b8e9-2e2678f2fe3d.png&cd=attachment&ts=496913&p=fs&cid=1&sig=5ed84e4db6a6ff0e54b89399a17ec25f85ce6eabb463d3519cd63a92b0faa243&v=0)

Codex finished implementing M1. Testing, I see one should select a scoped fixture, in which we run and test the scenario, and target results come back along with the evidence-backed explanation.

## Response:
8/29/2026, 8:46:25 PM

> **Confirming scoped fixture understanding**
>
> **Confirming scoped fixture understanding**
>
> **Evaluating fixture result expectations and UI layout**
>
> **Evaluating fixture result expectations and UI layout**
>
> **Confirmed fixture scope and evaluated expected results UI layout**
>
> 
>
> Worked for 17s

Yes—that is the intended M1 flow. The selected “fixture” is a controlled synthetic eCTD case, not yet an applicant-uploaded package. RegBridge parses it, applies the scoped prospective rule, and returns the decision, repair action, evidence, and reasoning trace.

For testing, verify this matrix:

| Fixture | Expected prospective result |
|---|---|
| Removed `3.2.S.1.1` | `REUSE_WITH_NEW_CONTEXT` → `3.2.S.1` |
| Removed `3.2.S.1.2` | `REUSE_WITH_NEW_CONTEXT` → `3.2.S.1` |
| Removed `3.2.S.1.3` | `REUSE_WITH_NEW_CONTEXT` → `3.2.S.1` |
| Available `3.2.S.1` | Safe/no relocation finding |
| Unmapped `3.2.S.1.4` | `HUMAN_REGULATORY_REVIEW` |

“Current operational” should not execute the prospective compatibility rule; it should report that FDA forward compatibility is currently unavailable.

Three UI improvements are worth sending Codex:

- Rename **Fixture** to **Controlled test case** or **Scenario variant**; “fixture” sounds developer-facing.
- Remove the duplicated prospective-scenario disclaimer—keep the prominent warning banner and shorten the subtitle.
- After “Parse and analyze,” automatically scroll/focus to the result. The large heading currently pushes the important output below the initial viewport.

The implementation direction looks correct for M1. The crucial check is that these five variants genuinely traverse the parser, graph, and rule engine rather than returning case-specific predefined results.

## Prompt:
8/29/2026, 9:18:20 PM

**How should M2 govern the two verified passages summarized above under author-01 with expert\_validated: false?**

## Prompt:
8/29/2026, 9:18:53 PM

I found one genuine policy gap in M2.

The official evidence supports the facts, but it does not uniquely determine the Case B decision:

- FDA M4 guidance, October 2017, SHA-256 `cc5672cdc3feb352d01c2cbfc823ea6cc3d45e657f3a4ca806cf486b41933cde`, Appendix A, PDF page 25 / printed page 22: the v4 keywords were v3.2.2 attributes; the manufacturer keyword is optional, and—when multiple manufacturer/site/process sections are unnecessary—general values such as `all` are not recommended. It suggests a stable firm/site/process-distinguishing value when a keyword is useful.
- FDA eCTD v4.0 Technical Conformance Guide v1.5, SHA-256 `dccd247940cdf5bc7cbf6a5e31b8f2547ad7f61650ae1a138113feb315f8002e`, §1.5.5, PDF page 12: an existing document may be reused by identifier, but its hyperlinks must be relevant to the new context.
- The already approved TCG passages also require matching context-group keywords for replacement and direct creation of a new context group when keywords change.

The first passage is a nonbinding recommendation, so making every occurrence of `manufacturer="all"` a hard failure would overstate the source. The clean implementation is a narrowly adjudicated, lifecycle-sensitive demo rule. I need you to lock that operationalization and approve the two new evidence spans. Current FDA availability will remain `not_operational` everywhere; none of this changes that.

**How should M2 govern the two verified passages summarized above under author-01 with expert\_validated: false?**

## Response:
8/29/2026, 9:18:58 PM

I agree M2 should be split into one advisory metadata finding and one hard lifecycle rule. I’m checking the repository’s exact decision, review-status, and enforcement enums so the adjudication can be pasted into Codex without introducing a vocabulary mismatch.

> **Planning governance rule design**
>
> **Planning governance rule design**
>
> **Defining lifecycle-sensitive keyword rules**
>
> **Defining lifecycle-sensitive keyword rules**
>
> **Planned lifecycle-sensitive governance keyword rules**
>
> 
>
> **Planning governance rule design**
>
> **Planning governance rule design**
>
> **Defining lifecycle-sensitive keyword rules**
>
> **Defining lifecycle-sensitive keyword rules**
>
> **Planned lifecycle-sensitive governance keyword rules**
>
> 
>
> **Searching Documentation for Validation Terms**
>
>
> **Clarifying governance decision for summaries**
>
> **Clarifying governance decision for summaries**
>
> **Defining decision matrix for evidence span approval**
>
> **Defining decision matrix for evidence span approval**
>
> **Defined governance and evidence approval decision criteria**
>
> 
>
> **Clarifying governance decision for summaries**
>
> **Clarifying governance decision for summaries**
>
> **Defining decision matrix for evidence span approval**
>
> **Defining decision matrix for evidence span approval**
>
> **Defined governance decision and evidence span approval matrix**
>
> 
>
> **Clarifying governance decision for summaries**
>
> **Clarifying governance decision for summaries**
>
> **Defining decision matrix for evidence span approval**
>
> **Defining decision matrix for evidence span approval**
>
> **Establishing nuanced reuse and review rules**
>
> **Establishing nuanced reuse and review rules**
>
> **Established summary governance and evidence reuse review rules**
>
> 
>
> **Clarifying governance decision for summaries**
>
> **Clarifying governance decision for summaries**
>
> **Defining decision matrix for evidence span approval**
>
> **Defining decision matrix for evidence span approval**
>
> **Establishing nuanced reuse and review rules**
>
> **Establishing nuanced reuse and review rules**
>
> **Assigning risk levels and finalizing decision outcomes**
>
> **Assigning risk levels and finalizing decision outcomes**
>
> **Established governance rules and decision matrix for summary evidence reuse**
>
> 
>
> **Clarifying governance decision for summaries**
>
> **Clarifying governance decision for summaries**
>
> **Defining decision matrix for evidence span approval**
>
> **Defining decision matrix for evidence span approval**
>
> **Establishing nuanced reuse and review rules**
>
> **Establishing nuanced reuse and review rules**
>
> **Assigning risk levels and finalizing decision outcomes**
>
> **Assigning risk levels and finalizing decision outcomes**
>
> **Finalizing evidence span statuses and rule enforcement**
>
> **Finalizing evidence span statuses and rule enforcement**
>
> **Finalized governance rules and evidence span decision outcomes**
>
> 
>
> **Searched documentation and uploads for validation details**
>
> 
>
> Worked for 1m 23s

M2 should use a lifecycle-sensitive branch, not treat `manufacturer="all"` as a universal failure.

Approve the two evidence spans as `source_verified` under `author-01`. Then author-adjudicate the operational rules separately with `expert_validated: false`.

| Scenario | M2 decision | Treatment |
|---|---|---|
| Preserve the existing context-group lifecycle | `REUSE_AS_LEGACY_REFERENCE` | Retain/match `manufacturer="all"` and display a medium advisory that the value is no longer recommended. |
| Intentionally remove or replace `all` | `REUSE_WITH_NEW_CONTEXT` | Create a new context group, suspend the old content, and reuse the existing document by identifier. |
| Migration intent is unspecified | `HUMAN_REGULATORY_REVIEW` | The sources do not uniquely determine whether lifecycle preservation or metadata normalization is preferred. |
| Reused document has irrelevant or unverified hyperlinks | `HUMAN_REGULATORY_REVIEW` | Do not approve reuse until hyperlink relevance is established or the document is revised. |

For the canonical Case B fixture, I recommend explicitly setting:

```yaml
migration_intent: normalize_discouraged_metadata
manufacturer_partitioning_required: false
hyperlink_status: relevant_or_none
```

Its expected result becomes:

```yaml
decision: REUSE_WITH_NEW_CONTEXT
repair: CREATE_NEW_CONTEXT_GROUP_AND_SUSPEND_OLD
target_manufacturer_keyword: omitted
reuse_existing_document_identifier: true
severity: medium
```

The important distinction is:

- The recommendation against `all` is `advisory`.
- The lifecycle consequence once the keyword is changed or removed is `hard`.
- The advisory rule must never independently produce a hard failure.

Paste this approval to Codex:

> I approve the two new M2 evidence spans as `source_verified` under reviewer `author-01`, with `expert_validated: false`:
>
> 1. FDA M4 guidance, October 2017, SHA-256 `cc5672cdc3feb352d01c2cbfc823ea6cc3d45e657f3a4ca806cf486b41933cde`, Appendix A, PDF page 25/printed page 22.
> 2. FDA eCTD v4.0 Technical Conformance Guide v1.5, SHA-256 `dccd247940cdf5bc7cbf6a5e31b8f2547ad7f61650ae1a138113feb315f8002e`, §1.5.5, PDF page 12.
>
> Please govern M2 through separate rules:
>
> **Rule M2-A — discouraged general manufacturer value**
>
> - Trigger: the legacy manufacturer value is normalized to `all`.
> - Review status: `author_adjudicated_for_demo`.
> - Verification basis: `direct_standard_encoding`.
> - Bindingness: `nonbinding_recommendation`.
> - Enforcement mode: `advisory`.
> - Severity: `medium`.
> - Effect: report that `all` is not recommended when manufacturer/site/process differentiation is unnecessary.
> - This rule must not independently produce a hard failure, forced metadata change, lifecycle break, or claim of noncompliance.
>
> **Rule M2-B — preserve existing lifecycle**
>
> - Trigger: `manufacturer="all"` and the declared intent is to preserve the existing context-group lifecycle.
> - Decision: `REUSE_AS_LEGACY_REFERENCE`.
> - Require the context-group keywords to continue matching.
> - Preserve the advisory finding from M2-A.
> - Do not describe continued use of `all` as preferred or generally recommended.
>
> **Rule M2-C — normalize metadata**
>
> - Trigger: the declared intent is to remove or replace `manufacturer="all"`.
> - Decision: `REUSE_WITH_NEW_CONTEXT`.
> - Repair: `CREATE_NEW_CONTEXT_GROUP_AND_SUSPEND_OLD`.
> - Reuse the existing document through its identifier when eligible; do not require resubmission of the unchanged physical file or document element.
> - If manufacturer differentiation is unnecessary, omit the optional manufacturer keyword.
> - If differentiation is necessary, require an explicitly supplied stable firm/site/process-distinguishing value; do not have the model invent one.
> - Verification basis: `mechanical_derivation`.
> - Enforcement mode: `hard`, but only after the metadata-change intent is explicit.
>
> **Rule M2-D — hyperlink relevance gate**
>
> - Reuse by identifier is eligible only when existing hyperlinks are relevant to the new context.
> - A model-generated relevance judgment remains a `semantic_signal`, not a hard fact.
> - If hyperlinks are irrelevant, contradictory, or not sufficiently assessed, return `HUMAN_REGULATORY_REVIEW`; do not silently approve reuse.
>
> If migration intent is absent, return `HUMAN_REGULATORY_REVIEW` and present the two supported alternatives rather than choosing one.
>
> For the canonical Case B fixture, set the declared intent to normalize the discouraged metadata, specify that manufacturer partitioning is unnecessary, and use no hyperlinks or hyperlinks already verified as relevant. Its reference decision is `REUSE_WITH_NEW_CONTEXT`, with the manufacturer keyword omitted.
>
> Current FDA forward-compatibility availability must remain `not_operational` throughout the registry, API, UI, evaluation records, paper, and demonstration. These M2 rules execute only within the clearly labeled controlled prospective FDA/CDER scenario.

This makes Case B stronger: the system demonstrates that guidance can influence a recommendation without being misrepresented as a binding prohibition.

## Prompt:
8/29/2026, 9:22:29 PM

Okay, I went with that message, the questions were 3-at-once. Here is the second one:

"**Which author-adjudicated Case B operationalization should the plan use for exact manufacturer="all"?**" - Take into consideration that the previous might answer might have changed how this question should be framed, let me know. but this is the second one.

## Prompt:
8/29/2026, 9:23:17 PM

Okay, I went with that message, the questions were 3-at-once. Here is the second one:

"**Which author-adjudicated Case B operationalization should the plan use for exact manufacturer="all"?**" - Take into consideration that the previous might answer might have changed how this question should be framed, let me know. but this is the second one.

If does have options: "Lifecycle-sensitive", "Advisroy only", and "Always repair", if the answer is out of this, let me know too. Think through it properly.

## Response:
8/29/2026, 9:23:17 PM

> **Selecting Lifecycle-sensitive Answer Option**
>
> **Selecting Lifecycle-sensitive Answer Option**
>
> **Selected a lifecycle-sensitive answer option**
>
> 
>
> Worked for 5s

Choose **Lifecycle-sensitive**.

The previous answer already established this as the governing operationalization. More precisely, `manufacturer="all"` alone generates an advisory finding, while the declared lifecycle intent determines the decision:

- Preserve existing context-group lifecycle → `REUSE_AS_LEGACY_REFERENCE` plus advisory.
- Normalize/remove `all` → `REUSE_WITH_NEW_CONTEXT`.
- Intent unspecified → `HUMAN_REGULATORY_REVIEW`.

So **Advisory only** is incomplete: it correctly describes the status of the FDA recommendation, but ignores the hard lifecycle consequences once the keyword changes.

**Always repair** is unsupported because it would convert a nonbinding recommendation into a mandatory correction.

If you can add a note with the selection, use:

> Select **Lifecycle-sensitive**. Exact `manufacturer="all"` triggers an advisory finding but does not by itself force repair. Preserve it when existing context-group lifecycle continuity is explicitly requested; create a new context group when normalization is explicitly requested; and abstain when that intent is unspecified. Current FDA availability remains `not_operational`.

Thus, the question remains valid, although a more precise formulation would be:

> **How should Case B combine the advisory finding for exact `manufacturer="all"` with context-group lifecycle intent?**

## Prompt:
8/29/2026, 9:26:27 PM

Last question of the 3-at-one batch: "**What decision policy should M2 use for semantic stale-content or hyperlink signals?" options here are "conservative review: clean evidence permits legacy reuse; supported stale or ambiguous signals yield HUMAN\_REGULATORY\_REVIEW with a bounded suggested check, never a hard prohibition or lifecycle break.", "statel needs context: supported statel signals yield REUSE\_WITH\_NEW\_CONTEXT, while ambiguity yields human review", and "Signals only: Display semantic findings but do not let them alter the deterministic resue decision.", I can also add my own. Think through this too**

## Response:
8/29/2026, 9:26:28 PM

> **Defining nuanced semantic signal criteria**
>
> **Defining nuanced semantic signal criteria**
>
> **Defined nuanced semantic signal criteria**
>
> 
>
> Worked for 10s

Choose the first option: **Conservative review**, but tighten its wording slightly.

Use:

> **Conservative review:** Deterministic structural and lifecycle rules establish initial reuse eligibility. If the required semantic inspection is completed and finds no supported stale-content or hyperlink risk, retain that deterministic decision. Supported stale signals, ambiguous relevance, or inadequate inspection yield `HUMAN_REGULATORY_REVIEW` with a bounded suggested check or repair. Semantic signals never independently produce a hard prohibition, lifecycle break, `REUSE_WITH_NEW_CONTEXT`, or compliance determination.

Why:

- `REUSE_WITH_NEW_CONTEXT` does not necessarily solve stale wording or irrelevant hyperlinks; the document itself may require inspection or revision.
- “Signals only” is too weak because it would allow a supported stale hyperlink to be displayed while leaving an unsafe reuse decision unchanged.
- Conservative escalation follows the existing governance: semantic inference may escalate to review but cannot impose definitive regulatory action.

One important nuance: “clean evidence permits legacy reuse” should mean **retain an otherwise-supported deterministic reuse decision**. The semantic model must not independently approve reuse merely because it failed to detect a problem.

For Case C:

- Deterministically eligible + completed inspection + no supported risk → retain `REUSE_AS_LEGACY_REFERENCE`.
- Supported stale content or irrelevant hyperlink → `HUMAN_REGULATORY_REVIEW`.
- Ambiguous relevance or insufficient inspection → `HUMAN_REGULATORY_REVIEW`.
- Suggested action should be bounded, such as “verify hyperlink target,” “compare applicant-name references,” or “revise and reassess”—not an automatic lifecycle decision.

## Prompt:
8/29/2026, 9:39:44 PM

Okay, next set of questions after processing all your answers: "**How should the preserve-existing-lifecycle rule be classified?". Options: "Hard eligibility gate: Use author\_adjudicated\_for\_demo +mechanical\_derivation + hard only for explicit preserve intent, exact keyword matching, and completed clean semantic inspection; it establishes controlled techniacl eligbility, not FDA acceptance", "Contextual advisory: use author\_adjudicated\_for\_demo + author\_interpretation + advisory, with synthesis retaining legacy resue only as a qualified recommendation.", "Synthesis policy: Do not represent M\@-B as a declarative rule; implement the safe outcome only in decision synthesis", I can add my own too.**

## Response:
8/29/2026, 9:39:44 PM

> **Confirming lifecycle rule preservation criteria**
>
> **Confirming lifecycle rule preservation criteria**
>
> **Refining hard eligibility criteria for preservation**
>
> **Refining hard eligibility criteria for preservation**
>
> **Refined lifecycle rule preservation eligibility criteria**
>
> 
>
> **Confirming lifecycle rule preservation criteria**
>
> **Confirming lifecycle rule preservation criteria**
>
> **Refining hard eligibility criteria for preservation**
>
> **Refining hard eligibility criteria for preservation**
>
> **Defining layered eligibility and synthesis rules**
>
> **Defining layered eligibility and synthesis rules**
>
> **Defined layered lifecycle preservation eligibility and synthesis rules**
>
> 
>
> **Confirming lifecycle rule preservation criteria**
>
> **Confirming lifecycle rule preservation criteria**
>
> **Refining hard eligibility criteria for preservation**
>
> **Refining hard eligibility criteria for preservation**
>
> **Defining layered eligibility and synthesis rules**
>
> **Defining layered eligibility and synthesis rules**
>
> **Defined layered lifecycle preservation eligibility and synthesis rules**
>
> 
>
> Worked for 30s

Choose **Hard eligibility gate**, but use a refined version rather than the option exactly as written.

The exact keyword-matching requirement is mechanically derived from the already verified lifecycle passages. Treating the entire preservation path as merely advisory would understate that technical constraint. Keeping it only in synthesis would also make the reasoning less auditable.

Use this wording:

> **Hard controlled-eligibility gate:** Represent M2-B as `author_adjudicated_for_demo` + `mechanical_derivation` + `hard`. It applies only when preservation intent is explicit, required context-group keywords match exactly, all other deterministic eligibility checks pass, and the document has either no hyperlinks or hyperlinks whose relevance has been author-verified for the controlled fixture. A model-only “no problem detected” result cannot independently satisfy the hyperlink-relevance condition. Supported stale signals, ambiguity, or incomplete required inspection instead yield `HUMAN_REGULATORY_REVIEW`. Passing this gate establishes only controlled prospective technical eligibility—not FDA acceptance—and final synthesis may retain `REUSE_AS_LEGACY_REFERENCE` while displaying the separate advisory concerning `manufacturer="all"`.

The resulting separation is:

- Exact keyword matching and lifecycle eligibility → `hard`.
- FDA’s recommendation against general values such as `all` → `advisory`.
- Stale-content or hyperlink inference → `semantic_signal`.
- Final `REUSE_AS_LEGACY_REFERENCE` → synthesized only after every applicable gate passes.

I would not choose **Contextual advisory**, because exact keyword matching is not merely a preference. I would not choose **Synthesis policy**, because hiding the eligibility condition inside synthesis weakens evidence traceability and makes the rule harder to test independently.

## Prompt:
8/30/2026, 12:35:23 PM

While working on M3, I found two evaluation-validity gaps that M3 must resolve before implementation:

1. Twenty-nine of the 30 labels are still `candidate`; I cannot promote them to `author_adjudicated_for_demo` without your explicit author-01 approval.
2. Seven draft “mutations” currently point to unchanged source fixtures, so treating them as independent benchmark cases would inflate the sample size. They need real synthetic fixture variants before freezing.

The proposed author-adjudicated label groups are:

- A001–A005 → `REUSE_WITH_NEW_CONTEXT`, blocking, create/suspend context, human approval required.
- A006–A007 → `REUSE_AS_LEGACY_REFERENCE`, informational, no material repair.
- A008–A009 → `HUMAN_REGULATORY_REVIEW`, unresolved, author-review exact heading mapping.
- A010 → `HUMAN_REGULATORY_REVIEW`, unresolved, wait for operational availability.
- B001/B004 → `REUSE_WITH_NEW_CONTEXT`, blocking, create/suspend context.
- B002/B009 → `REUSE_AS_LEGACY_REFERENCE`, medium, preserve exact keywords while retaining the advisory.
- B003 → `HUMAN_REGULATORY_REVIEW`, declare migration intent.
- B005 → `HUMAN_REGULATORY_REVIEW`, explicitly declare manufacturer partitioning. This also fixes the current misleading fallback repair.
- B006/B008 → `REUSE_AS_LEGACY_REFERENCE`, informational, no material repair.
- B007 → `HUMAN_REGULATORY_REVIEW`, because creating a new target artifact is outside the approved identifier-reuse rule.
- B010 → `HUMAN_REGULATORY_REVIEW`, wait for operational availability.
- C001–C003/C006–C008 → `HUMAN_REGULATORY_REVIEW`, with stale-content or hyperlink-verification repair as applicable.
- C004/C005/C009 → `REUSE_AS_LEGACY_REFERENCE`, informational, no material repair.
- C010 → `HUMAN_REGULATORY_REVIEW`, wait for operational availability.

All remain `expert_validated: false`, use `author-01`, and are controlled prospective reference labels—not FDA acceptance judgments or expert ground truth.

How should M3 handle the proposed 30-case author-adjudicated label matrix above? "Approve Matric: freeze the grouped decisions, severities, repairs, author-01 status, and expert\_validated false as proposed", "Keep candidates: Build the harness but leave M3 scientifically incomplete because aggregate reference-label metrics cannot be released.", "Revise labels: Pause label freezing so you can supply corrections to one or more case groups."?

## Response:
8/30/2026, 12:35:25 PM

I’m checking the actual case definitions and mutation specifications before approving the matrix. The grouped labels are broadly consistent with the policies we locked, but the severity and “human approval required” fields—especially A001–A005 and the Case B preservation variants—must match what the fixtures genuinely encode.

> **Listing Project Files Excluding Build Outputs**
>
>
> **Listed project files excluding build outputs**
>
> 
>
> Worked for 55s

Do not select **Approve Matrix** exactly as written. Use a custom **conditional approval**. If Codex forces one of the three options, select **Revise labels**.

The grouped outcomes are substantively consistent with our policies, but seven cases cannot be author-adjudicated or frozen before their actual decision-relevant mutations exist. Approving labels for unchanged fixtures would validate labels independently of their inputs.

Send Codex:

> I conditionally approve the proposed 30-case matrix as the **target label specification**, not yet as the frozen benchmark.
>
> Before promotion to `author_adjudicated_for_demo`:
>
> 1. Replace the seven unchanged mutation references with genuine synthetic variants that differ in decision-relevant inputs—not merely filenames, IDs, or inconsequential bytes.
> 2. Produce a pre-freeze ledger for all 30 cases containing:
>    - fixture/package hash;
>    - decision-relevant predicates;
>    - exact difference from its source case;
>    - reference decision, severity, and action;
>    - applicable rule and evidence IDs;
>    - human-approval requirement;
>    - split assignment.
> 3. Verify that no two cases presented as independent examples have identical decision-relevant inputs.
> 4. Keep any case whose realized fixture does not support its proposed label as `candidate` and return it for correction.
>
> Subject to those gates, I approve the grouped decisions under `author-01`, with `expert_validated: false`, and the following clarifications:
>
> - A001–A005: `blocking` means that same-context continuation is blocked; document reuse through a new context remains supported. `human_approval_required: true`.
> - B001/B004: because they create a new context group and suspend the old one, also set `human_approval_required: true`.
> - B002/B009: the medium finding is the advisory concerning exact `manufacturer="all"`; it is not a hard compliance failure.
> - C001–C003/C006–C008: record bounded `suggested_check` or `suggested_repair` actions, not automatically executable or mandatory repairs.
> - All `HUMAN_REGULATORY_REVIEW` cases inherently require human review.
> - Availability cases A010/B010/C010 must remain prospective and `not_operational`.
>
> After the ledger passes these checks, promote and freeze the 30 records atomically as controlled prospective reference labels.
>
> The matrix contains only three represented decision classes: `REUSE_WITH_NEW_CONTEXT`, `REUSE_AS_LEGACY_REFERENCE`, and `HUMAN_REGULATORY_REVIEW`. Report class-wise results and macro-F1 only over these represented classes. Do not describe this as evaluation across the complete six-label decision taxonomy.

This preserves the proposed outcomes while ensuring the benchmark cases—not just their intended labels—are genuinely frozen and independently testable.

## Prompt:
8/30/2026, 12:37:45 PM

![65236705-a5ad-4608-923c-1fa269d7c348.png](https://chatgpt.com/backend-api/estuary/content?id=file_000000001bd881f7b480315edaebbfb3&fn=65236705-a5ad-4608-923c-1fa269d7c348.png&cd=attachment&ts=496913&p=fs&cid=1&sig=0980444ec36e1d6f9df1c316508607ce55244f772409baeecfd8371adc1ef6f6&v=0)

Second question

## Response:
8/30/2026, 12:37:47 PM

> **Deciding stratified 4-2-4 split strategy**
>
> **Deciding stratified 4-2-4 split strategy**
>
> **Planning family-aware stratified splitting**
>
> **Planning family-aware stratified splitting**
>
> **Planned family-aware stratified 4-2-4 splitting strategy**
>
> 
>
> **Deciding stratified 4-2-4 split strategy**
>
> **Deciding stratified 4-2-4 split strategy**
>
> **Planning family-aware stratified splitting**
>
> **Planning family-aware stratified splitting**
>
> **Planned family-aware stratified 4-2-4 splitting strategy**
>
> 
>
> **Deciding stratified 4-2-4 split strategy**
>
> **Deciding stratified 4-2-4 split strategy**
>
> **Planning family-aware stratified splitting**
>
> **Planning family-aware stratified splitting**
>
> **Confirming stratified split with family grouping**
>
> **Confirming stratified split with family grouping**
>
> **Planned and confirmed family-aware stratified 4-2-4 splitting**
>
> 
>
> Worked for 24s

Choose **4/2/4 stratified**, with one important refinement: make it **group-aware** to prevent near-duplicate leakage.

Send Codex:

> Use the **4/2/4 stratified policy**: four train, two development, and four held-out test cases per archetype. Materialize all seven virtual perturbations before hashing, adjudication, split freezing, or evaluation.
>
> Additional requirements:
>
> - Stratify by archetype, reference decision, and risk/ambiguity status—not archetype alone.
> - Treat train as a label-visible prompt-development set, not necessarily model-training data.
> - Keep sibling mutations or near-duplicates derived from the same source-fixture family within one split. Do not place superficial variants of the same fixture across train and test.
> - Freeze each realized fixture’s hash, decision-relevant predicates, label, evidence/rule IDs, and split assignment before baseline development begins.
> - Use only train and development cases for prompt construction, threshold selection, retrieval tuning, or debugging.
> - Report the 12 held-out test cases as the headline evaluation.
> - Results across all 30 cases may appear only as a clearly labeled secondary diagnostic, not as the primary performance claim.
> - Describe the test set as **held out**, not independently blinded, unless someone genuinely prevents the developers from seeing it.

Why not the others:

- **6/2/2** leaves only six held-out cases, making final comparisons especially unstable.
- **All-case reporting** allows prompt-development exposure to contaminate the headline result.

The 4/2/4 split remains small, so M3 should emphasize per-case results, class-wise metrics, unsafe false negatives, and confidence intervals—not rely on a single aggregate score.

## Prompt:
8/30/2026, 12:39:04 PM

![0cc0ed56-05a5-444c-aa78-8b487dc7cd82.png](https://chatgpt.com/backend-api/estuary/content?id=file_0000000023ac81f7968a533ad563fdd1&fn=0cc0ed56-05a5-444c-aa78-8b487dc7cd82.png&cd=attachment&ts=496913&p=fs&cid=1&sig=128573c33086a5b1324396b8c28c2fede2d5b57f917e9efd6bd1888a40db5ffd&v=0)

third question

## Response:
8/30/2026, 12:39:05 PM

> **Defining unsafe false negative criteria**
>
> **Defining unsafe false negative criteria**
>
> **Selecting broad unsafe false negative reporting**
>
> **Selecting broad unsafe false negative reporting**
>
> **Defined criteria and reporting for unsafe false negatives**
>
> 
>
> **Defining unsafe false negative criteria**
>
> **Defining unsafe false negative criteria**
>
> **Selecting broad unsafe false negative reporting**
>
> **Selecting broad unsafe false negative reporting**
>
> **Defined broad unsafe false negative reporting criteria**
>
> 
>
> Worked for 19s

Choose **Report both**.

Use the action-required definition as the primary safety metric and the high/blocking subset as a sensitivity analysis. Restricting the primary metric to high/blocking cases would wrongly omit semantic ambiguity and `not_operational` cases where unconditional reuse is unsafe.

Send Codex:

> Select **Report both**.
>
> **Primary unsafe false-negative definition**
>
> Count an unsafe false negative when:
>
> ```text
> reference decision ∈ {
>   REUSE_WITH_NEW_CONTEXT,
>   REUSE_AFTER_METADATA_REPAIR,
>   BREAK_LIFECYCLE_AND_RESUBMIT,
>   DO_NOT_REUSE,
>   HUMAN_REGULATORY_REVIEW
> }
>
> AND
>
> predicted decision = REUSE_AS_LEGACY_REFERENCE
> without a required condition or review
> ```
>
> This measures failure to detect that some intervention, abstention, or contextual change is required.
>
> Report:
>
> ```text
> unsafe FNR =
> unsafe unconditional-reuse misses
> ÷
> reference action-required cases
> ```
>
> Include the raw numerator, denominator, rate, and confidence interval because the test set is small.
>
> **Sensitivity analysis**
>
> Report the same miss rate for only reference cases whose severity is `high` or `blocking`. Do not substitute this narrower result for the primary metric.
>
> Also report a separate **review-bypass rate**:
>
> ```text
> reference = HUMAN_REGULATORY_REVIEW
> AND prediction gives a definitive action without the required review
> ```
>
> A prediction such as `REUSE_WITH_NEW_CONTEXT` for a human-review reference case may not be an unconditional-reuse false negative, but it is still an unsupported review bypass and an exact-decision error.
>
> Keep unsafe false negatives distinct from conservative false positives. Predicting human review for a clean legacy-reuse case may reduce usefulness, but it is not the same safety failure as approving unconditional reuse when action or review was required.

This gives M3 one clear primary safety claim while preserving the narrower severity-based view and capturing unsupported bypass of required human review.

## Prompt:
8/30/2026, 12:44:12 PM

![19c70545-8876-46d9-8685-12d432678bec.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000382881f793fcc4ff1ece4a23&fn=19c70545-8876-46d9-8685-12d432678bec.png&cd=attachment&ts=496913&p=fs&cid=1&sig=076a1a5eb0b05a7746244b440fa07aeb18384a04e5727f78ca515a0b171e2b9f&v=0)

Good, next things. The family-safe 4/2/4 split can be made both leakage-resistant and class-balanced on the 12-case headline test:

- Train: A001/A004/A006/A007; B002/B003/B008/B009; C001/C003/C007/C010.
- Development: A003/A010; B006/B007; C005/C006.
- Held-out test: A002/A005/A008/A009; B001/B004/B005/B010; C002/C004/C008/C009.

The held-out test then has exactly four cases in each represented class: legacy reuse, new context, and human review. Related variants remain together.

The seven real mutations would become: a replacement-lifecycle A004; an append/replacement-lifecycle A005; a valid-heading replacement A007; a distinct unmapped-heading A009; alternate stale-heading language in C007; a stale responsible-applicant statement in C008; and an explicitly benign historical-heading statement in C009. Each will receive a distinct decision fingerprint and package hash. Should I appove the extact family-safe split and seven decision-relevant fixture mutations described?

## Response:
8/30/2026, 12:44:14 PM

> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Verified claim labels and planned minimal-swap class balancing**
>
> 
>
> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Verified claim label distributions and planned minimal-swap class balancing**
>
> 
>
> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Designing pair swaps for balance preservation**
>
> **Designing pair swaps for balance preservation**
>
> **Verified claim labels and designed minimal balancing swaps**
>
> 
>
> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Designing pair swaps for balance preservation**
>
> **Designing pair swaps for balance preservation**
>
> **Reevaluating family grouping and test balance**
>
> **Reevaluating family grouping and test balance**
>
> **Planned minimal pair swaps to balance claim labels and test families**
>
> 
>
> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Designing pair swaps for balance preservation**
>
> **Designing pair swaps for balance preservation**
>
> **Reevaluating family grouping and test balance**
>
> **Reevaluating family grouping and test balance**
>
> **Balancing classes while preserving family pairs**
>
> **Balancing classes while preserving family pairs**
>
> **Balanced claim classes while preserving family pairings**
>
> 
>
> **Verifying claim label distributions**
>
> **Verifying claim label distributions**
>
> **Planning class balancing with minimal swaps**
>
> **Planning class balancing with minimal swaps**
>
> **Designing pair swaps for balance preservation**
>
> **Designing pair swaps for balance preservation**
>
> **Reevaluating family grouping and test balance**
>
> **Reevaluating family grouping and test balance**
>
> **Balancing classes while preserving family pairs**
>
> **Balancing classes while preserving family pairs**
>
> **Balanced claim classes while preserving family pairs**
>
> 
>
> Worked for 53s

Select **Revise assignment**. The proposed held-out test is not actually class-balanced.

Its current counts are:

- `REUSE_WITH_NEW_CONTEXT`: A002, A005, B001, B004 → **4**
- `REUSE_AS_LEGACY_REFERENCE`: C004, C009 → **2**
- `HUMAN_REGULATORY_REVIEW`: A008, A009, B005, B010, C002, C008 → **6**

The seven mutation concepts are reasonable, but the split should not be frozen with the stated 4/4/4 claim.

Send Codex:

> Revise the assignment. I approve the seven proposed mutation concepts conditionally, subject to materialized packages, distinct hashes, decision-relevant fingerprints, and the pre-freeze ledger. I do not approve the proposed split because its held-out distribution is 4 new-context, 2 legacy-reuse, and 6 human-review cases—not 4/4/4.
>
> If the declared fixture-family relationships permit it, the minimal group-preserving correction is to exchange the A006/A007 family with the A008/A009 family:
>
> - Revised train A: `A001/A004/A008/A009`
> - Development A: `A003/A010`
> - Revised test A: `A002/A005/A006/A007`
>
> Keep the proposed B and C assignments unchanged.
>
> The resulting held-out test is:
>
> - New context: A002, A005, B001, B004
> - Legacy reuse: A006, A007, C004, C009
> - Human review: B005, B010, C002, C008
>
> This produces exactly four cases per represented class while keeping A006/A007 and A008/A009 together.
>
> Before freezing, verify this against explicit `fixture_family_id` values. If that exchange would cross a broader source-fixture family, do not force it; instead regenerate the split using group-aware stratification and show the recalculated class table.
>
> Distinct package hashes alone are insufficient. Each of the seven materialized mutations must also demonstrate a genuine decision-relevant change in its fingerprint. C007 and C009 should receive explicit family identifiers because their stale-heading and benign historical-heading formulations may be contrastive relatives.

So: approve the mutation plan conditionally, but revise and recompute the split before freezing.

## Prompt:
8/30/2026, 12:45:51 PM

![bf3f6856-2388-4ee1-bc34-97046cc49340.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000ad4881f797ce88d04e721248&fn=bf3f6856-2388-4ee1-bc34-97046cc49340.png&cd=attachment&ts=496913&p=fs&cid=1&sig=9caee3f9b75940a729089a7e4e2b8acb0a49077a5ea599125dbfe5252901756b&v=0)

## Response:
8/30/2026, 12:45:51 PM

> **Clarifying pipeline validation with fixture baselines**
>
> **Clarifying pipeline validation with fixture baselines**
>
> **Defining offline fixture usage guidelines**
>
> **Defining offline fixture usage guidelines**
>
> **Clarified pipeline validation and defined offline fixture guidelines**
>
> 
>
> Worked for 11s

Choose **Pipeline validation only**.

Deterministic fixture responses are useful for verifying orchestration, schemas, metrics, evidence traces, split enforcement, and table generation—but they are not observations of model behavior.

Send Codex:

> Use deterministic fixture mode for **pipeline validation only**. M3 implementation may complete without live-model credentials, but fixture-mode results must not support model-accuracy, model-comparison, or RegBridge-superiority claims.
>
> Mark every such run:
>
> ```yaml
> run_type: deterministic_fixture_validation
> empirical_model_run: false
> eligible_for_performance_claims: false
> ```
>
> Keep fixture-validation tables visually and structurally separate from experimental results. They may verify:
>
> - evaluation-harness correctness;
> - label and split loading;
> - metric calculations;
> - unsafe-false-negative calculations;
> - evidence and decision-trace serialization;
> - reproducibility and failure handling.
>
> A genuine deterministic **rule-only baseline** may still produce valid experimental results if it executes general rules against held-out fixtures without reading case IDs, reference labels, expected-output files, or fixture-specific answer mappings. Do not confuse that baseline with scripted fixture-mode model responses.
>
> Before the paper makes comparative claims, run the model-dependent systems with declared live models and record model/version, provider, date, parameters, prompt hash, standards snapshot, retrieval configuration, repetitions, failures, and cost. Apply the same frozen held-out cases and information-access policy to every comparable system.

**Require live run** would unnecessarily block engineering completion. **Treat as experiment** would make the eventual evaluation scientifically indefensible.

## Prompt:
8/30/2026, 12:47:19 PM

![50ed2146-40fd-4ca9-9f48-4c648bc1b5a8.png](https://chatgpt.com/backend-api/estuary/content?id=file_000000008ac881f787766417a02a3b56&fn=50ed2146-40fd-4ca9-9f48-4c648bc1b5a8.png&cd=attachment&ts=496913&p=fs&cid=1&sig=7a2161dc4f9ca2318fdfa0712a6e999f375045a391e67d04d1041d3436e9726a&v=0)

## Response:
8/30/2026, 12:47:19 PM

> **Deciding BM25 top-3 retrieval protocol**
>
> **Deciding BM25 top-3 retrieval protocol**
>
> **Defining BM25 query construction and tokenization**
>
> **Defining BM25 query construction and tokenization**
>
> **Defined BM25 retrieval protocol and query tokenization**
>
> 
>
> **Deciding BM25 top-3 retrieval protocol**
>
> **Deciding BM25 top-3 retrieval protocol**
>
> **Defining BM25 query construction and tokenization**
>
> **Defining BM25 query construction and tokenization**
>
> **Defined BM25 query construction and top-three retrieval protocol**
>
> 
>
> Worked for 21s

Choose **BM25 top-3**. It is the strongest transparent lexical baseline here and keeps B1 distinct from the six-span long-context baseline.

Send Codex:

> Freeze **BM25 top-3** for B1.
>
> Use:
>
> ```yaml
> retrieval: BM25
> top_k: 3
> k1: 1.5
> b: 0.75
> idf: log(1 + (N - df + 0.5)/(df + 0.5))
> ```
>
> Protocol requirements:
>
> - Search only the six frozen, source-verified evidence spans.
> - Use fixed span boundaries and hashes.
> - Construct the query from a fixed serialization of the case input.
> - Exclude case IDs, reference labels, expected decisions, rationales, required rule IDs, and acceptable evidence IDs.
> - Apply Unicode normalization and lowercase tokenization while preserving dotted CTD identifiers such as `3.2.S.1.1`.
> - Use no stemming, learned query rewriting, graph traversal, or model-generated query expansion.
> - Rank by descending BM25 score and break exact ties by stable evidence-span ID.
> - Freeze the implementation before evaluating the held-out test set.
> - Log the query, returned span IDs, scores, ordering, corpus hash, and retrieval-configuration hash.
>
> Report retrieval performance separately using evidence recall@3, precision@3, and MRR where a specific relevant span is defined.
>
> BM25 top-5 would expose five of six spans and make B1 too similar to the long-context baseline. TF-IDF top-3 is defensible but less appropriate as the primary lexical baseline for short passages with differing lengths and repeated regulatory terminology.

If embeddings are added later, retain this frozen BM25 top-3 system as the named B1 baseline.

## Prompt:
8/30/2026, 12:50:35 PM

![fa641453-4776-4b33-bcb2-2cc9e5034a07.png](https://chatgpt.com/backend-api/estuary/content?id=file_0000000069f881f59c8b6816ec1e7f16&fn=fa641453-4776-4b33-bcb2-2cc9e5034a07.png&cd=attachment&ts=496913&p=fs&cid=1&sig=8978ebea47f4931ddc01e6c4d4c4f4e273ac09751fd701e3efdef76f4f66ab59&v=0)

Treating C007’s stale-heading formulation and C009’s benign historical-heading formulation as a contrastive family changes the C split. The family-safe corrected assignment is:

- A train A001/A004/A008/A009; development A003/A010; test A002/A005/A006/A007.
- B train B002/B003/B008/B009; development B006/B007; test B001/B004/B005/B010.
- C train C001/C006/C007/C009; development C003/C010; test C002/C004/C005/C008.

Explicit family IDs will bind A001/A004, A002/A005, A006/A007, A008/A009; B001/B004/B005/B010, B002/B003/B009, B006/B007; and C001/C007/C009, C002/C008, C003/C010. Singleton cases retain their own family IDs.

The held-out test remains exactly balanced: four new-context, four legacy-reuse, and four human-review labels. It also keeps the stale-versus-benign heading contrast out of the held-out set, preventing that contrast from leaking across splits. Should I approve this corrected family-aware 4/2/4 assignment as the frozen split target?

## Response:
8/30/2026, 12:50:36 PM

> **Verifying internal family assignments**
>
> **Verifying internal family assignments**
>
> **Assessing family clustering impact on test independence**
>
> **Assessing family clustering impact on test independence**
>
> **Verified family assignments and assessed clustering effects on test independence**
>
> 
>
> **Verifying internal family assignments**
>
> **Verifying internal family assignments**
>
> **Assessing family clustering impact on test independence**
>
> **Assessing family clustering impact on test independence**
>
> **Assessed family assignments and their impact on test independence**
>
> 
>
> **Verifying internal family assignments**
>
> **Verifying internal family assignments**
>
> **Assessing family clustering impact on test independence**
>
> **Assessing family clustering impact on test independence**
>
> **Finalizing conditional approval for family-based split**
>
> **Finalizing conditional approval for family-based split**
>
> **Finalized conditional approval for family-based data splitting**
>
> 
>
> Worked for 25s

Yes—select **Approve corrected split**, subject to the stated validation gates.

The assignment is now internally consistent:

- Every declared family remains within one split.
- Each archetype has 4 train, 2 development, and 4 test cases.
- The held-out test contains:
  - 4 `REUSE_WITH_NEW_CONTEXT`
  - 4 `REUSE_AS_LEGACY_REFERENCE`
  - 4 `HUMAN_REGULATORY_REVIEW`

Send Codex:

> I approve the corrected family-aware 4/2/4 assignment as the frozen split target, using the exact family IDs and assignments proposed.
>
> Freeze it only after:
>
> - all seven mutations are materially realized;
> - package hashes and decision fingerprints are distinct where required;
> - every case belongs to exactly one documented lineage-based family;
> - the pre-freeze ledger validates labels, evidence, rules, repairs, and split assignments;
> - automated checks confirm no family crosses a split;
> - the held-out class counts remain exactly 4/4/4.
>
> Once frozen, test cases and family assignments must not be changed in response to baseline or RegBridge performance. Train and development data alone may be used for prompt, retrieval, or implementation tuning.
>
> Record that the 12 test cases represent only six independent fixture families:
>
> - two A families;
> - one B family;
> - three C families.
>
> Therefore, describe the benchmark as **case-balanced but family-clustered**. Do not imply 12 statistically independent observations. Report raw case-level outcomes and include a family-clustered sensitivity analysis where feasible; avoid strong significance claims from this small test set.

The B test set being one four-case family limits its independent diversity, but it is preferable to leaking related variants across splits. This limitation should simply be disclosed.

## Prompt:
8/30/2026, 12:54:15 PM

PLan for M3 Created:

# M3 — Frozen Benchmark, Baselines, and Evaluation

## Summary

Implement a leakage-resistant 30-case benchmark, B0/B1/B2/RegBridge comparison harness, reproducible metrics, manifests, exports, and API/CLI entry points. The 12 held-out cases are the headline evaluation; all-case results are secondary diagnostics.

Deterministic fixture runs are marked:

- `run_type: deterministic_fixture_validation`
- `empirical_model_run: false`
- `eligible_for_performance_claims: false`

Only the genuine rule-only B2 outputs may be treated as experimental results. No model-comparison or RegBridge-superiority claim is permitted without a later declared live-model run.

## Benchmark realization and atomic freeze

Materialize the seven currently virtual mutations:

- A004: replacement lifecycle under mapped heading `3.2.S.1.1`.
- A005: append/replacement lifecycle variation under `3.2.S.1.2`.
- A007: valid `3.2.S.1` replacement lifecycle.
- A009: distinct unsupported heading such as `3.2.S.1.5`, requiring abstention.
- C007: alternate stale text presenting `3.2.S.1.2` as current guidance.
- C008: stale responsible-applicant statement conflicting with regional metadata.
- C009: explicit benign historical reference that says the old heading is not current guidance.

Freeze these family assignments:

| Split | A families/cases | B families/cases | C families/cases |
|---|---|---|---|
| Train | `a-removed-3211-lifecycle`: A001/A004; `a-unmapped-heading`: A008/A009 | `b-manufacturer-all-preservation`: B002/B003/B009; `b-product-keyword-scope`: B008 | `c-heading-context-contrast`: C001/C007/C009; `c-ambiguous-wording`: C006 |
| Development | `a-removed-3213`: A003; `a-operational-guard`: A010 | `b-specific-manufacturer-scope`: B006/B007 | `c-external-link-operational`: C003/C010 |
| Test | `a-removed-3212-lifecycle`: A002/A005; `a-valid-321-lifecycle`: A006/A007 | `b-manufacturer-all-normalization`: B001/B004/B005/B010 | `c-applicant-mismatch`: C002/C008; `c-clean-current`: C004; `c-relevant-internal-link`: C005 |

The test set must validate as exactly four `REUSE_WITH_NEW_CONTEXT`, four `REUSE_AS_LEGACY_REFERENCE`, and four `HUMAN_REGULATORY_REVIEW` cases across six independent fixture families.

For every case, freeze:

- package, selected-file, target-context, and decision-fingerprint hashes;
- selected leaf and complete decision-relevant predicates;
- exact mutation and lineage;
- reference decision, severity, action, action mode, rule/evidence IDs, and human-review requirement;
- fixture family and split;
- author-01 adjudication event with `expert_validated: false`.

Generate JSON and Markdown pre-freeze ledgers. The freeze command must fail without promotion if a fixture is missing, a mutation has no decision-relevant fingerprint change, two independent cases have identical full fingerprints, a family crosses splits, evidence/rules are unknown, or class counts differ. On success, validate the ledger against the approved label specification and atomically create the frozen benchmark and digest.

Correct the two discovered analyzer gaps before freezing:

- B005 returns `DECLARE_MANUFACTURER_PARTITIONING`, not the unrelated heading-review fallback.
- B007 abstains with `SELECT_SUPPORTED_REUSE_OPERATION` because new-artifact creation is outside the approved identifier-reuse rule.

Semantic HUMAN cases use bounded `suggested_check` actions rather than mandatory or automatically executable repairs.

## Baselines and public interfaces

Introduce typed `BenchmarkCase`, `CaseInput`, `SystemPrediction`, `RetrievalTrace`, `EvaluationRun`, and `MetricsReport` contracts. Reference labels must never enter `CaseInput`, prompts, retrieval queries, or analyzers.

Implement:

- **B0:** direct model decision from all six hashed source-verified evidence spans plus bounded case material; no graph or executable rules.
- **B1:** dependency-free BM25 over only those six spans using `top_k=3`, `k1=1.5`, `b=0.75`, and the approved IDF formula. Use NFKC/casefold tokenization, preserve dotted CTD identifiers, and break ties by evidence ID. Log the label-free query, scores, ordering, corpus hash, and configuration hash.
- **B2:** production parser, graph facts, and deterministic rules with semantic analysis intentionally omitted. Semantic omission must not itself cause abstention; deterministic hyperlink and operational guards still apply.
- **RegBridge:** the complete existing hybrid pipeline.

B0 and B1 share one direct-decision output schema, model, temperature zero, 16,000-character input limit, and 800-token output limit. RegBridge uses its evidence-bounded semantic schema; this unavoidable difference is recorded in the manifest.

Move fixture lookup keys out of serialized model requests so case or fixture IDs cannot leak into prompts. Synthetic B0/B1/RegBridge responses are explicitly tagged as contract fixtures, never empirical model observations.

Add:

- `POST /api/v1/baselines/run` for a named system and frozen case.
- `POST /api/v1/evaluations` for an allowlisted evaluation configuration.
- `GET /api/v1/evaluations/{id}` with explicit queued/running/completed/failed state, metrics, cases, and artifact identifiers.
- Concurrency limit of one evaluation and no arbitrary paths or shell arguments.
- `.\scripts\evaluate.ps1` and `make evaluate` as the one-command deterministic evaluation entry points.

Keep the full comparison dashboard in M4; M3 adds schemas, API contracts, scope disclosures, and machine-readable outputs.

## Evaluation, metrics, and artifacts

Evaluate systems without label access, then join predictions to labels only inside the scorer.

Primary unsafe false-negative rate:

```text
reference decision requires any action, context change, repair, non-reuse, or review
AND prediction is unconditional REUSE_AS_LEGACY_REFERENCE
```

Report numerator, denominator, rate, and 95% Wilson interval. Also report:

- the same rate restricted to high/blocking reference severity;
- review-bypass rate where a HUMAN reference receives a definitive prediction without required review;
- conservative false positives separately;
- per-class precision/recall/F1 and macro-F1 over only the three represented classes;
- accuracy and balanced accuracy;
- heading-mapping, evidence-citation, repair/action, and abstention accuracy;
- BM25 recall@3, precision@3, and MRR;
- latency, failures, requests, tokens, and nullable cost;
- calibration only when meaningful, otherwise a recorded not-applicable reason.

Report case-level results and family-clustered sensitivity. Use the six test families as clusters, show family-level unsafe-miss counts, and use a stable-seed cluster bootstrap for exploratory intervals. Make no independence or significance claims.

Each run writes:

- manifest JSON with source-tree, benchmark, standards, evidence, rule, graph, prompt, retrieval, and configuration digests;
- raw JSONL predictions and retrieval traces;
- per-case CSV, metrics JSON/CSV, and Markdown summary;
- separately labeled validation tables under `results/validation/` and `paper/tables/validation/`.

Headline tables use only the 12 held-out cases. All-30 tables are labeled secondary diagnostics. Fixture validation outputs are physically and visually separated from future live experimental results.

## Tests and completion criteria

Add tests for:

- all seven realized mutations, package hashes, decision fingerprints, lineage, and visual PDF integrity;
- all 30 frozen labels, exact split/family assignments, 4/4/4 test balance, six test families, and atomic freeze failure behavior;
- prompt/query leakage of case IDs, labels, rationales, rules, and expected evidence;
- BM25 tokenization, formula, stable ties, rankings, logs, and retrieval metrics;
- all four systems through one runner, including expected B2 semantic misses;
- B005/B007 corrective behavior and B2’s non-semantic policy;
- unsafe-FNR, review-bypass, macro-F1, Wilson intervals, and family-clustered sensitivity;
- run-manifest reproduction with fixed clock/seed and deterministic content digests;
- API validation, job states, concurrency, path rejection, and OpenAPI/schema drift;
- network-free fixture evaluation and redacted live-model failures.

M3 is complete when `check` passes and one evaluation command produces auditable outputs for all four systems, a second run reproduces prediction/metric content digests, current FDA availability remains `not_operational`, all labels remain non-expert-validated controlled prospective labels, and no held-out result has influenced prompts, retrieval, rules, or split assignments.

All good

## Response:
8/30/2026, 12:54:15 PM

> **Identifying ambiguity in A005 lifecycle operation**
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarified A005 lifecycle operation and append versus replacement rules**
>
> 
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Clarified A005 lifecycle rules and reviewed fingerprint evaluation metrics**
>
> 
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Clarified A005 lifecycle rules and reviewed fingerprint evaluation consistency**
>
> 
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Listing precise plan correction recommendations**
>
> **Listing precise plan correction recommendations**
>
> **Clarified A005 lifecycle rules and recommended plan corrections**
>
> 
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Identifying ambiguity in A005 lifecycle operation**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Clarifying append vs replacement lifecycle rules**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Reviewing fingerprint consistency and evaluation metrics**
>
> **Listing precise plan correction recommendations**
>
> **Listing precise plan correction recommendations**
>
> **Highlighting missing manual author-01 approval step**
>
> **Highlighting missing manual author-01 approval step**
>
> **Clarified A005 lifecycle rules, fingerprint metrics, and approval corrections**
>
> 
>
> Worked for 41s

The M3 plan is strong and consistent with the decisions made. I would approve it after five small corrections:

1. **Require final author approval after ledger generation.**  
   The freeze command should stop after producing the pre-freeze ledger. Codex must not create the `author-01` adjudication event automatically. You must explicitly approve the realized ledger before promotion and atomic freezing.

2. **Disambiguate A005.**  
   “Append/replacement lifecycle variation” is unclear. Specify one selected-leaf operation—or explicitly define multiple leaves, their operations, and the predecessor relationship. The decision fingerprint must identify the exact operation being analyzed.

3. **Remove the independence claim.**  
   Replace “six independent fixture families” with:

   > six non-overlapping held-out fixture families

   The later statement that no independence claims will be made is correct.

4. **Forbid silent input truncation.**  
   B0/B1 should use identical case serialization and fixed evidence ordering. If the 16,000-character limit is exceeded, fail validation rather than silently truncate evidence. Alternatively, define and freeze an explicit span-boundary truncation policy before evaluation.

5. **Keep B2 tests implementation-general.**  
   “Expected B2 semantic misses” must be tested through rule behavior and missing semantic capability—not case-ID-specific expected-output mappings.

You can tell Codex:

> Approve the M3 plan with the five corrections above. In particular, generate and validate the pre-freeze ledger, then pause for explicit `author-01` approval before creating adjudication events or freezing the benchmark.

With those adjustments, the plan is methodologically sound for M3 and keeps fixture validation clearly separated from the later live-model experiment.

## Prompt:
8/30/2026, 1:17:14 PM

It paused, and I approved it.

## Response:
8/30/2026, 1:17:19 PM

Good—that satisfies the required human governance gate. Codex can now promote the validated records to `author_adjudicated_for_demo`, record `author-01` with `expert_validated: false`, and atomically freeze the benchmark.

The frozen ledger, benchmark digest, family assignments, fixture hashes, and split configuration should now remain immutable. Any later correction should create a new benchmark version rather than modifying this frozen one.

## Prompt:
8/31/2026, 8:48:40 AM

For M3, did you mean actual RAG among the baselines or something else?

## Response:
8/31/2026, 8:48:41 AM

> **Clarifying B1 retrieval-augmented generation setup**
>
> **Clarifying B1 retrieval-augmented generation setup**
>
> **Clarified the B1 retrieval-augmented generation setup**
>
> 
>
> Worked for 12s

Yes—B1 is intended to be an **actual RAG baseline**, specifically lexical RAG rather than embedding-based RAG.

Its live pipeline is:

```text
Case input
→ fixed label-free query
→ BM25 retrieval over six evidence spans
→ top three passages
→ LLM structured decision
```

The baselines differ as follows:

| System | Evidence access | Reasoning mechanism |
|---|---|---|
| B0 | All six spans supplied directly | LLM only; long-context baseline |
| B1 | BM25 retrieves top three spans | LLM over retrieved evidence; actual flat RAG |
| B2 | Graph facts and deterministic rules | No LLM semantic analysis |
| RegBridge | Versioned graph, rules and bounded retrieval | Hybrid deterministic + LLM reasoning |

Two important distinctions:

- RAG does not require embeddings or a vector database. BM25 retrieval followed by LLM generation is genuine sparse/lexical RAG.
- During deterministic fixture mode, BM25 retrieval is real and its retrieval metrics are valid, but the canned generation response is not empirical LLM performance. B1 becomes a complete experimental RAG baseline only during the later declared live-model run.

So M3 builds the real B1 RAG architecture now; fixture mode validates it offline, and the live-model run later provides publishable end-to-end B1 results.

## Prompt:
8/31/2026, 8:49:59 AM

The GitHub repo has the new M3 implementation, you can check it out if need. Here is the Summary of the implementation and it's execution: "# M3 deterministic fixture validation 
 
> These outputs are `deterministic_fixture_validation`, not empirical model results, and are ineligible for RegBridge-superiority or model-performance claims. Only B2 is a genuine rule-only experimental output. FDA availability remains `not_operational`. 
 
Labels are controlled prospective `author_adjudicated_for_demo` research labels with `expert_validated: false`. 
 
## Headline: 12 held-out cases 
 
| System | Unsafe FNR (n/N) | 95% Wilson interval | Review bypass | Macro-F1 | Accuracy | 
|---|---:|---:|---:|---:|---:| 
| B0 | 0.000 (0/8) | 0.000-0.324 | 0.000 | 1.000 | 1.000 | 
| B1 | 0.000 (0/8) | 0.000-0.324 | 0.000 | 0.915 | 0.917 | 
| B2 | 0.250 (2/8) | 0.071-0.591 | 0.500 | 0.822 | 0.833 | 
| RegBridge | 0.000 (0/8) | 0.000-0.324 | 0.000 | 1.000 | 1.000 | 
 
Family-clustered intervals are exploratory. No independence or significance claims are made. 
All six non-overlapping held-out families are included in cluster resampling; zero-denominator replicates are omitted. 
 
| System | Held-out family | Unsafe misses | Action-required cases | 
|---|---|---:|---:| 
| B0 | a-removed-3212-lifecycle | 0 | 2 | 
| B0 | a-valid-321-lifecycle | 0 | 0 | 
| B0 | b-manufacturer-all-normalization | 0 | 4 | 
| B0 | c-applicant-mismatch | 0 | 2 | 
| B0 | c-clean-current | 0 | 0 | 
| B0 | c-relevant-internal-link | 0 | 0 | 
| B1 | a-removed-3212-lifecycle | 0 | 2 | 
| B1 | a-valid-321-lifecycle | 0 | 0 | 
| B1 | b-manufacturer-all-normalization | 0 | 4 | 
| B1 | c-applicant-mismatch | 0 | 2 | 
| B1 | c-clean-current | 0 | 0 | 
| B1 | c-relevant-internal-link | 0 | 0 | 
| B2 | a-removed-3212-lifecycle | 0 | 2 | 
| B2 | a-valid-321-lifecycle | 0 | 0 | 
| B2 | b-manufacturer-all-normalization | 0 | 4 | 
| B2 | c-applicant-mismatch | 2 | 2 | 
| B2 | c-clean-current | 0 | 0 | 
| B2 | c-relevant-internal-link | 0 | 0 | 
| RegBridge | a-removed-3212-lifecycle | 0 | 2 | 
| RegBridge | a-valid-321-lifecycle | 0 | 0 | 
| RegBridge | b-manufacturer-all-normalization | 0 | 4 | 
| RegBridge | c-applicant-mismatch | 0 | 2 | 
| RegBridge | c-clean-current | 0 | 0 | 
| RegBridge | c-relevant-internal-link | 0 | 0 | 
 
## Secondary diagnostic: all 30 cases 
 
| System | Unsafe FNR | Macro-F1 | Accuracy | 
|---|---:|---:|---:| 
| B0 | 0.000 | 1.000 | 1.000 | 
| B1 | 0.000 | 0.877 | 0.900 | 
| B2 | 0.217 | 0.855 | 0.833 | 
| RegBridge | 0.000 | 1.000 | 1.000 | 
"

## Response:
8/31/2026, 8:49:59 AM

> **Assessing M3 implementation validity**
>
> **Assessing M3 implementation validity**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Assessed M3 implementation and validated B1/B2 fixture metrics**
>
> 
>
> **Assessing M3 implementation validity**
>
> **Assessing M3 implementation validity**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Assessed M3 implementation and validated B1/B2 fixture metrics**
>
> 
>
> **Assessing M3 implementation validity**
>
> **Assessing M3 implementation validity**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Recommending M3 audit and test validations**
>
> **Recommending M3 audit and test validations**
>
> **Assessed M3 validity and recommended audit and fixture validations**
>
> 
>
> **Assessing M3 implementation validity**
>
> **Assessing M3 implementation validity**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Validating B1 and B2 fixture performance metrics**
>
> **Recommending M3 audit and test validations**
>
> **Recommending M3 audit and test validations**
>
> **Clarifying result presentation and audit recommendations**
>
> **Clarifying result presentation and audit recommendations**
>
> **Assessed M3 implementation, validated fixture metrics, and recommended audits**
>
> 
>
> Worked for 1m 5s

M3 looks methodologically disciplined. The results behave exactly as the benchmark was designed to test.

The defensible empirical finding is:

> On the 12 held-out controlled cases, B2 correctly classified 10/12 cases but unconditionally reused both applicant-mismatch cases that required human review, producing an unsafe FNR of 2/8 and a review-bypass rate of 2/4.

Because both errors belong to one fixture family, present this as evidence of a specific rule-only semantic blind spot—not an estimate of its real-world prevalence.

A few presentation safeguards:

- Rename “Headline” to **M3 harness validation** until live-model results exist.
- Add a `Result status` column:
  - B0/B1/RegBridge: `fixture validation only`
  - B2: `genuine deterministic experimental output`
- Do not place B0/RegBridge’s perfect fixture scores in the paper’s empirical results table. They only confirm that the harness and contracts execute correctly.
- B1’s end-to-end 0.917 accuracy is also non-empirical. However, its actual BM25 retrieval metrics—recall@3, precision@3 and MRR—are valid retrieval measurements and should appear separately.
- Keep the Wilson calculations for testing the scorer, but do not interpret intervals for canned outputs.
- Report B2’s family-level result too: unsafe misses occurred in one of the three held-out families containing action-required cases.

The next publishable experiment is the declared live-model run using the frozen benchmark. Use the same base model for B0, B1 and RegBridge’s semantic component where possible, so the principal difference is architecture rather than model capability.

I can assess the summary confidently, but a code-level audit would require the repository URL plus the exact branch or commit used for this run.

## Prompt:
8/31/2026, 6:27:01 PM

I realized RegBridge cannot currently record a semantic finding that cites metadata. RegBridge's B003 response cited `case-evidence-001`, the `manufacturer="all"` metadata. That's the **correct** citation: M2-A is a manufacturer-keyword rule, so a finding about it should cite the keyword evidence. The graph then refused it, because `CITES` permits `MODEL_FINDING → DOSSIER_EVIDENCE` only, and metadata lives in `KEYWORD` nodes.

So this isn't a model failure or a validation catch. It's a **representational gap in your graph contract**: RegBridge structurally cannot record a semantic finding about metadata. Since Case B is your entire metadata archetype, RegBridge would fail on that family every time.

## Response:
8/31/2026, 6:27:02 PM

> **Assessing graph model citations**
>
> **Assessing graph model citations**
>
> **Planning graph schema version update**
>
> **Planning graph schema version update**
>
> **Assessed graph model citations and planned schema version update**
>
> 
>
> **Assessing graph model citations**
>
> **Assessing graph model citations**
>
> **Planning graph schema version update**
>
> **Planning graph schema version update**
>
> **Assessed graph model citations and planned schema version update**
>
> 
>
> **Assessing graph model citations**
>
> **Assessing graph model citations**
>
> **Planning graph schema version update**
>
> **Planning graph schema version update**
>
> **Refining evidence citation model**
>
> **Refining evidence citation model**
>
> **Assessed graph citations and refined the evidence model for schema updates**
>
> 
>
> **Assessing graph model citations**
>
> **Assessing graph model citations**
>
> **Planning graph schema version update**
>
> **Planning graph schema version update**
>
> **Refining evidence citation model**
>
> **Refining evidence citation model**
>
> **Designing schema migration for evidence IDs**
>
> **Designing schema migration for evidence IDs**
>
> **Planned graph schema updates and refined evidence citation migration**
>
> 
>
> Worked for 39s

You are correct. This is a graph-contract defect, and M3 should not be considered fully validated until it is corrected.

The right fix is not simply allowing:

```text
MODEL_FINDING → CITES → KEYWORD
```

That would conflate the subject of a finding with the evidence supporting it. A normalized `KEYWORD` node represents a regulatory concept/value; it is not the actual dossier occurrence the model inspected.

The graph should represent both:

```text
MODEL_FINDING ──ABOUT──> KEYWORD
MODEL_FINDING ──CITES──> METADATA_EVIDENCE
METADATA_EVIDENCE ──OBSERVES──> KEYWORD
```

A metadata-evidence node should contain:

```yaml
type: METADATA_EVIDENCE
field: manufacturer
raw_value: all
normalized_value: all
owner_context_group: ...
source_file: ...
xml_locator: ...
source_hash: ...
parser_provenance: ...
```

Send Codex:

> Confirmed: this is a representational gap, not a model error. Implement metadata occurrences as evidence-bearing nodes.
>
> - Add `METADATA_EVIDENCE` as an evidence subtype, or expand `DOSSIER_EVIDENCE` into a discriminated evidence union containing document, metadata and structural evidence.
> - Keep normalized `KEYWORD` nodes separate.
> - Permit `FINDING → CITES → EVIDENCE_ITEM`.
> - Add `FINDING → ABOUT → KEYWORD`.
> - Link `METADATA_EVIDENCE → OBSERVES → KEYWORD`.
> - Do not broadly permit `CITES → KEYWORD`.
> - Evidence IDs supplied to models must resolve to exact dossier occurrences with raw value, owner, locator and provenance—not merely normalized ontology concepts.
>
> Treat this as a versioned graph-schema correction. Do not overwrite the frozen M3 artifacts. Create a new graph/benchmark build manifest and rerun deterministic validation while retaining the previous run for auditability. The labels, families and split assignments remain unchanged unless their evidence-ID records must be migrated.
>
> Add regression tests proving:
>
> 1. B003 can cite its manufacturer metadata successfully.
> 2. Every Case B metadata finding can be committed to the graph.
> 3. A direct `CITES → KEYWORD` edge remains invalid.
> 4. A finding about a keyword without occurrence-level evidence is rejected.
> 5. Invented or unknown metadata-evidence IDs are rejected.
> 6. The model receives metadata evidence without receiving reference labels.
> 7. The corrected graph produces reproducible content digests across two runs.

If `case-evidence-001` currently identifies a `KEYWORD`, do not silently repurpose it if node types are contractually stable. Introduce an occurrence-level evidence ID and record an explicit migration mapping in the new manifest.

The present B0/B1 fixture tables and B2 results are not automatically invalidated, but RegBridge’s M3 validation result must be regenerated. Its previous perfect fixture score cannot be treated as successful end-to-end contract validation because the graph could not represent a valid Case B finding.

## Prompt:
8/31/2026, 6:42:43 PM

Got this back: "One graph-contract detail needs clarification before implementation:

Should the new `ABOUT` edge be:

- `MODEL_FINDING → KEYWORD` — while `CITES` remains `MODEL_FINDING → DOSSIER_EVIDENCE` occurrence, or
- `DOSSIER_EVIDENCE → KEYWORD` — linking the occurrence to its normalized concept?

I infer the first: the finding cites an exact occurrence and is about a normalized keyword concept. This best matches your governance language and keeps direct `CITES → KEYWORD` invalid.

The retry instruction clearly supersedes the earlier broader retry policy, so there is no contradiction there: only transport/API failures will remain retryable; schema, citation, persistence, synthesis, and graph failures will halt immediately."

## Response:
8/31/2026, 6:42:43 PM

> **Clarifying distinct graph edge relationships**
>
> **Clarifying distinct graph edge relationships**
>
> **Clarified distinct graph edge relationships**
>
> 
>
> Worked for 11s

Your inference is correct: use `MODEL_FINDING → ABOUT → KEYWORD`.

Also retain the occurrence-to-concept relationship, but give it a different edge type:

```text
MODEL_FINDING ──CITES──> METADATA_EVIDENCE
MODEL_FINDING ──ABOUT──> KEYWORD
METADATA_EVIDENCE ──OBSERVES──> KEYWORD
```

These edges express different facts:

- `CITES`: the exact dossier occurrence supporting the finding.
- `ABOUT`: the normalized concept the finding concerns.
- `OBSERVES`: the keyword/value represented by that metadata occurrence.

Send Codex:

> Implement the first interpretation:
>
> ```text
> MODEL_FINDING → ABOUT → KEYWORD
> ```
>
> Additionally implement:
>
> ```text
> METADATA_EVIDENCE → OBSERVES → KEYWORD
> ```
>
> Therefore, B003 should produce:
>
> ```text
> finding
>   ├── CITES ──> manufacturer metadata occurrence
>   └── ABOUT ──> normalized manufacturer="all" keyword
>
> metadata occurrence
>   └── OBSERVES ──> normalized manufacturer="all" keyword
> ```
>
> `CITES → KEYWORD` remains invalid. An `ABOUT` edge alone is also insufficient: a finding must still cite occurrence-level evidence.
>
> Add an integrity check requiring the keyword targeted by `ABOUT` to agree with the keyword observed by the cited metadata evidence for this rule, unless an explicitly supported cross-concept relationship exists.
>
> If the graph has a general `FINDING` supertype, allow `ABOUT` from that type so rule and model findings can share the contract. Otherwise, keep the immediate M3 scope as `MODEL_FINDING → KEYWORD`.
>
> Your retry interpretation is also correct. Only transport/API failures are retryable. Schema, citation, graph, persistence and synthesis failures must halt immediately, roll back partial writes, and return an auditable non-retryable failure.

This preserves the crucial separation between what the finding is **about** and what evidence it **cites**.

## Prompt:
9/1/2026, 11:35:06 AM

Implemented and verified. Phase 1 is complete; Phase 2 was not started.

Key outcomes:

- Graph schema v2 now enforces:
  - `MODEL_FINDING → CITES → DOSSIER_EVIDENCE`
  - `MODEL_FINDING → ABOUT → KEYWORD`
  - `DOSSIER_EVIDENCE → OBSERVES → KEYWORD`
- `CITES → KEYWORD` and occurrence-free `ABOUT` findings are rejected.
- `ABOUT` and `OBSERVES` keyword targets must agree.
- B003’s untouched first response now replays successfully against the corrected graph.
- All ten Case B metadata findings commit successfully.
- Case A/C evidence uses the same occurrence-level contract without an analogous domain/range gap.
- Only transport/API failures retry. Schema, citation, graph, persistence, and synthesis failures halt immediately with rollback and an explicit cause.
- Direct-contract `unresolved` severity is intentional. Only `SemanticFinding` is restricted to informational/low/medium/high.

Phase 1 completed with 54/54 valid outcomes, zero retries, zero invalid outputs, zero ceiling hits, and zero tested identifier leaks across 52 provider attempts. B2 was freshly rescored without model calls.

| SystemAccuracy\*Macro-F1\*Unsafe-FNRReview bypassOutside classes |       |       |      |      |      |
| ---------------------------------------------------------------- | ----- | ----- | ---- | ---- | ---- |
| B0                                                               | 0.833 | 0.820 | 0/15 | 0/10 | 1/18 |
| B1                                                               | 0.611 | 0.502 | 0/15 | 1/10 | 0/18 |
| RegBridge                                                        | 0.889 | 0.866 | 0/15 | 0/10 | 0/18 |
| B2                                                               | 0.833 | 0.864 | 3/15 | 3/10 | 0/18 |

\*Development diagnostics only—not acceptance criteria or performance claims.

| SystemReasoning tokens min / median / p95 / maxCost |                         |           |
| --------------------------------------------------- | ----------------------- | --------- |
| B0                                                  | 516 / 516 / 1552 / 1552 | $0.609325 |
| B1                                                  | 516 / 516 / 1543 / 1543 | $0.586645 |
| RegBridge                                           | 19 / 179 / 516 / 516    | $0.212845 |

Total cost: **$1.408815**.

The pre-committed formula yields a proposed Phase 2 cap of **4,000 tokens**: `(2 × 1552) + 800 = 3904`, rounded with the 4,000 floor. It remains unapproved.

Verification:

- Backend: 165 tests passed.
- Ruff, mypy across 76 source files, and schema-drift checks passed.
- Frontend: lint and typecheck passed; 4 Vitest tests passed; production build passed.
- Deterministic validation reproduced identical prediction, metric, and graph digests twice.
- Frozen benchmark digest remains `9b1e94fd…fc75`.
- Prior v1 validation artifacts were not rewritten.
- FDA availability remains `not_operational`; `expert_validated` remains false.

[Attachment: attempts.jsonl]

[Attachment: attempts.partial.jsonl]

[Attachment: b2-contract-rescore.json]

[Attachment: completion-audit.json]

[Attachment: COMPLETION-AUDIT.md]

[Attachment: manifest.json]

[Attachment: manifest.partial.json]

[Attachment: metrics.json]

[Attachment: metrics.partial.json]

[Attachment: per-case.csv]

[Attachment: per-case.partial.csv]

[Attachment: predictions.jsonl]

[Attachment: predictions.partial.jsonl]

[Attachment: REPORTING-AMENDMENT.json]

[Attachment: retrieval.jsonl]

[Attachment: retrieval.partial.jsonl]

[Attachment: summary.md]

[Attachment: summary.partial.md]

## Response:
9/1/2026, 11:35:20 AM

I’ll verify the audit trail rather than relying only on the summary—especially the 18-case development scope, the 54 model outcomes versus 52 provider attempts, the “outside classes” handling, retry accounting, and whether the proposed 4,000-token Phase 2 cap follows the pre-committed rule without using held-out results.

The audit supports the core claim: Phase 1 used live model calls on train/development only, while the held-out split was not loaded. I’m checking two remaining points before recommending Phase 2 approval: whether the single 4,000-token cap preserves cross-system fairness, and whether the manifest cleanly distinguishes the executed configuration from the later reporting-only amendment.

> **Reviewing Completion Audit Reports**
>
>
> **Verifying capacity calculation formula**
>
> **Verifying capacity calculation formula**
>
> **Verified capacity calculation formula**
>
> 
>
> **Reviewed completion audit reports**
>
> 
>
> **Inspecting Benchmark Manifest and Outputs**
>
>
> **Assessing Phase2 token cap approval**
>
> **Assessing Phase2 token cap approval**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Assessed Phase2 token cap approval and reviewed baseline configuration requirements**
>
> 
>
> **Assessing Phase2 token cap approval**
>
> **Assessing Phase2 token cap approval**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Assessed Phase2 token cap approval and reviewed baseline requirements**
>
> 
>
> **Assessing Phase2 token cap approval**
>
> **Assessing Phase2 token cap approval**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Recommended Phase2 token cap approval with execution conditions**
>
> 
>
> **Assessing Phase2 token cap approval**
>
> **Assessing Phase2 token cap approval**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Advising precommitment of triple Phase2 runs**
>
> **Advising precommitment of triple Phase2 runs**
>
> **Approved Phase2 token cap with baseline checks and triple-run precommitment**
>
> 
>
> **Assessing Phase2 token cap approval**
>
> **Assessing Phase2 token cap approval**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Reviewing baseline metrics and configuration requirements**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Recommending Phase2 cap approval with execution conditions**
>
> **Advising precommitment of triple Phase2 runs**
>
> **Advising precommitment of triple Phase2 runs**
>
> **Summarizing Phase1 results and Phase2 approval conditions**
>
> **Summarizing Phase1 results and Phase2 approval conditions**
>
> **Recommended Phase2 cap approval with execution conditions**
>
> 
>
> **Inspected benchmark manifest, predictions, retrievals, and outputs**
>
> 
>
> Worked for 2m 26s

Phase 1 passes the methodological checks. The 54 outcomes versus 52 provider attempts is coherent because RegBridge resolved A010 and C010 deterministically without model calls. The graph-v2 correction is now properly validated.

I would approve the **4,000-token Phase 2 cap**. The calculation follows the pre-committed rule, applies one ceiling across B0, B1 and RegBridge, and comfortably exceeds the largest Phase 1 output.

Before starting Phase 2, freeze these conditions:

- `max_output_tokens: 4000` per live call.
- Final structured answer limit remains 800 tokens.
- Same reasoning effort, prompts, schemas, evidence, BM25 configuration and graph-v2 contract.
- Pin `gpt-5.5-2026-04-23` if the endpoint supports that snapshot; otherwise record the resolved model version.
- Freeze and approve a new post-amendment configuration digest. Do not reuse the old execution digest.
- Any ceiling, schema, graph, citation or synthesis failure counts as a failed outcome—no retry and no post-test cap increase.
- Keep labels inaccessible until scoring.
- Do not tune anything after the held-out run begins.

One remaining policy should be frozen now: model repetition. Because temperature is unsupported and the held-out set contains only 12 cases, I recommend **three independent Phase 2 runs** for B0, B1 and RegBridge; B2 runs once because it is deterministic. Report each run, mean/range across runs and decision consistency. Treat majority-vote results only as secondary.

You can send Codex:

> I approve Phase 1 as complete and approve a Phase 2 per-call `max_output_tokens` cap of 4,000, with the 800-token structured-answer limit unchanged. Create and present the final post-amendment Phase 2 manifest and configuration digest before loading the held-out split.
>
> Freeze three independent live runs for B0, B1 and RegBridge, with no intervening changes; run B2 once. Ceiling or non-transport failures are final recorded failures and must not trigger retries or a cap increase. No held-out result may influence prompts, retrieval, graph rules, schemas or configuration.

The development diagnostics are encouraging but correctly non-claim-bearing: RegBridge eliminated the semantic safety misses seen in B2 while using substantially fewer reasoning tokens, and B1’s weak retrieval explains much of its lower accuracy. Phase 2 is what determines whether those patterns survive held-out evaluation.

## Prompt:
9/1/2026, 12:34:00 PM

Done: "Phase 2 completed successfully under the frozen configuration: 108/108 live outcomes, zero retries, invalid outputs, truncations, audit failures, or digest mismatches.

### Held-out results

| SystemRepAccuracyMacro-F1Unsafe-FNRReview bypassOutside class |      |      |      |     |     |      |
| ------------------------------------------------------------- | ---- | ---- | ---- | --- | --- | ---- |
| B0                                                            | 1    | .583 | .641 | 0/8 | 1/4 | 3/12 |
| B0                                                            | 2    | .500 | .556 | 0/8 | 1/4 | 3/12 |
| B0                                                            | 3    | .417 | .504 | 0/8 | 1/4 | 4/12 |
| B1                                                            | 1    | .500 | .556 | 0/8 | 1/4 | 3/12 |
| B1                                                            | 2    | .417 | .448 | 0/8 | 1/4 | 3/12 |
| B1                                                            | 3    | .500 | .556 | 0/8 | 0/4 | 3/12 |
| RegBridge                                                     | 1    | .917 | .915 | 0/8 | 0/4 | 0/12 |
| RegBridge                                                     | 2    | .917 | .915 | 0/8 | 0/4 | 0/12 |
| RegBridge                                                     | 3    | .917 | .915 | 0/8 | 0/4 | 0/12 |
| B2                                                            | once | .833 | .822 | 2/8 | 2/4 | 0/12 |

No majority vote or pooled prediction was calculated. Although B0/B1 had zero unsafe misses, their review-bypass results remain equally important; unsafe-FNR alone is not a complete safety assessment.

All outside-class predictions were `REUSE_AFTER_METADATA_REPAIR`:

- B0: 25%–33.3%; sensitivity-only accuracy excluding them: .625–.778.
- B1: 25% each repetition; sensitivity-only accuracy: .556–.667.
- RegBridge: 0%; sensitivity accuracy: .917.

Accuracy ranges were B0 `.417–.583`, B1 `.417–.500`, and RegBridge `.917–.917`.

B1’s measured BM25 results were identical across repetitions: recall\@3 `.7024`, precision\@3 `.4762`, MRR `1.0`.

### Family sensitivity

- B0, B1, RegBridge: unsafe misses in 0/3 action-required held-out families; exploratory clustered interval `[0, 0]`.
- B2: unsafe misses in 1/3 action-required families—two misses in `c-applicant-mismatch`; exploratory interval `[0, 1]`.

These intervals are exploratory only. No independence or significance claim is made.

### Usage

| SystemAttemptsReasoning min / median / p95 / maxCost |    |                         |           |
| ---------------------------------------------------- | -- | ----------------------- | --------- |
| B0                                                   | 36 | 516 / 516 / 1552 / 2070 | $1.309500 |
| B1                                                   | 36 | 434 / 516 / 1034 / 1552 | $1.086315 |
| RegBridge                                            | 33 | 17 / 112 / 346 / 444    | $0.348510 |

Total cost: **$2.744325**. The three fewer RegBridge calls were legitimate deterministic branches. Maximum final structured answer was 201 tokens—well below 800—and maximum total output was 2,271—below the frozen 4,000 cap.

### Integrity and disclosures

- Frozen prompt: `e7e140da…4167`
- Frozen configuration: `4f26aefc…d3c3`
- Post-run freeze gate: passed.
- Benchmark remains exactly 12 held-out cases, six families, and 4/4/4 classes.
- Frozen benchmark SHA-256 remains `9b1e94fd…fc75`.
- Tested prompt-output leakage: zero case, fixture, leaf, locator, durable-evidence, or UUID hits.
- `eligible_for_performance_claims: true` appears only on completed Phase 2 held-out artifacts.
- `not_operational` and `expert_validated: false` remain unchanged.

The graph disclosure now explicitly records that the proposed discriminated evidence union was **not implemented**. It was replaced by the simpler, semantically equivalent `DOSSIER_EVIDENCE` occurrence node with an `evidence_kind` discriminator. This approved deviation appears in the design documentation, deterministic graph manifest, and Phase 2 manifest.

The Phase 1 partial snapshot now says that 54 inference outcomes were recorded while terminal publication/audit remained pending; future runs do not publish a complete 54/54 snapshot with `state: running`.

Verification before freeze passed Ruff, mypy over 79 source files, schema drift, and all **175 backend tests**. Deterministic validation subsequently reproduced identical prediction, metric, and graph digests twice."

[Attachment: attempts(1).jsonl]

[Attachment: attempts.partial(1).jsonl]

[Attachment: b2-held-out-rescore.json]

[Attachment: completion-audit(1).json]

[Attachment: manifest(1).json]

[Attachment: manifest.partial(1).json]

[Attachment: manifest.pre-run.json]

[Attachment: metrics(1).json]

[Attachment: metrics.partial(1).json]

[Attachment: per-case(1).csv]

[Attachment: per-case.partial(1).csv]

[Attachment: predictions(1).jsonl]

[Attachment: predictions.partial(1).jsonl]

[Attachment: retrieval(1).jsonl]

[Attachment: retrieval.partial(1).jsonl]

[Attachment: summary(1).md]

[Attachment: summary.partial(1).md]

## Response:
9/1/2026, 12:34:15 PM

I’m checking the final artifacts against the pre-run manifest and the policy we froze—particularly repetition counts, held-out isolation, the 4,000-token ceiling, eligibility flags, and whether the reported safety rates match the per-case predictions.

The execution controls check out: the pre-run and completed manifests use the same frozen prompt/configuration digests, all calls stayed below the cap, and the three missing RegBridge provider calls are deterministic branches—not missing outcomes. I’m tracing the actual error cases now so the final paper claim describes what RegBridge fixed and what it still missed.

The primary pattern is clear and internally consistent. One post-run interpretation issue matters for the paper: RegBridge’s sole repeated error is a conservative false positive on A005, caused by the synthetic phrase “remains located under legacy heading,” which the semantic layer reasonably treated as potentially stale content. I’m quantifying cross-repetition decision stability so that this is reported transparently rather than hidden inside the average score.

> **Inspecting experiment manifests and audits**
>
>
> **Verifying outcome count accuracy**
>
> **Verifying outcome count accuracy**
>
> **Verified outcome count accuracy**
>
> 
>
> **Inspected experiment manifests and audits**
>
> 
>
> **Analyzing Prediction Validity and Performance Metrics**
>
>
> **Assessing ambiguity in A005 fixture labels**
>
> **Assessing ambiguity in A005 fixture labels**
>
> **Assessed ambiguity in A005 fixture labels**
>
> 
>
> **Inspecting A005 legacy heading references**
>
>
> **Identifying baseline model confusion over operational availability**
>
> **Identifying baseline model confusion over operational availability**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Identified baseline availability confusion and flagged RegBridge false positive**
>
> 
>
> **Identifying baseline model confusion over operational availability**
>
> **Identifying baseline model confusion over operational availability**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Identified baseline availability confusion and RegBridge synthetic-text false positive**
>
> 
>
> **Identifying baseline model confusion over operational availability**
>
> **Identifying baseline model confusion over operational availability**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Summarizing model accuracy, cost, and reporting corrections**
>
> **Summarizing model accuracy, cost, and reporting corrections**
>
> **Flagged availability confusion and corrected RegBridge evaluation reporting**
>
> 
>
> **Identifying baseline model confusion over operational availability**
>
> **Identifying baseline model confusion over operational availability**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Flagging synthetic text false positive in RegBridge evaluation**
>
> **Summarizing model accuracy, cost, and reporting corrections**
>
> **Summarizing model accuracy, cost, and reporting corrections**
>
> **Formulating RegBridge performance claims and next steps**
>
> **Formulating RegBridge performance claims and next steps**
>
> **Summarized RegBridge evaluation findings and next steps**
>
> 
>
> **Analyzed prediction metrics, incorrect cases, reports, and legacy heading references**
>
> 
>
> **Analyzing Prediction Decision Consistency**
>
>
> **Summarizing Phase2 assessment and metrics**
>
> **Summarizing Phase2 assessment and metrics**
>
> **Summarized Phase 2 assessment and metrics**
>
> 
>
> **Summarizing Phase2 assessment and metrics**
>
> **Summarizing Phase2 assessment and metrics**
>
> **Summarized Phase 2 assessment and metrics**
>
> 
>
> **Analyzed prediction decision consistency**
>
> 
>
> Worked for 1m 58s

This is a successful Phase 2 result. M3 can now support carefully bounded empirical claims on the controlled held-out benchmark.

### Defensible headline

> Across three frozen held-out repetitions, RegBridge achieved 91.7% accuracy and 0.915 macro-F1 in every run, with no unsafe reuse, review bypass, or outside-class prediction. It also produced unanimous decisions for all 12 cases while using substantially less model compute than the direct-context and BM25-RAG baselines.

| System | Mean accuracy | Accuracy range | Unanimous cases |
|---|---:|---:|---:|
| B0 | 0.500 | 0.417–0.583 | 10/12 |
| B1 | 0.472 | 0.417–0.500 | 8/12 |
| RegBridge | 0.917 | 0.917–0.917 | 12/12 |
| B2 | 0.833 | Single deterministic run | Deterministic |

RegBridge’s observed model cost was approximately:

- 3.76× lower than B0.
- 3.12× lower than B1.

Describe this as observed efficiency under the disclosed architectures—not an intrinsic model-cost advantage.

### Important interpretation

RegBridge’s sole error was A005 in all three repetitions. The semantic layer interpreted:

> “Appended synthetic content remains located under legacy heading 3.2.S.1.2.”

as potentially stale dossier wording and conservatively returned `HUMAN_REGULATORY_REVIEW` instead of the reference `REUSE_WITH_NEW_CONTEXT`.

That is:

- an exact-label false positive;
- not an unsafe false negative;
- consistent with the conservative semantic policy;
- partly attributable to unnatural synthetic wording that resembles a statement inside the dossier.

Do not relabel or modify A005 after seeing the results. Disclose it as a construct-validity limitation. Any cleaner variation should belong to a separately labelled post-hoc robustness study.

### One reporting correction

Replace “108/108 live outcomes” with:

> **108/108 scheduled Phase 2 evaluation outcomes completed: 105 provider-backed model outcomes and three deterministic RegBridge branches, plus one separate 12-case deterministic B2 evaluation.**

This avoids describing deterministic branches as live model calls.

The B1 result is also informative: MRR of 1.0 means a relevant passage was consistently ranked first, while recall@3 of 0.702 shows that the three-passage retrieval often omitted part of the complete evidence set.

The project can now move to M4 and paper/video preparation. Preserve this result bundle and commit unchanged; any subsequent experiments should receive new run IDs and be labelled secondary or exploratory.

## Prompt:
9/1/2026, 12:43:11 PM

In terms of an AAAI submission 2-page paper. What is the concept we can write, I got this feedback from somewhere else: 
"RegBridge is deterministic under a nondeterministic model
Across the three repetitions, RegBridge's decisions and actions are **identical on every case** — zero differences. That could mean the model simply produced the same thing three times. It didn't:

| SystemCases where reasoning tokens variedCases where output text variedAccuracy swing |           |      |               |
| ------------------------------------------------------------------------------------- | --------- | ---- | ------------- |
| B0                                                                                    | 7/12      | 8/12 | .417–.583     |
| B1                                                                                    | 7/12      | 8/12 | .417–.500     |
| RegBridge                                                                             | **11/11** | 1/11 | **.917–.917** |

The model underneath RegBridge varied on *every single case*. The final decisions didn't move at all. The deterministic synthesis layer absorbed the variance completely, while the pure-LLM baselines swung up to 0.17 in accuracy from nothing but sampling.

That is a genuine architectural finding, it's measured rather than asserted, and — importantly — it doesn't depend on winning an accuracy race that n=12 can't settle. It also directly answers the reproducibility limitation you inherited when gpt-5.5 rejected `temperature` at default 1.0.

### Unsafe-FNR is no longer degenerate

In Phase 1, B0 and B1 scored 0/15 unsafe misses only because they never predicted the triggering class. On held-out, all systems did predict it: B0 seven times, B1 five, RegBridge twelve (four per repetition). So **0/8 is now a real result**, not an artifact of an unused label. That's worth a sentence in the paper — it's what makes the safety column meaningful.

B2 remains the only system with unsafe misses: 2/8, both in `c-applicant-mismatch`.

### Two things the paper must not claim

**RegBridge does not beat B2 on accuracy in any defensible sense.** .917 vs .833 is 11/12 vs 10/12 — one case. Wilson intervals are roughly [0.65, 0.99] and [0.55, 0.95]; they overlap almost entirely. The defensible statement is that a deterministic rules-only system reaches comparable accuracy while producing unsafe reuse decisions that RegBridge does not.

**B0 and B1's deficit is substantially vocabulary width, not reasoning.** They put 25–33% of predictions outside the represented classes. Sensitivity-only accuracy is .625–.778 for B0 and .556–.667 for B1, against a raw .417–.583. Report both, and don't let the raw gap carry the argument alone.

### The limitation to write down now

RegBridge and B2 share the rule base, and the reference labels were author-adjudicated by the person who wrote those rules. Both rule-based systems are being scored against labels derived from the same interpretive source, while the LLM baselines aren't. That's your sharpest reviewer attack, it's unavoidable without a domain expert, and it belongs in limitations stated plainly rather than found.

### What this means for the framing

The evidence supports: **deterministic synthesis over model output yields stable, traceable decisions where direct LLM use does not, at accuracy comparable to rules alone and with fewer unsafe reuse decisions.** That's honest, it's supported by three independent repetitions, and it survives the small-n problem because the determinism result doesn't depend on the accuracy margin.

It does not support "the hybrid architecture is more accurate." Don't reach for that."

What do you think of this? I want the paper wording to be done today, while I'm prepping up M4 till the end, then run a similar test with a local Chat completion model supported for this experiment

## Response:
9/1/2026, 12:43:12 PM

> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Evaluated AAAI requirements and clarified RegBridge reasoning variability claim**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Evaluated AAAI requirements and clarified RegBridge reasoning variability claim**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Refining analysis of decision stability and error patterns**
>
> **Refining analysis of decision stability and error patterns**
>
> **Evaluated AAAI requirements and refined RegBridge stability analysis**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Refining analysis of decision stability and error patterns**
>
> **Refining analysis of decision stability and error patterns**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Refined AAAI submission framing for RegBridge stability and label mismatches**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Refining analysis of decision stability and error patterns**
>
> **Refining analysis of decision stability and error patterns**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Refined AAAI paper framing, analysis, and drafting plan**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Refining analysis of decision stability and error patterns**
>
> **Refining analysis of decision stability and error patterns**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Refining paper title and abstract draft**
>
> **Refining paper title and abstract draft**
>
> **Refined AAAI paper framing, structure, title, and abstract**
>
> 
>
> **Evaluating AAAI submission requirements**
>
> **Evaluating AAAI submission requirements**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Clarifying RegBridge reasoning variability claim**
>
> **Refining analysis of decision stability and error patterns**
>
> **Refining analysis of decision stability and error patterns**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Highlighting label-space mismatch and paper framing**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Outlining AAAI paper structure and drafting plan**
>
> **Refining paper title and abstract draft**
>
> **Refining paper title and abstract draft**
>
> **Finalizing concise paper concept and feedback response**
>
> **Finalizing concise paper concept and feedback response**
>
> **Refined AAAI paper framing, structure, title, abstract, and feedback response**
>
> 
>
> Worked for 1m 53s

The feedback is largely excellent, and it identifies the strongest paper concept. However, two claims need tightening.

## Recommended paper concept

> **RegBridge stabilizes evidence-grounded regulatory decisions by placing deterministic validation and synthesis between nondeterministic language-model findings and final lifecycle actions.**

A strong title would be:

> **RegBridge: Stable and Traceable Regulatory Reuse Decisions through Deterministic Synthesis**

This is stronger than framing the contribution as “better accuracy” or “knowledge graphs for eCTD.”

## What the feedback gets right

### 1. Stability is the central finding

RegBridge produced the same decisions and actions for all 12 cases across three executions, while B0 and B1 varied.

But do not write:

> RegBridge is deterministic under a nondeterministic model.

The complete system is not mathematically deterministic because different model findings could still alter synthesis. Write:

> RegBridge exhibited complete decision invariance across three repeated executions despite observable variation in model execution.

Also, reasoning-token variation does not prove that semantic reasoning changed. The precise observation is:

- Provider-reported reasoning-token usage varied on all 11 model-invoked cases.
- Semantic output text varied on one case.
- Final RegBridge decisions varied on zero cases.

Therefore:

> Deterministic synthesis absorbed the observed semantic-output variation and constrained execution-level variability from propagating to final decisions.

Use “repeated executions,” not “independent repetitions.”

### 2. The safety result is meaningful

The feedback is correct that zero unsafe-FNR was not produced by universal abstention. RegBridge issued `REUSE_AS_LEGACY_REFERENCE` on all four clean reuse cases in each repetition while never issuing it on an action-required case.

A precise sentence is:

> RegBridge’s zero unsafe-FNR did not result from universal abstention: it approved all four referenceable legacy-reuse cases in every repetition while escalating or changing context for all eight action-required cases.

Review bypass must remain alongside unsafe-FNR.

### 3. Do not claim meaningful accuracy superiority over B2

Correct. RegBridge achieved 11/12 and B2 achieved 10/12. That one-case difference cannot support a broad superiority claim.

The defensible statement is:

> The rule-only system achieved similar exact-match accuracy but unconditionally reused two applicant-mismatch documents requiring review; RegBridge made no such unsafe reuse decisions and instead incurred one conservative false positive.

### 4. B0/B1 require more careful wording

I would not say their deficit was “not reasoning.” The experiment cannot isolate that.

The accurate interpretation is:

> Part of the B0/B1 exact-match deficit arose from output-space mismatch: they could select all six decision classes, while the frozen reference set instantiated only three and RegBridge’s current synthesis rules emitted those same three.

Their outside-class outputs remain genuine primary errors. Sensitivity-only accuracy must remain secondary.

## Recommended abstract draft

> Legacy eCTD documents may remain technically referenceable while becoming unsafe to reuse because target headings, context metadata, or document references have changed. We present RegBridge, a human-in-the-loop decision-support prototype combining a versioned provenance graph, deterministic lifecycle constraints, and evidence-bounded language-model findings. The model cannot directly determine final regulatory action: its citations and graph relationships are validated before deterministic synthesis produces a reuse decision, repair action, and evidence trace. On 12 held-out, author-adjudicated prospective FDA/CDER cases, RegBridge produced identical decisions across three repeated executions, achieving 11/12 exact match per run with no unsafe legacy reuse or review bypass. Direct long-context and BM25-RAG baselines varied across executions, while a deterministic rule-only baseline achieved 10/12 but issued unsafe reuse decisions for two semantic applicant-mismatch cases. These results demonstrate controlled stability and traceability rather than FDA compliance: the benchmark is synthetic, lacks expert validation, and represents a currently non-operational forward-compatibility scenario.

## Two-page structure

1. **Problem and contribution:** Technical referenceability does not establish safe contextual reuse.
2. **System:** Evidence-bounded model findings → graph validation → deterministic synthesis → human-approved action.
3. **Demonstration:** Removed heading, `manufacturer="all"`, and stale content/hyperlinks.
4. **Evaluation:** Four systems, 12 held-out cases, three repeated executions, safety and stability metrics.
5. **Limitations:** Synthetic prospective cases, author–rule label coupling, no regulatory expert, three represented decision classes, six fixture families.

The limitation about label–rule coupling absolutely belongs in the paper:

> Reference labels were author-adjudicated by the researcher who formalized the rules, creating potential alignment between the benchmark and rule-based systems. Consequently, the results measure consistency with the controlled operationalization rather than independent regulatory ground truth.

## Local-model experiment

Run it, but label it **secondary cross-model robustness**, because its protocol is being created after inspecting the primary results. Freeze before execution:

- Exact model, quantization and chat template
- Temperature, top-p and seed
- Structured-output method
- Same prompts, graph, evidence and 4,000-token cap
- Three repeated executions
- No tuning on the held-out cases

If you want a genuinely confirmatory replication, it would require newly frozen cases that were not used to develop this framing.

The paper’s core claim should therefore be:

> **Deterministic synthesis over evidence-bounded model findings produced stable, traceable decisions across repeated executions, retained the semantic safety benefit absent from rules alone, and prevented model variability from directly controlling regulatory lifecycle actions.**

## Prompt:
9/1/2026, 1:20:16 PM

I dont want to use this session for the paper draft writing. I know it is not going to be complete for submission until I add the local-model experiment, but it should at least be drafted with what we can draft it with for a successful AAAI demonstration track submission. Give me a prompt I can give to Manus for it to work on the paper with my template lateex zip package. It has access to the repository so you have to give it the direction and instructions, it'll know what to do.

## Response:
9/1/2026, 1:20:18 PM

I’m using the writing-block skill because you need a complete, copy-ready instruction prompt for another agent. I’ll make it repository-aware, force evidence-backed use of the frozen artifacts, preserve the AAAI demo framing, and prevent Manus from overstating the current results or fabricating the pending local-model experiment.

> **Drafting Manus instruction for AAAI paper**
>
> **Drafting Manus instruction for AAAI paper**
>
> **Planning repo inspection and paper drafting**
>
> **Planning repo inspection and paper drafting**
>
> **Drafted Manus instructions for AAAI paper and repo inspection**
>
> 
>
> **Drafting Manus instruction for AAAI paper**
>
> **Drafting Manus instruction for AAAI paper**
>
> **Planning repo inspection and paper drafting**
>
> **Planning repo inspection and paper drafting**
>
> **Outlining precise paper drafting requirements**
>
> **Outlining precise paper drafting requirements**
>
> **Drafted precise Manus instructions for AAAI paper development**
>
> 
>
> **Drafting Manus instruction for AAAI paper**
>
> **Drafting Manus instruction for AAAI paper**
>
> **Planning repo inspection and paper drafting**
>
> **Planning repo inspection and paper drafting**
>
> **Outlining precise paper drafting requirements**
>
> **Outlining precise paper drafting requirements**
>
> **Drafted precise Manus instructions for AAAI paper development**
>
> 
>
> Worked for 1m 44s

Paste this into Manus with the LaTeX template ZIP attached.

**standard: **

You are preparing a near-submission-ready AAAI Demonstration Track paper for the RegBridge research project. You have access to the complete GitHub repository and an attached official LaTeX template ZIP.

Your task is to inspect the repository, verify the implemented system and experiment artifacts, and write the strongest defensible two-page demonstration paper possible using the evidence currently available. A secondary local-model robustness experiment will be added later. Do not fabricate, predict, or imply results from that pending experiment.

## 1. Required preliminary work

Before writing:

1. Inspect the repository’s `AGENTS.md` and `IMPLEMENTATION.md` completely.
2. Locate and inspect:
   - M1, M2 and M3 implementation records;
   - graph schema v2;
   - frozen benchmark and author-adjudication records;
   - Phase 1 and Phase 2 manifests;
   - completion audits;
   - metrics, predictions, attempts and retrieval traces;
   - B2 held-out rescore;
   - available UI screenshots and demonstration routes;
   - source/evidence manifests and FDA document provenance.
3. Record the exact repository commit used for the draft.
4. Treat machine-readable artifacts as the source of truth. Recalculate important numbers where feasible rather than copying summaries unquestioningly.
5. Inspect the LaTeX ZIP and obey its class, bibliography, margin, anonymity and submission-format requirements. Do not replace the official class or alter margins, spacing or font sizes to force content to fit.
6. Do not modify application or benchmark code. Paper-related files should be isolated in an appropriate paper directory.

If repository summaries conflict with manifests or raw predictions, use the frozen artifacts and document the discrepancy.

## 2. Paper objective

Draft a complete two-page AAAI Demonstration Track paper, with references using only the additional space permitted by the official template or call.

The paper must present RegBridge as an interactive human-in-the-loop decision-support demonstration—not as a production FDA submission generator and not merely as an eCTD converter or regulatory chatbot.

Recommended title:

**RegBridge: Stable and Traceable Regulatory Reuse Decisions through Deterministic Synthesis**

The central research claim is:

> RegBridge constrains evidence-bounded language-model findings through a versioned provenance graph, deterministic validation and lifecycle-aware synthesis, yielding stable and auditable regulatory reuse decisions without allowing the model to control final lifecycle actions directly.

The principal empirical finding is observed decision stability under repeated model execution—not a broad claim of superior accuracy.

## 3. Problem framing

Explain concisely:

- A legacy eCTD document may remain technically referenceable by identifier while becoming unsafe or inappropriate to reuse in a new regulatory context.
- Relevant risks include removed headings, changed context-group metadata and semantically stale content or hyperlinks.
- Existing technical conversion/reference mechanisms answer whether content can be referenced; RegBridge supports the human decision about whether and how it should be reused.
- Current FDA v3.2.2-to-v4.0 forward compatibility remains `not_operational`. The demonstration is a controlled prospective FDA/CDER research scenario.
- The system does not predict FDA acceptance or issue legally authoritative compliance determinations.

## 4. System contribution

Describe the architecture accurately and compactly:

1. Deterministic dossier parsing and structural facts.
2. A versioned evidence/provenance graph.
3. Author-adjudicated lifecycle and metadata constraints.
4. Evidence-bounded language-model semantic findings.
5. Citation, domain/range and graph-contract validation.
6. Deterministic synthesis into a decision, action, evidence trace and human-review requirement.

The model proposes bounded semantic findings but cannot directly write final graph facts or override deterministic hard constraints.

Graph schema v2 should be described at the appropriate level:

- `MODEL_FINDING → CITES → DOSSIER_EVIDENCE`
- `MODEL_FINDING → ABOUT → KEYWORD`
- `DOSSIER_EVIDENCE → OBSERVES → KEYWORD`

The implementation uses a `DOSSIER_EVIDENCE` occurrence node with an `evidence_kind` discriminator rather than a separate discriminated evidence-node union. This is an approved, documented design choice. Do not describe the unimplemented union as part of the system.

Avoid spending excessive space on low-level schema details; include them only where they support traceability and the distinction between evidence occurrences and normalized concepts.

## 5. Demonstration experience

Present the three interactive cases:

- **Case A — Removed heading:** legacy content under removed `3.2.S.1.1–3.2.S.1.3` headings is reused by identifier through a new context group under the supported `3.2.S.1` mapping.
- **Case B — Manufacturer metadata:** exact `manufacturer="all"` is handled through a lifecycle-sensitive policy. Preserving exact keywords retains legacy reuse with an advisory; changing or removing the value requires a new context group; missing intent yields human review.
- **Case C — Stale content or hyperlinks:** evidence-supported or ambiguous semantic risks yield bounded human review rather than an automatic prohibition or lifecycle break.

Describe what the audience sees and can interact with: controlled scenario selection, parsed dossier facts, applicable graph/rule path, decision, action, human-review boundary and exact evidence citations.

Use one compact, readable figure. Prefer a genuine interface screenshot or a compact architecture-plus-decision-trace figure derived from the implemented system. Do not fabricate an interface. Ensure the figure remains legible in two-column print.

## 6. Evaluation design

Describe:

- 30 controlled prospective cases.
- Family-aware 4/2/4 train/development/test split per archetype.
- 12 held-out cases.
- Six non-overlapping held-out fixture families.
- Exactly four held-out cases in each represented class:
  - `REUSE_WITH_NEW_CONTEXT`
  - `REUSE_AS_LEGACY_REFERENCE`
  - `HUMAN_REGULATORY_REVIEW`
- Labels are `author_adjudicated_for_demo`.
- `expert_validated: false`.
- Three repeated held-out executions for B0, B1 and RegBridge.
- One deterministic held-out execution for B2.
- No majority-vote or pooled prediction was used.
- Repetitions reuse the same cases and are not statistically independent.
- No independence or significance claim should be made.

Systems:

- **B0:** direct long-context model supplied all six frozen evidence spans.
- **B1:** actual flat lexical RAG using frozen BM25 top-3 retrieval.
- **B2:** genuine deterministic parser/graph/rule-only analyzer with semantic analysis omitted.
- **RegBridge:** complete hybrid system.

Disclose that B0 and B1 received the project’s six-decision action taxonomy. The benchmark instantiated only three classes, while RegBridge’s current synthesis rules structurally emitted those represented classes. Therefore, part of the exact-match difference reflects output-space mismatch.

## 7. Frozen held-out results

Verify all figures against the artifacts before inserting them.

Current reported results are:

- RegBridge: accuracy `0.917` and macro-F1 `0.915` in all three repetitions; unsafe-FNR `0/8`; review bypass `0/4`; outside-class predictions `0/12`.
- B0 accuracy range: `0.417–0.583`; macro-F1 range approximately `0.504–0.641`; unsafe-FNR `0/8`; review bypass `1/4` in each repetition; outside-class predictions `3/12–4/12`.
- B1 accuracy range: `0.417–0.500`; macro-F1 range approximately `0.448–0.556`; unsafe-FNR `0/8`; review bypass `0/4–1/4`; outside-class predictions `3/12` in each repetition.
- B2: accuracy `0.833`, macro-F1 `0.822`, unsafe-FNR `2/8`, review bypass `2/4`.
- B1 BM25: recall@3 `0.7024`, precision@3 `0.4762`, MRR `1.0`.
- RegBridge decisions were unanimous on `12/12` cases across repetitions.
- B0 decisions were unanimous on `10/12`.
- B1 decisions were unanimous on `8/12`.
- RegBridge observed cost: `$0.348510`.
- B0 observed cost: `$1.309500`.
- B1 observed cost: `$1.086315`.

Report cost as observed under the disclosed architectures, not as an intrinsic model-price advantage.

Correctly characterize execution counts:

> 108/108 scheduled Phase 2 evaluation outcomes completed: 105 provider-backed model outcomes and three deterministic RegBridge branches, plus a separate 12-case deterministic B2 evaluation.

## 8. Stability claim

Use careful wording.

Permitted:

> RegBridge exhibited complete decision invariance across three repeated executions despite observable variation in model execution.

> Provider-reported reasoning-token usage varied on all 11 model-invoked RegBridge cases, semantic output text varied on one case, and final decisions varied on zero cases.

> In the observed semantic-output variation, deterministic validation and synthesis prevented the variation from changing the final decision.

Do not write:

- “RegBridge is deterministic.”
- “The underlying model reasoned differently on every case.”
- “Deterministic synthesis guarantees identical decisions.”
- “The repetitions were independent.”

Reasoning-token variation demonstrates execution-level variation, not necessarily different semantic reasoning.

## 9. Interpretation of safety and accuracy

The paper may state:

> RegBridge’s zero unsafe-FNR did not result from universal abstention: it approved all four clean legacy-reuse cases in every repetition while escalating or changing context for all eight action-required cases.

Unsafe-FNR and review bypass must be reported together.

Do not claim RegBridge meaningfully “beat” B2 on accuracy. The defensible interpretation is:

> The rule-only system achieved similar exact-match accuracy but unconditionally reused two applicant-mismatch documents that required review. RegBridge made no unsafe reuse decisions and instead incurred one conservative false positive.

RegBridge’s repeated error was A005. The synthetic content stated that it “remains located under legacy heading `3.2.S.1.2`.” The semantic layer interpreted this as potentially stale wording and returned `HUMAN_REGULATORY_REVIEW` rather than the reference `REUSE_WITH_NEW_CONTEXT`.

Describe this as:

- an exact-label false positive;
- a conservative review escalation;
- not an unsafe false negative;
- a construct-validity limitation caused partly by synthetic wording.

Do not relabel A005 or change the frozen benchmark.

For B0/B1, do not say the performance deficit was simply “not reasoning.” State that part of the deficit arose from output-space mismatch. Outside-class predictions remain primary exact-match errors; sensitivity-only accuracy excluding them must remain clearly secondary.

## 10. Required limitations

State plainly:

- The benchmark is small, synthetic, controlled and prospective.
- It contains 12 held-out cases across six families.
- Only three of six decision classes are represented.
- FDA forward compatibility remains `not_operational`.
- Labels are author-adjudicated and not expert regulatory ground truth.
- The same researcher helped formalize the rules and adjudicate labels, creating possible alignment between rule-based systems and the reference labels.
- No regulatory professional validated the operationalizations.
- RegBridge’s current evidence concerns FDA/CDER and the scoped demonstration cases.
- Repeated executions are not independent observations.
- Results demonstrate behavior within the controlled benchmark, not FDA compliance, submission acceptance or real-world generalization.

Use wording similar to:

> Reference labels were author-adjudicated by the researcher who formalized the rules, creating potential alignment between the benchmark and rule-based systems. Consequently, the evaluation measures consistency with a controlled operationalization rather than independent regulatory ground truth.

## 11. Pending local-model experiment

Do not invent any local-model result.

The current paper must compile and read coherently without that experiment. Add clearly searchable LaTeX comments such as:

```latex
% TODO-LOCAL-MODEL: Add model identity, decoding configuration, repetitions and results.
```

Create a separate `LOCAL_MODEL_UPDATE.md` identifying:

- the abstract sentence to update;
- evaluation paragraph insertion point;
- table row(s) to add;
- limitations or reproducibility details to add;
- any result-dependent conclusion language.

The local-model experiment will be a secondary cross-model robustness study unless a new untouched confirmatory benchmark is created. Do not call it confirmatory in the current draft.

## 12. Citations and related work

Use only verified citations. At minimum, consider:

- Official FDA eCTD v4.0 Technical Conformance Guide.
- FDA CTOC headings.
- FDA M4 guidance supporting the manufacturer-keyword case.
- ICH/FDA forward-compatibility material used by the implementation.
- Wikontic as ontology-aware graph-construction inspiration.
- Relevant regulatory NLP or compliance RAG work already documented in the repository.

Do not fabricate bibliographic data, DOIs, publication venues or URLs. Verify every BibTeX entry against an authoritative source. Keep related work concise because this is a two-page demonstration paper.

## 13. Writing requirements

- Scientific, restrained and precise.
- Use first-person plural where appropriate.
- Lead with the decision-support problem and demonstration contribution.
- Avoid marketing language.
- Avoid “FDA compliant,” “guaranteed,” “authoritative,” “ground truth,” “production ready” and “regulatory approval.”
- Distinguish technical eligibility from regulatory acceptance.
- Distinguish observed stability from guaranteed determinism.
- Keep the main body within two pages without formatting hacks.
- Do not spend the paper primarily explaining the benchmark; preserve space for the interactive demonstration and system contribution.
- Include one compact figure and one compact results table at most, unless the official template comfortably allows more.
- Make captions self-contained.
- Do not invent author names. Follow the template’s anonymity rules or use explicit placeholders where information is unavailable.

## 14. Deliverables

Produce:

1. Complete LaTeX source using the supplied template.
2. Verified BibTeX file.
3. All figure assets.
4. A successfully compiled PDF.
5. `CLAIM_PROVENANCE.md`, mapping every quantitative or regulatory claim to repository artifacts or official evidence.
6. `LOCAL_MODEL_UPDATE.md`.
7. A short `PAPER_STATUS.md` listing:
   - exact repository commit;
   - template used;
   - compilation command;
   - current page count;
   - unresolved placeholders;
   - pending local-model work;
   - any claims deliberately excluded and why.

Compile and visually inspect the PDF. Resolve overflow, broken references, illegible figures and bibliography problems. Do not declare completion merely because LaTeX compiled.

At completion, report the created files, current page count, principal framing, remaining local-model insertion points and any evidence or formatting issue that still requires human input.

## Prompt:
9/1/2026, 1:57:52 PM

We can proceed with the M4 and completing all milestones. Then we take a look at the local model.

## Response:
9/1/2026, 1:57:52 PM

> **Defining M4 scope and next steps**
>
> **Defining M4 scope and next steps**
>
> **Defined M4 scope and next steps**
>
> 
>
> Worked for 12s

Yes—that is the correct sequence.

For M4, treat the completed M3 artifacts as immutable. M4 should consume them for:

- The comparison dashboard and per-case traces.
- The three-case interactive demonstration.
- Evidence, graph-path and rule explanations.
- Repetition stability, safety and cost summaries.
- Clear `not_operational`, prospective-scenario and `expert_validated: false` disclosures.
- Demo screenshots and the five-minute video workflow.
- Final end-to-end, accessibility and presentation testing.

M4 must not modify the frozen benchmark, labels, prompts, results or Phase 2 manifests. Any display correction should be recorded as presentation-only.

After all implementation milestones are complete, we can freeze a separate protocol for the local-model experiment and add its verified results to the existing LaTeX draft as secondary cross-model robustness evidence.

## Prompt:
9/1/2026, 2:03:16 PM

![f72f537f-75cd-4827-95c2-2bf2f11d81cd.png](https://chatgpt.com/backend-api/estuary/content?id=file_000000009f0c81f5bf484b99221fb59f&fn=f72f537f-75cd-4827-95c2-2bf2f11d81cd.png&cd=attachment&ts=496913&p=fs&cid=1&sig=c43bd9e465053482c59a0240079b22907bac470b19713765fed40cf677583f7c&v=0)

Got this: "One repository constraint needs an explicit choice before the M4 plan is safe: the completed live Phase 2 directory is intentionally ignored by Git. A dashboard that reads it directly would work on this machine but fail the “fresh local setup” exit criterion. The clean solution is a digest-verified, presentation-only snapshot derived from those immutable files; it would never rewrite them and would disclose its source run and hashes."

## Response:
9/1/2026, 2:03:29 PM

> **Defining derived snapshot criteria**
>
> **Defining derived snapshot criteria**
>
> **Detailing snapshot contents and verification**
>
> **Detailing snapshot contents and verification**
>
> **Defined derived snapshot criteria and verification details**
>
> 
>
> **Defining derived snapshot criteria**
>
> **Defining derived snapshot criteria**
>
> **Detailing snapshot contents and verification**
>
> **Detailing snapshot contents and verification**
>
> **Defined derived snapshot criteria and verification details**
>
> 
>
> Worked for 15s

Choose **Derived snapshot**. It is the only option that preserves provenance while allowing the demonstration to run from a fresh offline clone.

Send Codex:

> Use a digest-verified, presentation-only derived snapshot.
>
> The committed bundle must contain only what M4 needs:
>
> - source Phase 2 run ID;
> - repository commit;
> - frozen prompt, configuration and benchmark digests;
> - source artifact hashes;
> - disclosure fields including `not_operational`, `expert_validated: false`, and `eligible_for_performance_claims`;
> - per-system/per-repetition metrics;
> - sanitized per-case decisions, actions and evidence identifiers;
> - decision-stability, safety, retrieval, usage and cost summaries;
> - B2 results;
> - approved limitation and result-status text.
>
> Exclude:
>
> - provider response IDs;
> - raw API payloads;
> - complete prompts;
> - hidden reasoning;
> - retry internals;
> - credentials or environment information;
> - unnecessary raw model output.
>
> Implement a deterministic snapshot generator with a versioned schema. When the ignored immutable Phase 2 directory is available, regeneration must verify every expected source hash and fail on any mismatch before writing. It must never modify the source run.
>
> A fresh clone must not require the ignored source directory. It should validate the committed snapshot’s schema, self-digest and recorded provenance, then run the dashboard offline.
>
> The UI must disclose:
>
> > Presentation snapshot derived from frozen Phase 2 run `[run ID]`; results are displayed, not recomputed.
>
> Add tests ensuring:
>
> - identical inputs reproduce an identical snapshot digest;
> - changed or missing expected source files block regeneration;
> - no prohibited raw/provider fields enter the bundle;
> - dashboard values exactly match the snapshot;
> - a fresh offline clone can build and display all M4 result views;
> - future result sets create a new snapshot version rather than silently overwriting this one.

Do not commit the complete run. The raw artifacts remain the audit record; the committed snapshot is a minimal, reproducible presentation layer over that record.

## Prompt:
9/1/2026, 2:05:58 PM

![99e0b2c8-1269-4256-b859-63db341c10d3.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000abc081f59a253ceef1b75064&fn=99e0b2c8-1269-4256-b859-63db341c10d3.png&cd=attachment&ts=496913&p=fs&cid=1&sig=a3ee32ef95caa29028a75ecec9a09e5737fdfca444ac2148990813aacd23dceb&v=0)

next question

## Response:
9/1/2026, 2:06:02 PM

> **Choosing A+C for AAAI demo**
>
> **Choosing A+C for AAAI demo**
>
> **Scripting A+C demo with B contingency**
>
> **Scripting A+C demo with B contingency**
>
> **Chose A+C for AAAI demo and scripted B contingency**
>
> 
>
> Worked for 17s

Choose **A + C primary**.

They provide the clearest five-minute story:

- **Case A** demonstrates deterministic standards and lifecycle reasoning.
- **Case C** demonstrates why deterministic rules alone are insufficient and where bounded semantic analysis adds value.
- **Case B** is valuable but requires more explanation because its result depends on preservation intent, manufacturer partitioning and advisory-versus-hard enforcement.

Send Codex:

> Optimize and script **A + C primary**, with Case B fully functional as the third interactive booth case and contingency segment.
>
> Suggested timing:
>
> - **0:00–0:30 — Problem:** A document may be technically referenceable but unsafe to reuse in its new context. State that the scenario is prospective and FDA availability remains `not_operational`.
> - **0:30–1:35 — Case A:** Show the removed heading, explicit mapping to `3.2.S.1`, document-identifier reuse, new context group, suspension action and exact evidence trace.
> - **1:35–2:55 — Case C:** Show the applicant/content mismatch or stale hyperlink. Contrast B2’s unconditional reuse with RegBridge’s evidence-supported human-review escalation.
> - **2:55–4:10 — Architecture and results:** Show model finding → evidence/graph validation → deterministic synthesis, followed by decision stability, unsafe-FNR, review bypass and repeated-run comparison.
> - **4:10–4:35 — Case B preview:** Briefly show that metadata is lifecycle-sensitive rather than universally rejected. Do not attempt the full explanation unless time permits.
> - **4:35–5:00 — Closing:** Emphasize stable, traceable human decision support—not autonomous FDA compliance.
>
> Prioritize readable evidence and decision traces over showing every feature. The recording should never depend on network latency; use the approved controlled scenario and frozen presentation snapshot while clearly disclosing that results are displayed rather than recomputed.
>
> Case B must remain polished and accessible for live interaction, reviewer questions and contingency use, even though it is not a primary video segment.

This sequence directly supports the paper’s central claim: structural constraints handle Case A, semantic analysis prevents the rule-only failure in Case C, and deterministic synthesis keeps the final action stable and auditable.

## Prompt:
9/1/2026, 7:12:53 PM

Made Codex implement M4: "Implemented M4.
What changed:

- Added immutable M4 presentation snapshot support and read-only API:
  - `/api/v1/presentation/m3`
  - `/api/v1/presentation/m3/cases`
  - `/api/v1/presentation/m3/cases/{case_id}`
  - `/api/v1/demo/presets`
- Added snapshot generator/verifier under [backend/app/presentation]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\backend\\\app\\\presentation).
- Added committed presentation snapshot under [data/presentation/m4]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\data\\\presentation\\\m4).
  - Snapshot: `m4-phase2-20260901T170811002109Z-v1`
  - SHA-256: `824613fc4480ef9ea354eda60618567e45a37a691fac921e5d095a16b7cb27c0`
- Added the Phase 2 comparison dashboard at [frontend/src/pages/EvaluationDashboard.tsx]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\frontend\\\src\\\pages\\\EvaluationDashboard.tsx).
- Reworked the guided demo routes for Case A/B/C with reset behavior, persistent nav, graph/evidence explanations, and current-operational guard.
- Added accessible graph edge tables and M4 disclosures, including the actual graph contract deviation.
- Added Playwright + axe E2E/accessibility coverage at [frontend/e2e/m4.spec.ts]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\frontend\\\e2e\\\m4.spec.ts).
- Added screenshot capture workflow:
  - [scripts/m4-capture.ps1]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\scripts\\\m4-capture.ps1)
  - Generated four screenshots plus manifest under [paper/figures/m4]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\paper\\\figures\\\m4).
- Added final M4 verification command:
  - [scripts/m4-verify.ps1]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\scripts\\\m4-verify.ps1)
  - `make m4-verify`
- Updated docs:
  - [README.md]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\README.md)
  - [docs/milestones/M4.md]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\docs\\\milestones\\\M4.md)
  - [docs/DEMO\_M4.md]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\docs\\\DEMO\_M4.md)

Verification passed:

- `powershell -NoProfile -ExecutionPolicy Bypass -File scripts\m4-verify.ps1`
  - Backend lint/typecheck/tests: `182 passed`
  - M4 snapshot verification: passed
  - Protected M3 files checked: `12`
  - Screenshots checked: `4`
  - Two fixture-mode demo runs produced identical digests
  - Frontend lint/typecheck/tests/build: passed
  - Playwright E2E/accessibility: `2 passed`

Also ran:

- `powershell -NoProfile -ExecutionPolicy Bypass -File scripts\m4-capture.ps1`
  - Generated the four M4 presentation screenshots and hash manifest."

[Attachment: Pasted markdown.md]

## Response:
9/1/2026, 7:12:55 PM

> **Confirming milestone completion and next steps**
>
> **Confirming milestone completion and next steps**
>
> **Assessing milestone M4 completion and proposing freeze**
>
> **Assessing milestone M4 completion and proposing freeze**
>
> **Confirmed milestone M4 completion and proposed a freeze**
>
> 
>
> Worked for 38s

M4 appears complete based on the implementation and verification report. It closes the important demo-readiness gaps:

- Fresh offline setups can reproduce the presentation through a digest-verified snapshot.
- The dashboard clearly separates displayed Phase 2 results from newly computed results.
- All three cases remain available, while the walkthrough can emphasize A and C.
- Evidence, graph traces, operational-status disclosures, and the graph-contract deviation are visible.
- Accessibility, screenshots, deterministic replay, backend tests, and frontend E2E checks all passed.
- The protected M3 artifacts were not rewritten.

Before starting the local-model experiment, I recommend one manual five-minute rehearsal to verify pacing, screen readability, reset behavior, and that no Windows-local paths or sensitive raw metadata appear in the committed snapshot or screenshots.

Then freeze this state:

1. Record the Git commit SHA and M4 snapshot digest.
2. Tag it as the completed hosted-model demo baseline.
3. Keep the existing Phase 2 run immutable.
4. Add the local-model evaluation as a separate, secondary robustness experiment—not a replacement for Phase 2.
5. Predeclare the local model, quantization, inference parameters, prompt/config hashes, repetition count, and failure policy before evaluating the held-out cases.
6. Use only train/development cases for adapter troubleshooting or prompt compatibility. Do not revise anything after viewing local-model held-out results.

The local experiment’s strongest question should be:

> Does RegBridge’s validated synthesis architecture preserve decision stability, safety behavior, and traceability when the underlying language model is replaced with a locally hosted model?

That directly strengthens the portability claim while preserving the scientific integrity of the frozen M3/M4 results.

## Prompt:
9/1/2026, 7:16:56 PM

Wouldn't the best form of demonstration be an upload of a dossier with an injected case and running the systems on it? Maybe also run the 3 baselines on it too?

## Response:
9/1/2026, 7:16:57 PM

> **Planning controlled dossier demo with RegBridge**
>
> **Planning controlled dossier demo with RegBridge**
>
> **Designing multi-document dossier demo workflow**
>
> **Designing multi-document dossier demo workflow**
>
> **Designed a controlled multi-document RegBridge dossier demo workflow**
>
> 
>
> Worked for 11s

Yes. That would be a substantially stronger demonstration than starting from a fixture selector.

The fixture interface is valuable for repeatable testing, but the audience-facing workflow should resemble the real task:

> Upload a synthetic legacy dossier → select the target regulatory context → analyze its documents → compare system decisions → inspect the evidence-backed explanation.

## Recommended demonstration design

Create one controlled synthetic v3.2.2 dossier containing three injected documents:

| Document | Injected condition | Main capability demonstrated |
|---|---|---|
| A | Removed `3.2.S.1.2` heading | Structural and lifecycle reasoning |
| B | `manufacturer="all"` | Lifecycle-sensitive metadata reasoning |
| C | Stale applicant statement or hyperlink | Semantic inspection and conservative review |

The user uploads the ZIP once. RegBridge should genuinely:

1. Parse the dossier XML and files.
2. Identify the leaves, lifecycle operations, headings, keywords, and document evidence.
3. Construct the dossier graph.
4. Evaluate every candidate document.
5. Return a dossier-level risk summary.
6. Allow the presenter to open an individual document’s decision trace.

This is much more persuasive because the cases appear as detected dossier risks—not manually selected answers.

## How to include the baselines

All four systems should receive the same package-derived case representation:

- B0: all six standards passages plus extracted dossier material.
- B1: BM25-retrieved standards passages plus the same dossier material.
- B2: parser, graph facts, and deterministic rules without semantic analysis.
- RegBridge: complete graph-constrained hybrid pipeline.

Crucially, package-derived requests must not contain fixture IDs, expected labels, reference decisions, or benchmark rationales.

For the five-minute video, I would not run all four systems over all three documents. That could require too many model calls and leave little time for explanation. Instead:

- Run RegBridge across the complete dossier.
- Select the Case C document.
- Run or reveal the four-system comparison for that one document.
- Show why B2 approves reuse while RegBridge requests human review.
- Briefly show A and B in the dossier summary.

A good flow would be:

| Time | Demonstration |
|---|---|
| 0:00–0:30 | Explain the legacy-reuse problem and prospective status |
| 0:30–1:00 | Upload the controlled synthetic dossier |
| 1:00–1:40 | Parse and analyze it |
| 1:40–2:20 | Show the three detected document outcomes |
| 2:20–3:40 | Open Case C and compare B0/B1/B2/RegBridge |
| 3:40–4:30 | Show the evidence span, graph path, and bounded suggested check |
| 4:30–5:00 | Show evaluation dashboard and limitations |

## Live versus recorded results

Ideally, all four systems really execute after upload. If model latency makes that unsafe for a five-minute recording:

- Execute the deterministic parser, B2, and RegBridge workflow live.
- Start the model-based comparisons asynchronously.
- Permit reopening a digest-verified completed comparison.
- Clearly label cached outputs as a prior run of that exact uploaded package and configuration.

Do not silently present snapshot results as live computation.

## What should happen to the current M4 pages?

Keep them. They become:

- Controlled scenario explorer
- Rehearsal and fallback mode
- Booth interaction pages
- Evidence-focused deep dives
- Contingency if model or network execution fails

Add the upload workflow as the primary landing page and five-minute demonstration path.

## Scope boundary

This does not require full arbitrary-dossier support. For the research prototype, explicitly support:

- One documented synthetic dossier profile
- A bounded subset of `index.xml` and lifecycle structures
- PDF and metadata inspection needed by A, B, and C
- Safe rejection or abstention for unsupported structures

That is an honest research demonstration. The strongest demo claim becomes:

> RegBridge ingests a controlled legacy dossier, detects structural, metadata, and semantic reuse risks, and produces stable evidence-backed decisions while exposing how direct-LLM, retrieval, and rule-only baselines behave on the same dossier-derived input.

I would ask Codex to implement this as an M4.1 demonstration-integration milestone, without modifying the frozen M3 benchmark or Phase 2 results.

## Prompt:
9/2/2026, 11:47:25 AM

Okay, the direction forward is the implementation of an end-to-end upload. The main Regbridge page should allow me to use the product itself (no baseline numbers showing up, no comparisons). On that page, I should be able to:

1. Upload the dossier 
2. Click on parse and analyze
3. See the results (This is where your point 4,5,6 shows)

In the baselines page:

I should be able to do the same, but the baselines run against Regbridge and the resutls display properly. My questions here shouldn't the baselines be supplied with at least what to return vocabulary so we can see their concise decisions against Regbridge?

## Response:
9/2/2026, 11:47:31 AM

> **Clarifying decision vocabulary and schema**
>
> **Clarifying decision vocabulary and schema**
>
> **Defining system-specific decision inputs and vocabularies**
>
> **Defining system-specific decision inputs and vocabularies**
>
> **Defined decision vocabulary and system-specific input schema**
>
> 
>
> **Clarifying decision vocabulary and schema**
>
> **Clarifying decision vocabulary and schema**
>
> **Defining system-specific decision inputs and vocabularies**
>
> **Defining system-specific decision inputs and vocabularies**
>
> **Designing unified 3-class decision schema**
>
> **Designing unified 3-class decision schema**
>
> **Defined a unified three-class decision schema and vocabulary**
>
> 
>
> Worked for 33s

Yes. B0 and B1 should receive a strict output vocabulary and schema. Otherwise, differences in wording or label choice become mixed with differences in reasoning, making the comparison unnecessarily noisy.

The important distinction is:

> Supplying the permitted answer vocabulary is fair task specification. Supplying case-specific conditions, expected answers, rule outcomes, or reference rationales would be leakage.

## Shared comparison contract

All four systems should return the same top-level decision:

```json
{
  "decision": "REUSE_AS_LEGACY_REFERENCE",
  "requires_human_review": false,
  "suggested_action": "NONE",
  "rationale": "Concise explanation",
  "evidence_ids": ["..."]
}
```

For this demonstration, use the three represented decisions:

```text
REUSE_AS_LEGACY_REFERENCE
REUSE_WITH_NEW_CONTEXT
HUMAN_REGULATORY_REVIEW
```

Give every system neutral definitions:

- `REUSE_AS_LEGACY_REFERENCE`: reuse is supported without a material context change or unresolved review.
- `REUSE_WITH_NEW_CONTEXT`: the existing document may be reused, but a new context or associated lifecycle action is required.
- `HUMAN_REGULATORY_REVIEW`: the available information does not support an unconditional automated reuse decision.

Do not mention manufacturer `"all"`, removed headings, stale links, applicant mismatches, applicable rules, or expected evidence in those definitions.

The action vocabulary should also be controlled, but may include `OTHER_SUPPORTED_ACTION` so the schema does not force an incorrect action:

```text
NONE
CREATE_NEW_CONTEXT_AND_SUSPEND_OLD
VERIFY_DOCUMENT_CONTENT
VERIFY_HYPERLINK_CONTEXT
DECLARE_MANUFACTURER_PARTITIONING
SELECT_SUPPORTED_REUSE_OPERATION
WAIT_FOR_OPERATIONAL_AVAILABILITY
OTHER_SUPPORTED_ACTION
```

## Preserve RegBridge’s richer result

Internally, RegBridge can continue producing its full decision trace, graph path, findings, rule applications, repair details, and evidence provenance. The comparison page should project that richer result into the shared contract.

That gives you two layers:

| Layer | Purpose |
|---|---|
| Shared decision contract | Fair, concise cross-system comparison |
| Native system trace | Shows why RegBridge is architecturally different |

## Page separation

### Main RegBridge page

This should look like a real product, with no benchmark or baseline content:

1. Upload dossier.
2. Select target context and prospective/current mode.
3. Parse and analyze.
4. Show dossier summary.
5. Show document-level decisions and risks.
6. Open a document to inspect:
   - decision;
   - lifecycle action;
   - detected findings;
   - evidence spans;
   - graph trace;
   - suggested checks or repairs;
   - human-approval requirement;
   - FDA operational-status disclosure.

### Baselines page

The systems do not technically run “against RegBridge.” They run alongside RegBridge on identical package-derived inputs.

The page should allow:

1. Uploading a dossier or selecting a previously uploaded package by package hash.
2. Selecting one or more detected documents.
3. Running B0, B1, B2, and RegBridge.
4. Displaying a comparison table:

| System | Decision | Human review | Suggested action | Evidence | Runtime |
|---|---|---|---|---|---|
| B0 | … | … | … | … | … |
| B1 | … | … | … | … | … |
| B2 | … | … | … | … | … |
| RegBridge | … | … | … | … | … |

Clicking a system should reveal its native explanation:

- B0: full-context prompt evidence and direct rationale.
- B1: BM25 query, retrieved spans, rankings, and rationale.
- B2: deterministic facts and fired rules.
- RegBridge: model finding, occurrence evidence, normalized concept, graph validation, rule synthesis, and final decision.

## No accuracy for arbitrary uploads

An uploaded dossier normally has no adjudicated reference label. Therefore, the baseline page can report:

- agreement and disagreement;
- selected decisions;
- review recommendations;
- cited evidence;
- latency and token usage;
- retrieval details;
- validation failures.

It must not report accuracy, unsafe-FNR, or “winner” unless the uploaded package belongs to the frozen labeled benchmark.

## Scientific boundary

This new closed-vocabulary upload protocol should be versioned separately from the completed Phase 2 protocol. Do not retroactively recalculate or replace the frozen Phase 2 results.

For the future local-model experiment, freeze this shared three-decision schema before any held-out run. That experiment will then compare actual reasoning behavior without the earlier output-vocabulary mismatch affecting B0 and B1.

## Prompt:
9/2/2026, 11:53:22 AM

@GitHub You have access to my GitHub repository. I want you to get me the Codex prompt for the implementation of this, as it is necessary for the demo. Before doing that, I want you to check out the repository and let me know what gap is present before this can be implemented as we are arriving at this. Also, for the Codex work, users should be able to choose what LLM to use (currently, only Gpt-5.5 is available, but I will host a Qwen 3.6 (27B dense or 35B-A3B) local model on my work computer and expose it as an API pretty soon as well for the local model experiment). So, the  other model can be greyed out for now.

## Response:
9/2/2026, 11:53:23 AM

I’ll inspect the repository’s current upload, parsing, analysis, baseline, model-adapter, API, and frontend paths before drafting the Codex prompt. I’ll focus on the gap between the frozen fixture-oriented evaluation pipeline and a package-derived end-to-end product flow, including where model selection can be added without altering the immutable M3/M4 artifacts.

The repository already has most of the underlying pieces—an eCTD parser, analyzer, graph/rule pipeline, baseline runners, provider-neutral OpenAI-compatible client, and M4 presentation routes. I’m now tracing whether those pieces are connected through uploaded package state or remain bound to fixture IDs and benchmark cases; that boundary is likely the main implementation gap.

One important finding: the baseline vocabulary issue is already solved in the scientific pipeline. `serialize_direct_request()` supplies B0/B1 the full case-independent RegBridge decision/action vocabulary, with no case rules or expected answers. The new work should reuse that contract; it should not introduce a narrower post-hoc three-label prompt or alter the frozen Phase 2 protocol. I’m using the writing-block workflow now to turn the repository findings into a paste-ready Codex implementation brief.

> **Planning targeted file inspection**
>
> **Planning targeted file inspection**
>
> **Planned targeted file inspection**
>
> 
>
> **Searched installed repositories and inspected their contents**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Planned model selector design**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Designing detailed model catalog entries**
>
> **Designing detailed model catalog entries**
>
> **Planned model selector and detailed catalog entries**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Designing detailed model catalog entries**
>
> **Designing detailed model catalog entries**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Designed model selector, catalog entries, adapters, and analysis tracking**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Designing detailed model catalog entries**
>
> **Designing detailed model catalog entries**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Planning target-context UI and baseline integration**
>
> **Planning target-context UI and baseline integration**
>
> **Planned model selector, catalog, adapters, analysis tracking, and target-context integration**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Designing detailed model catalog entries**
>
> **Designing detailed model catalog entries**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Planning target-context UI and baseline integration**
>
> **Planning target-context UI and baseline integration**
>
> **Designing model selector and dossier analysis API**
>
> **Designing model selector and dossier analysis API**
>
> **Designed model selection, catalog, adapters, context UI, and analysis APIs**
>
> 
>
> **Planning model selector design**
>
> **Planning model selector design**
>
> **Designing detailed model catalog entries**
>
> **Designing detailed model catalog entries**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Unifying model adapters and refining analysis tracking**
>
> **Planning target-context UI and baseline integration**
>
> **Planning target-context UI and baseline integration**
>
> **Designing model selector and dossier analysis API**
>
> **Designing model selector and dossier analysis API**
>
> **Designed model selection, catalog, adapters, UI, and analysis APIs**
>
> 
>
> **Identifying key repository gaps**
>
> **Identifying key repository gaps**
>
> **Identified key repository gaps**
>
> 
>
> **Reviewed backend, frontend, parser, baseline, LLM, API, and dossier implementations**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Planned detailed Codex prompt content**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Outlining implementation phases and API details**
>
> **Outlining implementation phases and API details**
>
> **Planned Codex prompt content and implementation phases**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Outlining implementation phases and API details**
>
> **Outlining implementation phases and API details**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Planned Codex implementation phases, APIs, and dossier analysis adapters**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Outlining implementation phases and API details**
>
> **Outlining implementation phases and API details**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Planned Codex implementation phases, adapters, dossier workflows, and demo UI**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Outlining implementation phases and API details**
>
> **Outlining implementation phases and API details**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Defining model registry and fixture-based testing setup**
>
> **Defining model registry and fixture-based testing setup**
>
> **Planned Codex implementation phases, adapters, dossier workflows, and testing setup**
>
> 
>
> **Planning detailed Codex prompt content**
>
> **Planning detailed Codex prompt content**
>
> **Outlining implementation phases and API details**
>
> **Outlining implementation phases and API details**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Designing model adapters and dossier analysis workflow**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Specifying demo dossier generation and UI workflows**
>
> **Defining model registry and fixture-based testing setup**
>
> **Defining model registry and fixture-based testing setup**
>
> **Planned Codex implementation, model adapters, dossier workflows, and testing setup**
>
> 
>
> **Finalizing answer structure and gap analysis**
>
> **Finalizing answer structure and gap analysis**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Finalized answer structure and detailed codebase gaps**
>
> 
>
> **Finalizing answer structure and gap analysis**
>
> **Finalizing answer structure and gap analysis**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Finalized answer structure and detailed codebase gaps**
>
> 
>
> **Finalizing answer structure and gap analysis**
>
> **Finalizing answer structure and gap analysis**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Finalized answer structure and detailed codebase gaps**
>
> 
>
> **Finalizing answer structure and gap analysis**
>
> **Finalizing answer structure and gap analysis**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Detailing codebase gaps and vocabulary scope**
>
> **Finalized answer structure and detailed codebase gaps and vocabulary scope**
>
> 
>
> **Searched latest repository commit**
>
> 
>
> Worked for 12m 10s

I inspected `chirix33/regbridge` at commit [`5d955c2`](https://github.com/chirix33/regbridge/commit/5d955c286c16ac0f276c089c5580dc2b9f663a46). The foundation is strong, but the end-to-end product workflow is not connected yet.

## Gaps found

| Gap | Current repository state |
|---|---|
| Upload UI | The backend securely accepts ZIP uploads, but the React client only calls `parseFixture()`. [API routes](https://github.com/chirix33/regbridge/blob/main/backend/app/api/routes.py), [frontend client](https://github.com/chirix33/regbridge/blob/main/frontend/src/api/client.ts) |
| Dossier analysis | Analysis is invoked one leaf at a time. There is no dossier-level run, progress state, summary, or multi-document result contract. |
| Upload lifecycle | Parsed inventories live in a module-level dictionary with no retrieval endpoint, expiry, capacity bound, or page-refresh contract. |
| Baseline uploads | `/baselines/run` accepts only a frozen benchmark `case_id`. `BaselineRunner` reparses fixtures rather than accepting uploaded inventories. [Baseline runner](https://github.com/chirix33/regbridge/blob/main/backend/app/baselines/runner.py) |
| Live baseline service | Live B0/B1 execution exists inside the Phase 1/2 evaluation machinery, not as reusable product-facing functionality. |
| Model selection | Model configuration is global through `LLM_*` environment variables, and `AnalysisService` is cached as a singleton. Requests cannot choose an allowlisted model. [Configuration](https://github.com/chirix33/regbridge/blob/main/backend/app/config.py) |
| Adapter mismatch | The normal product service uses `/chat/completions` with `temperature: 0`, while the successful GPT-5.5 experiment used the Responses adapter without a temperature parameter. [Chat adapter](https://github.com/chirix33/regbridge/blob/main/backend/app/llm/openai_compatible.py), [Responses adapter](https://github.com/chirix33/regbridge/blob/main/backend/app/llm/responses.py) |
| Result identity | The analysis ID uses package, leaf, and target context but not model profile/configuration. Different-model analyses could overwrite the same SQLite record. [Analysis service](https://github.com/chirix33/regbridge/blob/main/backend/app/analyzer/service.py) |
| Demonstration package | The repository has separate case fixtures, but no single synthetic dossier containing the three archetypes. |
| Comparison meaning | Arbitrary uploads have no reference labels, so the comparison page must show agreement/disagreement—not accuracy, unsafe-FNR, or a winner. |

### Correction to my earlier vocabulary recommendation

B0 and B1 are already supplied a controlled output vocabulary. `serialize_direct_request()` includes `output_vocabulary()`, which contains all six RegBridge decisions and eleven defined actions. [Direct baseline contract](https://github.com/chirix33/regbridge/blob/main/backend/app/baselines/direct.py), [vocabulary](https://github.com/chirix33/regbridge/blob/main/backend/app/domain/vocabulary.py).

Therefore, do not restrict this new workflow post hoc to only three labels. Reuse the complete existing vocabulary and `DirectDecisionOutput`. The earlier “outside represented class” results were valid decisions outside the benchmark’s three represented reference classes—not unconstrained prose.

## Paste-ready Codex prompt

**standard: **

Implement an additive milestone titled:

# M4.1 — End-to-End Dossier Workspace and Interactive System Comparison

Before changing anything:

1. Read `AGENTS.md` and `IMPLEMENTATION.md` completely.
2. Inspect the current M4 implementation and repository status.
3. Preserve all completed M3 and M4 artifacts.
4. Update `IMPLEMENTATION.md` and add `docs/milestones/M4.1.md` before or alongside implementation so the new product workflow is governed by the repository specification.
5. Do not ask for decisions already settled below. Stop only for a conflict that materially affects scientific validity, regulatory scope, security, or frozen artifacts.

## Goal

Replace the fixture-first audience experience with a real end-to-end product workflow:

```text
Upload controlled synthetic eCTD v3.2.2 dossier
→ parse package
→ analyze every supported leaf
→ display dossier summary
→ inspect document decisions, evidence, graph, repair, and trace
```

Add a separate interactive comparison workspace:

```text
Upload or reuse the same parsed dossier
→ select documents and one available model
→ run B0, B1, B2, and RegBridge on identical package-derived inputs
→ display concise side-by-side decisions and native traces
```

The primary RegBridge workspace must contain no baseline metrics, benchmark scores, or system comparisons.

## Immutable research boundaries

Do not modify, regenerate, reinterpret, or replace:

- the frozen 30-case benchmark;
- its split, families, labels, or digest;
- completed Phase 1 or Phase 2 live artifacts;
- the M4 presentation snapshot;
- existing paper validation tables;
- existing performance claims or disclosures.

The new workflow is a product demonstration and package-level comparison capability. It is not a new benchmark evaluation.

Preserve everywhere:

- FDA/CDER-only scope;
- prospective forward-compatibility framing;
- current FDA availability as `not_operational`;
- `expert_validated: false`;
- author-adjudicated rules as controlled research operationalizations;
- no FDA-acceptance, compliance, or regulatory-advice claim;
- public, synthetic, or deliberately de-identified uploads only.

## 1. Model-profile registry

Replace request-time dependence on one global model with an allowlisted server-side model-profile registry.

Add a typed model profile containing at least:

- stable `model_id`;
- display name;
- availability: `available`, `coming_soon`, or `misconfigured`;
- disabled reason;
- adapter type;
- configured model name;
- structured-output capability;
- reasoning capability;
- configuration digest;
- whether network access is required.

Expose:

```text
GET /api/v1/models
```

Return only safe public metadata. Never return API keys, raw credentials, authorization headers, or unnecessary internal endpoint details.

Create these public options:

1. `gpt-5.5`
   - label: `GPT-5.5`
   - default option;
   - available when its server-side configuration is valid;
   - use the already tested Responses API adapter;
   - do not send a temperature parameter;
   - retain structured-output validation and evidence de-aliasing.

2. `qwen3.6-local`
   - label: `Qwen 3.6 local — coming soon`
   - subtitle may mention `27B Dense / 35B-A3B`;
   - return `coming_soon`;
   - render disabled in the UI;
   - do not attempt an API call;
   - prepare an additive profile/configuration boundary so it can later use an OpenAI-compatible chat-completions endpoint without changing product contracts.

Do not accept arbitrary model names, endpoints, or credentials from the browser. Requests supply only an allowlisted `model_id`.

Keep fixture/stub models available internally for network-free tests, but do not present them as public LLM choices.

The selected model must be recorded in every applicable run and result:

- model profile ID;
- requested model name;
- provider-reported model name when available;
- adapter type;
- configuration digest;
- prompt version;
- request digest;
- token usage;
- latency;
- status or bounded failure.

Use the same selected model for B0, B1, and RegBridge in a comparison. B2 must be labeled model-free.

Do not modify the frozen Phase 2 configuration. This is a separately versioned product execution profile.

## 2. Resolve model-dependent result identity

The current analysis identifier does not distinguish models.

Ensure analyses performed with different model profiles or execution configurations cannot overwrite one another. Include a stable execution-profile/configuration digest in analysis identity, or introduce a separate run identity that uniquely owns its analyses.

Tests must prove:

- same package, leaf, target context, and configuration produce the same deterministic identity;
- changing the selected model changes the run/analysis identity;
- one model’s result cannot overwrite another model’s result.

## 3. Bounded upload repository

Retain the existing secure ZIP parser and its current protections:

- upload and expanded-size limits;
- path traversal prevention;
- normalized duplicate-path rejection;
- symlink rejection;
- compression-ratio bounds;
- DTD/entity rejection;
- supported MIME/signature checks;
- bounded PDF extraction.

Replace the unbounded module-level `_inventories` dictionary with a typed, bounded local upload/inventory repository.

Requirements:

- raw ZIP is discarded after parsing;
- inventories receive opaque server-generated IDs;
- expose inventory retrieval by opaque ID;
- use a capacity bound and expiry/TTL suitable for a local demo;
- reject traversal-like or malformed IDs;
- never log full PDF text;
- make expiry and server-restart behavior explicit;
- continue to require synthetic or de-identified input.

Expose or preserve:

```text
POST /api/v1/applications/parse
GET  /api/v1/applications/{inventory_id}
```

The existing fixture routes may remain for controlled regression and guided case pages.

## 4. Dossier-level analysis job

Add typed contracts such as:

- `DossierAnalysisRequest`;
- `DossierAnalysisRun`;
- `DossierAnalysisSummary`;
- `DossierLeafResult`;
- `DossierLeafFailure`.

Expose:

```text
POST /api/v1/dossier-analyses
GET  /api/v1/dossier-analyses/{run_id}
```

Request fields must include:

- inventory ID;
- selected allowlisted model ID;
- explicit target context;
- optional leaf IDs, defaulting to all supported leaves.

Supported states:

```text
queued
running
completed
partial_failed
failed
```

The run should analyze supported leaves through the existing production parser, rules, graph validation, semantic inspection, synthesis, and persistence path. Do not hard-code outcomes for the composite demo package.

Return a dossier summary containing at least:

- package digest;
- application metadata;
- total supported leaves;
- analyzed, failed, and skipped counts;
- counts by decision and severity;
- number requiring human approval;
- parser warnings;
- model profile and configuration digest;
- per-leaf results;
- analysis and graph identifiers.

A failure on one leaf must be explicit. It must not silently become a permissive decision. Report partial completion honestly.

Only transport/provider failures may receive the existing bounded retry treatment. Schema, citation, graph, persistence, and synthesis failures must halt the affected leaf with rollback and an explicit sanitized cause.

## 5. Main RegBridge workspace

Make `/` the primary product workspace. Move the current scope-oriented page to `/about` or another stable route.

The main page must allow the user to:

1. choose a ZIP dossier;
2. choose an available LLM;
3. view and confirm the target context;
4. click `Parse and analyze`;
5. inspect the dossier-level and document-level results.

The target-context panel must visibly disclose:

- FDA;
- CDER;
- NDA;
- eCTD v3.2.2 source;
- eCTD v4.0 target;
- standards snapshot;
- prospective versus current-operational mode;
- identifier-reuse operation;
- metadata migration intent and manufacturer partitioning when applicable.

Do not infer metadata intent silently. A demo preset may prefill it, but it must remain visible and user-confirmed.

Render:

- upload/parse state;
- dossier inventory summary;
- parser warnings;
- decision/severity summary cards;
- document results table;
- human-review count;
- per-document decision;
- repair or suggested check;
- findings;
- regulatory and dossier evidence;
- uncertainty;
- model record;
- chronological trace;
- accessible graph and edge table.

Opening a document should reveal its complete result without leaving the product workflow.

Do not show on this page:

- B0/B1/B2;
- accuracy;
- macro-F1;
- unsafe-FNR;
- Phase 2 results;
- system rankings;
- benchmark reference labels.

Keep the existing research-prototype, `not_operational`, and non-expert-validation disclosures visible without overwhelming the workflow.

## 6. Shared output vocabulary

Do not create a post-hoc three-class model prompt.

Reuse:

- `Decision`;
- `ActionCode`;
- `DirectDecisionOutput`;
- `output_vocabulary()`;
- its effect-only action definitions.

B0 and B1 must receive the same complete, case-independent vocabulary currently used in the frozen experiment:

- all six permitted decisions;
- all existing action codes and neutral definitions.

Do not provide:

- benchmark class frequencies;
- expected decisions;
- case IDs;
- fixture IDs;
- reference labels;
- adjudication rationales;
- rule-trigger conditions;
- expected evidence;
- RegBridge’s result.

The UI may render friendly display text, but must retain the exact canonical decision and action values in the API result.

## 7. Package-derived comparison service

The current baseline API is frozen-case-only. Add a new comparison service rather than changing the meaning of the M3 endpoint.

Expose:

```text
POST /api/v1/comparisons
GET  /api/v1/comparisons/{comparison_id}
```

The request must include:

- inventory ID;
- selected model ID;
- target context;
- selected leaf IDs, defaulting to all supported leaves;
- systems fixed to B0, B1, B2, and RegBridge.

Build a package-derived, label-free inference input from the parsed inventory. It must not contain benchmark IDs, fixture IDs, reference decisions, rules expected to fire, or expected evidence.

Run:

- B0: bounded dossier material plus all six source-verified standards spans, without graph or executable rules;
- B1: the same dossier material plus BM25 top-3 evidence using the frozen transparent retrieval configuration;
- B2: production parser, graph facts, and deterministic rules with semantic assistance omitted;
- RegBridge: the complete hybrid pipeline.

B0 and B1 must use `DirectDecisionOutput` and the existing shared vocabulary.

Extract reusable live direct-decision functionality from the evaluation implementation instead of calling fixture `contract_fixture_decision()` for uploaded dossiers. Do not make the product comparison service depend on frozen benchmark loaders.

B2 and RegBridge must operate directly on the supplied `ApplicationInventory`; they must not reparse a `FixtureCatalog` case.

For every leaf/system combination, record:

- package and selected-file digests;
- package-derived input digest;
- system;
- selected model or `model-free`;
- decision;
- severity;
- action;
- human-review requirement;
- rationale;
- evidence IDs;
- rule IDs where applicable;
- retrieval trace for B1;
- graph/analysis reference for RegBridge and B2 where applicable;
- latency;
- token usage;
- explicit failure.

The comparison must fail closed on invalid model output. Never replace an invalid response with a fixture answer.

## 8. Baselines/comparison page

Add:

```text
/baselines
```

The page must support:

- uploading a new dossier;
- reusing the currently parsed inventory when available;
- selecting one or more leaves;
- selecting an available model;
- running the four systems;
- polling and displaying progress;
- rerunning after an explicit reset.

Use the same selected model for B0, B1, and RegBridge. Render Qwen greyed out with `Coming soon`. Clearly mark B2 as `No LLM`.

Display a side-by-side table with:

- system;
- decision;
- severity;
- action;
- human review;
- evidence;
- status;
- latency.

Expandable details should show:

- B0 supplied evidence and direct rationale;
- B1 BM25 query aliases, ranked spans, scores, and rationale;
- B2 deterministic facts and fired rules;
- RegBridge semantic finding, evidence occurrence, graph validation, deterministic synthesis, and final trace.

For an arbitrary upload, do not display:

- accuracy;
- unsafe-FNR;
- review-bypass rate;
- reference decision;
- correct/incorrect;
- winning system;
- superiority language.

Instead show:

- agreement/disagreement;
- decisions and actions;
- evidence coverage;
- failures;
- latency and usage.

Keep `/evaluation` as the immutable labeled Phase 2 dashboard. Do not merge it with `/baselines`.

## 9. Composite synthetic demonstration dossier

Create a deterministic, public synthetic dossier containing three leaves in one package:

- Case A: removed `3.2.S.1.2` heading requiring `REUSE_WITH_NEW_CONTEXT`;
- Case B: `manufacturer="all"` with an explicit visible preserve-existing-lifecycle target intent, producing legacy reuse while retaining the advisory;
- Case C: stale responsible-applicant wording or another already-approved semantic mismatch, producing `HUMAN_REGULATORY_REVIEW`.

The package must:

- contain no sponsor-confidential or personal data;
- be generated reproducibly;
- have a stable package hash;
- be a real ZIP accepted through the upload API;
- pass the same parser and analyzer paths as any other upload;
- not carry expected decisions inside model-facing material;
- include lineage and an implementation manifest outside the uploaded model material.

Provide a deterministic generator and an easy way to obtain the ZIP for the five-minute demonstration. Do not add a hidden “load expected result” path.

## 10. Adapter preparation for local Qwen

Prepare, but do not activate, the `qwen3.6-local` model profile.

The future local profile must be able to configure server-side:

- base URL;
- API key or local placeholder;
- actual served model name;
- timeout;
- chat-completions adapter;
- JSON-schema/structured-output capability;
- token limits;
- optional temperature support.

Do not assume that the local endpoint implements OpenAI Responses API or strict JSON Schema. Keep capability checks explicit. The profile must remain unavailable until its endpoint and structured-output behavior have been separately validated.

Enabling Qwen later must require:

- configuration validation;
- a capability/contract test;
- an explicit profile availability change;
- a separate frozen local-model experimental configuration.

Do not treat interactive product runs as the local-model paper experiment.

## 11. Frontend and navigation

Recommended navigation:

```text
Analyzer | Baselines | Evaluation | Guided cases | About
```

Preserve:

- `/demo/case-a`;
- `/demo/case-b`;
- `/demo/case-c`;
- `/evaluation`.

Use React, TypeScript, Tailwind, and Iconoir consistently. Preserve keyboard access, focus management, semantic tables, visible busy/error states, screen-reader announcements, and graph text alternatives.

Do not put regulatory logic in React.

## 12. Tests

Add backend tests for:

- raw ZIP upload through the public API;
- inventory retrieval, capacity, expiry, and malformed IDs;
- all upload security limits;
- dossier analysis across multiple leaves;
- partial failure behavior;
- model catalog availability and secret redaction;
- rejection of unavailable and arbitrary model IDs;
- GPT-5.5 routing through the Responses adapter;
- Qwen disabled without any attempted call;
- analysis identity separation by model/configuration;
- package-derived baseline input with zero label/fixture leakage;
- B0/B1 shared output vocabulary;
- B0/B1 live structured-output validation;
- B1 stable BM25 retrieval;
- B2 semantic omission;
- same model selection for B0/B1/RegBridge;
- no model call for B2;
- arbitrary-upload comparison without reference metrics;
- graph persistence and rollback;
- unchanged `not_operational` and `expert_validated: false`.

Add frontend unit/E2E/accessibility tests for:

- upload and analyze on `/`;
- GPT-5.5 selectable;
- Qwen visible but disabled;
- dossier summary and per-leaf drill-down;
- absence of baseline numbers on `/`;
- upload/reuse on `/baselines`;
- comparison progress and results;
- absence of accuracy/winner claims on arbitrary uploads;
- B1 retrieval drill-down;
- RegBridge graph/evidence trace;
- current-operational guard;
- reset and error recovery;
- keyboard and axe accessibility.

The E2E test must upload the real generated three-leaf ZIP rather than call a fixture-ID route.

## 13. Verification and documentation

Add an additive verification command such as:

```text
scripts/m4-1-verify.ps1
make m4-1-verify
```

It must run:

- backend lint;
- backend typecheck;
- complete backend tests;
- schema/OpenAPI drift checks;
- frontend lint;
- frontend typecheck;
- frontend tests;
- production build;
- Playwright E2E/accessibility;
- deterministic composite-package generation and hash verification;
- network-free fixture/stub demonstration;
- checks that protected M3/M4 artifacts remain unchanged.

Update:

- `IMPLEMENTATION.md`;
- `README.md`;
- `.env.example`;
- API/OpenAPI schemas;
- frontend contracts;
- `docs/milestones/M4.1.md`;
- demonstration instructions and screenshots.

## Completion criteria

M4.1 is complete only when:

1. A user can upload the composite ZIP from the main page, click `Parse and analyze`, and inspect dossier summary, three document decisions, repairs/checks, evidence, graph, and traces.
2. No baseline or benchmark result appears on the main Analyzer page.
3. The Baselines page can run B0/B1/B2/RegBridge on identical package-derived inputs.
4. B0/B1 receive the existing full shared output vocabulary but no labels, expected answers, or rule conditions.
5. The selected model is the same for B0/B1/RegBridge and is recorded in every result.
6. GPT-5.5 is available through its validated Responses adapter.
7. Qwen is visible and greyed out with a clear coming-soon explanation.
8. B2 performs no model call.
9. Arbitrary-upload comparisons show no reference-label metrics or superiority claims.
10. Different model profiles cannot overwrite one another’s analyses.
11. Current FDA availability remains `not_operational`.
12. Every result remains `expert_validated: false`.
13. Frozen M3/M4 artifacts and digests are unchanged.
14. Existing tests continue to pass, and the new verification command passes twice.
15. The final report lists exact commands, test counts, new routes, generated package hash, screenshots, remaining limitations, and any approved deviations.

## Prompt:
9/2/2026, 12:11:58 PM

Okay, I have a question before I give this to Codex: v3.2.2 uses index.xml, I believe. This workflow won't read and validate the XML, will it? If yes, explain. If no, explain too in terms of research direction and goal and demonstration goal. I just want an explanation first

## Response:
9/2/2026, 12:12:01 PM

Yes—the intended workflow should genuinely read `index.xml`; otherwise the upload would only be theater. I’m separating two meanings of “validate”: the repository already performs bounded parsing and integrity checks, but it is not currently a complete official eCTD v3.2.2 schema/validation-criteria engine. I’m checking one checksum detail before describing that boundary precisely.

> **Clarifying parser validation scope**
>
> **Clarifying parser validation scope**
>
> **Identifying checksum algorithm discrepancy**
>
> **Identifying checksum algorithm discrepancy**
>
> **Clarified parser validation scope and identified checksum discrepancy**
>
> 
>
> **Searching 11 websites**
>
>
> **Clarifying checksum attribute usage**
>
> **Clarifying checksum attribute usage**
>
> **Clarified checksum attribute usage**
>
> 
>
> **Searching 17 websites**
>
>
> **Explaining XML parser DTD handling limitations**
>
> **Explaining XML parser DTD handling limitations**
>
> **Clarifying parser limitations and improvement options**
>
> **Clarifying parser limitations and improvement options**
>
> **Explained XML parser DTD limitations and improvement options**
>
> 
>
> **Explaining XML parser DTD handling limitations**
>
> **Explaining XML parser DTD handling limitations**
>
> **Clarifying parser limitations and improvement options**
>
> **Clarifying parser limitations and improvement options**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Explained XML parser limitations, checksum handling, and improvement options**
>
> 
>
> **Explaining XML parser DTD handling limitations**
>
> **Explaining XML parser DTD handling limitations**
>
> **Clarifying parser limitations and improvement options**
>
> **Clarifying parser limitations and improvement options**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Explained XML parser limitations and checksum handling gaps**
>
> 
>
> **Explaining XML parser DTD handling limitations**
>
> **Explaining XML parser DTD handling limitations**
>
> **Clarifying parser limitations and improvement options**
>
> **Clarifying parser limitations and improvement options**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Detailing checksum handling and XML parsing gaps**
>
> **Outlining controlled profile parsing and validation limits**
>
> **Outlining controlled profile parsing and validation limits**
>
> **Explained XML parser limitations, checksum handling, and validation options**
>
> 
>
> **Searched 17 websites**
>
> 
>
> Worked for 1m 29s

Yes—the proposed workflow will genuinely read `index.xml`. But there is an important distinction:

> RegBridge currently performs secure, deterministic parsing and bounded structural validation of a controlled v3.2.2 profile. It does not perform complete official eCTD v3.2.2 conformance validation.

## What happens after upload

The existing endpoint already accepts ZIP bytes and calls `parse_zip()`. The parser then:

1. Safely extracts the archive.
2. Requires `index.xml` and `us-regional.xml`.
3. Parses both XML files deterministically—no LLM is involved.
4. Walks the CTD heading hierarchy in `index.xml`.
5. Extracts each leaf’s:
   - ID;
   - heading;
   - title;
   - file path;
   - lifecycle operation;
   - `modified-file` reference;
   - manufacturer, substance, product, and dosage-form attributes;
   - declared checksum.
6. Resolves the referenced PDF.
7. Computes file and package hashes.
8. Extracts bounded PDF text and hyperlinks.
9. Produces the `ApplicationInventory` used by the rule engine, graph, semantic model, and decision synthesizer.

That behavior is in the current [eCTD parser](https://github.com/chirix33/regbridge/blob/main/backend/app/parsers/ectd322.py) and [parser models](https://github.com/chirix33/regbridge/blob/main/backend/app/parsers/models.py).

Therefore, the three injected cases would be detected from the actual uploaded package:

| Case | Where RegBridge obtains the signal |
|---|---|
| A: removed heading | Heading hierarchy surrounding the leaf in `index.xml` |
| B: `manufacturer="all"` | Manufacturer attribute in `index.xml` |
| C: stale applicant or hyperlink | PDF text/hyperlinks compared with applicant metadata from `us-regional.xml` |

The expected decisions must not appear in the uploaded package or prompt.

## What “validation” it currently performs

The parser currently validates things such as:

- ZIP size and expanded size;
- path traversal;
- duplicate normalized paths;
- symbolic links;
- decompression bombs;
- XML syntax;
- rejection of DTD/entity declarations;
- existence of required XML files;
- presence and uniqueness of leaf IDs;
- recognizable CTD headings;
- allowed lifecycle-operation values;
- presence of `modified-file` for replacement;
- referenced-file existence;
- PDF extension and file signature;
- declared-versus-computed checksum under its current internal assumption;
- bounded PDF extraction.

These are real validation steps. The XML is not merely uploaded and ignored.

## What it does not validate

It is not currently a complete FDA/ICH eCTD v3.2.2 validator. In particular:

### 1. No official DTD validation

The parser rejects any `DOCTYPE` or entity declaration as a security precaution. It does not validate `index.xml` against a pinned ICH eCTD DTD.

That is secure, but it means a standards-authentic XML file containing a normal DTD declaration could be rejected rather than safely validated against a local trusted DTD.

### 2. Simplified package layout

The parser currently expects both:

```text
index.xml
us-regional.xml
```

at the ZIP root.

A more authentic FDA sequence commonly places the regional backbone under a Module 1 path. The parser does not yet discover multiple accepted sequence-root/layout variants.

### 3. Checksum mismatch with authentic v3.2.2

This is the most concrete compatibility gap.

Official eCTD v3.2.2 leaf checksums use MD5 and identify the algorithm through `checksum-type="md5"`. [FDA’s eCTD v3.2.2 backbone specification](https://www.fda.gov/media/159380/download) shows the MD5 leaf convention, and FDA validation criteria check for valid MD5 formatting and type. [FDA validation criteria](https://www.fda.gov/media/87056/download).

The current RegBridge parser computes SHA-256 and compares the declared XML checksum as though it were SHA-256. SHA-256 remains appropriate for RegBridge’s immutable research provenance, but it must be separate from the legacy package’s declared MD5 checksum.

A more authentic representation should record both:

```text
declared_checksum_type: md5
declared_checksum: <32-character value>
computed_declared_checksum: <computed MD5>
provenance_sha256: <RegBridge internal SHA-256>
```

### 4. No complete validation-criteria coverage

It does not comprehensively validate:

- every DTD or XSD rule;
- every FDA validation criterion;
- full folder and filename conventions;
- cumulative lifecycle across multiple sequences;
- every Module 1 structure;
- complete STF semantics;
- all leaf and node-extension conditions;
- complete cross-sequence `modified-file` resolution;
- whether the resulting package would pass FDA technical validation.

## Is that acceptable for the research?

Yes—provided we describe it accurately.

RegBridge’s research contribution is not:

> We built another complete eCTD validator.

It is:

> Given securely parsed legacy dossier structure and content, can a hybrid graph, constraint, and semantic architecture support stable, traceable document-reuse decisions?

Full FDA validation would be a large engineering project and would distract from the primary contribution. Commercial publishing tools already perform extensive schema and technical validation.

However, the demonstration must use authentic data flow. The XML must genuinely supply the lifecycle, heading, metadata, and document references. Otherwise, reviewers could dismiss the upload as a decorative wrapper around fixtures.

The defensible demonstration wording is:

> RegBridge securely parses a controlled FDA eCTD v3.2.2 package profile and analyzes the supported heading, lifecycle, metadata, and document-content predicates. It is not a complete FDA submission validator.

## My recommendation before sending the Codex prompt

The end-to-end implementation should include a small authenticity-hardening subtask:

- support a realistic sequence directory layout;
- distinguish declared MD5 checksums from internal SHA-256 provenance;
- verify `checksum-type`;
- record the declared DTD version;
- safely recognize a pinned expected DTD declaration without allowing external entity resolution;
- clearly report unsupported structures;
- keep complete FDA validation explicitly out of scope.

Without those changes, the workflow will still read real XML, but only from RegBridge’s simplified controlled profile. With them, the uploaded synthetic package becomes much closer to an authentic v3.2.2 sequence while keeping the research scope manageable.

## Prompt:
9/2/2026, 12:16:55 PM

Okay, so you want to update the Codex prompt to include the authenticity-hardening subtask? You can do it.

## Response:
9/2/2026, 12:16:56 PM

I’ll add it as a binding addendum to the earlier implementation prompt so you do not have to resend the entire long prompt. It will make the uploaded package structurally authentic enough for the demo while explicitly stopping short of turning RegBridge into a full FDA validation engine.

> **Preparing prompt update addendum**
>
> **Preparing prompt update addendum**
>
> **Clarifying prompt revision with technical details**
>
> **Clarifying prompt revision with technical details**
>
> **Prepared a technically detailed prompt update addendum**
>
> 
>
> **Preparing prompt update addendum**
>
> **Preparing prompt update addendum**
>
> **Clarifying prompt revision with technical details**
>
> **Clarifying prompt revision with technical details**
>
> **Defining robust XML parsing and checksum validation**
>
> **Defining robust XML parsing and checksum validation**
>
> **Prepared a technically detailed prompt addendum with XML parsing and checksum validation requirements**
>
> 
>
> **Preparing prompt update addendum**
>
> **Preparing prompt update addendum**
>
> **Clarifying prompt revision with technical details**
>
> **Clarifying prompt revision with technical details**
>
> **Defining robust XML parsing and checksum validation**
>
> **Defining robust XML parsing and checksum validation**
>
> **Prepared a technically detailed prompt update with XML parsing and checksum validation**
>
> 
>
> Worked for 39s

Append this to the previous Codex prompt. It supersedes any assumption that the composite dossier may use only the repository’s simplified XML layout.

**standard: **

# Binding Addendum — Authenticity-Hardened eCTD v3.2.2 Input Profile

This addendum is part of M4.1 and supersedes conflicting assumptions in the earlier prompt.

The end-to-end upload must genuinely derive decisions from the uploaded XML and referenced documents. It must not merely associate a ZIP or fixture identifier with predefined case data.

RegBridge is not becoming a complete FDA eCTD validator. Implement a clearly identified, authenticity-hardened controlled input profile sufficient to demonstrate real XML-derived lifecycle, heading, metadata, and document-content reasoning.

## A. Claim boundary

Use this exact capability boundary in documentation and UI:

> RegBridge securely parses and validates a controlled FDA eCTD v3.2.2 package profile for supported structural, lifecycle, metadata, checksum, and document-evidence predicates. It does not perform complete FDA submission validation.

Do not claim:

- complete ICH DTD conformance;
- complete FDA validation-criteria coverage;
- validation of an entire application history;
- FDA submission readiness;
- FDA acceptance;
- production publishing-system equivalence.

The research contribution remains lifecycle-sensitive, evidence-grounded reuse-risk decision support after bounded deterministic parsing.

## B. Version the supported profile

Introduce a stable profile identifier, for example:

```text
fda-ectd-322-regbridge-demo-profile-v1
```

Every parsed inventory and dossier-analysis run must record:

- input profile ID and version;
- detected sequence root;
- detected backbone paths;
- XML version information;
- package-validation checks;
- warnings;
- unsupported structures;
- whether parsing was complete or bounded.

Do not return a generic “valid eCTD” boolean. Return scoped check results such as:

```text
passed
warning
unsupported
failed
```

A package passes the RegBridge profile only when every required profile check passes. That status must not be described as FDA validation.

## C. Authentic sequence-root discovery

Do not require `index.xml` and `us-regional.xml` to both be at the ZIP root.

Safely support:

1. a ZIP whose extraction root is the sequence root; and
2. a ZIP containing one application/sequence wrapper, such as:

```text
synthetic-application/
  0000/
    index.xml
    index-md5.txt
    m1/
      us/
        us-regional.xml
    m2/
    m3/
    util/
      dtd/
```

Locate exactly one supported sequence root containing `index.xml`.

Reject:

- no sequence root;
- multiple ambiguous `index.xml` candidates;
- traversal paths;
- paths outside the extracted archive;
- multiple sequence histories unless explicitly supported later.

Record the selected sequence root. Do not silently select the first match.

Locate `us-regional.xml` in the supported FDA Module 1 path. The old simplified root-level layout may remain for legacy regression fixtures, but it must be identified as `legacy_controlled_layout` and must not be used for the new audience-facing composite dossier.

## D. Safe XML and DOCTYPE handling

The current unconditional rejection of every `DOCTYPE` prevents authentic-looking v3.2.2 XML from being parsed.

Implement safe, offline handling that:

- never resolves network resources;
- never permits arbitrary filesystem resolution;
- never expands external entities;
- never accepts an unrecognized external identifier;
- rejects internal entity declarations;
- recognizes only explicitly allowlisted expected DTD identifiers or paths;
- resolves a DTD only from a pinned repository-controlled local copy if actual DTD validation is implemented;
- records the declared DTD identifier and DTD version.

Do not claim DTD validation merely because the declaration was recognized.

Represent these separately:

```text
doctype_recognized
dtd_version_supported
dtd_validation_performed
dtd_validation_result
```

If complete pinned-local DTD validation is too expansive for M4.1, securely recognize and record the expected declaration, perform the controlled profile checks below, and set:

```text
dtd_validation_performed: false
```

That is acceptable when disclosed.

## E. XML structural checks

For the controlled profile, deterministically inspect and report at least:

- XML is well formed;
- recognized eCTD namespace/root;
- supported declared eCTD/DTD version;
- required backbone files are present;
- leaf IDs are present and unique within the parsed backbone;
- `xlink:href` is relative and safe;
- referenced physical files exist when the operation requires a file;
- lifecycle operation is supported;
- required `modified-file` is present for `append`, `replace`, and `delete`;
- heading is recognizable or explicitly reported as unsupported;
- leaf title presence;
- checksum type and format;
- checksum match;
- PDF extension, MIME expectation, and signature;
- bounded PDF text/hyperlink extraction status.

Do not treat an unrecognized heading as a malformed dossier. Parse it when safely possible and let RegBridge return the approved mapping abstention boundary.

## F. Separate legacy MD5 from provenance SHA-256

Correct the current checksum representation.

For authentic eCTD v3.2.2 compatibility, read:

```text
checksum-type="md5"
checksum="<32 hexadecimal characters>"
```

Record separately:

```text
declared_checksum_type
declared_checksum
computed_declared_checksum
declared_checksum_matches
provenance_sha256
```

Requirements:

- calculate MD5 only to verify compatibility with the declared legacy eCTD checksum;
- clearly document that MD5 is used because the legacy format requires it, not as RegBridge’s security or provenance hash;
- retain SHA-256 for internal package, source-file, fixture, manifest, and research-provenance identities;
- reject unsupported checksum types within this profile;
- reject malformed nonempty MD5 values;
- fail the applicable file check when a required declared checksum does not match.

Where Python exposes `usedforsecurity=False`, use it for the compatibility MD5 calculation or provide a narrowly documented compatible wrapper.

Also support and verify `index-md5.txt` when present in the controlled profile:

- require exactly one valid 32-character MD5 value;
- compare it with the uploaded `index.xml`;
- record the result independently from package SHA-256.

Do not replace any existing frozen SHA-256 research digests.

## G. Lifecycle-sensitive file handling

Correctly distinguish operations that introduce a physical file from operations that only modify lifecycle state.

For `new`, `append`, and `replace`:

- require the profile-defined file reference;
- resolve it safely;
- verify its declared MD5;
- compute its provenance SHA-256.

For `append`, `replace`, and `delete`:

- require and parse `modified-file`;
- preserve the original relative reference;
- validate safe syntax;
- record whether the referenced prior-sequence leaf was resolved, unresolved, or outside the uploaded single-sequence scope.

For `delete`:

- do not require a newly submitted PDF;
- permit the legacy empty-checksum behavior where supported by the pinned profile;
- do not invent or load a physical document;
- record that full historical lifecycle resolution is outside the single-sequence profile when the prior sequence is unavailable.

Full multi-sequence lifecycle reconstruction remains out of scope for M4.1. An unresolved historical reference must be disclosed and must not silently become a permissive reuse conclusion.

## H. Backbone XML references versus analyzable dossier documents

An authentic `index.xml` may reference regional XML or other backbone-related files.

Do not try to analyze every referenced XML file as a PDF.

Represent package members distinctly, for example:

```text
BACKBONE_XML
REGIONAL_XML
DOSSIER_DOCUMENT
STUDY_TAGGING_FILE
SUPPORT_FILE
UNSUPPORTED
```

Only supported dossier documents become document-analysis candidates.

Backbone and regional XML references should still receive:

- path checks;
- presence checks;
- checksum checks;
- provenance hashes;
- relationship records.

Extend the inventory contract with a typed package-file or backbone-reference collection rather than forcing every package member into `ParsedLeaf` as an analyzable PDF.

## I. Regional metadata

Parse applicant/application metadata from the supported `us-regional.xml` path.

At minimum, extract when present:

- application number;
- application type or supported submission metadata;
- applicant name;
- regional XML version;
- regional XML provenance hash.

The Case C applicant comparison must use the value actually parsed from `us-regional.xml`. It must not obtain the expected applicant name from a fixture catalog, frontend constant, benchmark label, or hidden manifest.

## J. Composite dossier requirements

The new three-document synthetic upload must use the authenticity-hardened layout, not the legacy simplified layout.

It must contain:

```text
<application>/<sequence>/index.xml
<application>/<sequence>/index-md5.txt
<application>/<sequence>/m1/us/us-regional.xml
<application>/<sequence>/m3/.../case-a.pdf
<application>/<sequence>/m3/.../case-b.pdf
<application>/<sequence>/m3/.../case-c.pdf
```

Include pinned local DTD/support files only when needed by the chosen safe profile.

The three signals must originate from actual package content:

- Case A heading from the relevant `index.xml` hierarchy;
- Case B `manufacturer="all"` from the relevant XML attribute;
- Case C stale responsible-applicant wording from the PDF, compared with applicant metadata parsed from `us-regional.xml`.

Every physical file must have:

- the proper legacy declared MD5 where required;
- a separately computed RegBridge SHA-256 provenance digest.

The generator must deterministically rebuild:

- XML;
- PDFs;
- MD5 values;
- `index-md5.txt`;
- ZIP ordering and timestamps where necessary for a stable package hash;
- the external generation manifest.

Expected decisions, reference labels, benchmark case IDs, fixture IDs, and adjudication rationales must not appear inside the model-facing package material.

## K. Package-validation report in the UI

After upload, display a compact section titled:

```text
Controlled v3.2.2 profile checks
```

Show:

- detected sequence root;
- profile version;
- XML/version status;
- backbone and regional metadata status;
- checksum verification summary;
- referenced-file summary;
- PDF extraction summary;
- warnings and unsupported structures.

Use wording such as:

```text
Supported profile checks passed
```

Never display:

```text
FDA-valid dossier
FDA-compliant package
Submission accepted
Complete eCTD validation passed
```

The main result must continue to emphasize reuse-risk decisions rather than XML validation.

## L. Baseline fairness

All systems must receive facts derived from the same parsed package.

B0 and B1 may receive the bounded package-validation facts necessary to understand the document, but not:

- reference labels;
- expected outcomes;
- hidden fixture metadata;
- rules expected to fire;
- RegBridge’s decision.

B2 and RegBridge must consume the same deterministic parsed inventory.

The baseline comparison should not reward RegBridge merely for receiving XML fields that are withheld from B0/B1. Serialize equivalent bounded case material for the direct-model systems.

## M. Required authenticity tests

Add tests for:

- sequence root at archive root;
- one application/sequence wrapper;
- missing and ambiguous `index.xml`;
- supported Module 1 regional path;
- legacy simplified layout reported separately;
- recognized and unrecognized DOCTYPE;
- no external network/entity resolution;
- malicious internal entity rejection;
- supported DTD version;
- unsupported or missing DTD version;
- valid MD5 leaf checksum;
- malformed MD5;
- checksum mismatch;
- SHA-256 provenance remaining independent from MD5;
- valid and invalid `index-md5.txt`;
- new, append, replace, and delete lifecycle requirements;
- safe and unsafe `modified-file`;
- XML/backbone references not treated as PDFs;
- applicant metadata derived from `us-regional.xml`;
- the composite dossier producing three document candidates;
- mutations to the XML or PDF changing the applicable result through the parser rather than through fixture lookup;
- no expected-decision or fixture-identifier leakage;
- unchanged frozen M3/M4 artifacts and digests.

Include at least one metamorphic test for each archetype:

1. move Case A from the removed heading to valid `3.2.S.1` and verify the structural finding changes;
2. change Case B from `manufacturer="all"` to a stable distinguishing value and verify the metadata finding changes;
3. make the Case C applicant statement agree with `us-regional.xml` and verify the semantic risk changes or disappears.

These tests must use the same upload, parser, analyzer, graph, and synthesis path as the demonstration.

## N. Updated M4.1 completion gates

In addition to all earlier M4.1 gates, completion now requires:

1. The audience-facing composite ZIP uses the authenticity-hardened v3.2.2 profile.
2. Decisions are derived from uploaded `index.xml`, `us-regional.xml`, and PDFs.
3. The system separately verifies legacy MD5 compatibility and SHA-256 research provenance.
4. The UI shows scoped profile checks without claiming complete FDA validation.
5. The composite upload produces the three archetype results without fixture-ID lookup or hard-coded outcomes.
6. A modified XML heading, manufacturer attribute, or PDF applicant statement causes the relevant result to change through the production pipeline.
7. Unsupported or ambiguous XML structures fail closed or produce an explicit bounded warning/review result.
8. Full DTD/FDA validation remains explicitly outside scope unless actually implemented and verified.

## Prompt:
9/2/2026, 11:11:10 PM

Codex implemented it successfully in the demonstration-ui-flow-implementation branch: "M4.1 is fully implemented and verified.

Key outcomes:

- `/` is now the dossier Analyzer workspace.
- `/baselines` runs package-derived B0/B1/B2/RegBridge comparisons.
- `/evaluation`, guided cases, and `/about` remain available.
- New APIs:
  - `GET /api/v1/models`
  - `GET /api/v1/applications/{inventory_id}`
  - `POST/GET /api/v1/dossier-analyses`
  - `POST/GET /api/v1/comparisons`
- GPT-5.5 uses the allowlisted Responses adapter without temperature.
- Qwen 3.6 is visible but disabled as coming soon.
- Uploads use a bounded, expiring, restart-volatile repository.
- Transport failures may retry twice; downstream contract/persistence failures do not retry.
- M3/M4 protected artifacts passed pre/post hash verification unchanged.

The authentic-profile composite ZIP is [regbridge-m4-1-composite.zip]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\data\\\demo-dossiers\\\m4-1\\\regbridge-m4-1-composite.zip), SHA-256:

`81d77881a1ab90bcbcbad38b836f4a829852b75e68906c0b23171aa85609e597`

It produces three XML/PDF-derived document candidates and the three intended decisions without fixture lookup. The two-run fixture content digest was identical:

`1c158085d60aa09c82f9c436d48f6fed3514135bf7fb23b8c211c146fa2dcfb8`

Verification ran twice with:

```
.\scripts\m4-1-verify.ps1
```

Each pass completed:

- 202 backend tests
- 7 frontend unit tests
- 4 Playwright E2E/accessibility tests across 1440×900 and 1280×720
- Ruff, mypy, ESLint, TypeScript, production build, schema drift, package reproducibility, and protected-artifact checks

Presentation screenshots and their hash manifest are in [paper/figures/m4-1]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\paper\\\figures\\\m4-1). Operator instructions are in [DEMO\_M4\_1.md]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\docs\\\DEMO\_M4\_1.md), and milestone governance is in [M4.1.md]\(C:\\\Users\\\david\\\OneDrive\\\Documents\\\regbridge\\\docs\\\milestones\\\M4.1.md).

Remaining declared limits: no complete DTD/FDA validation, no multi-sequence history reconstruction, Qwen remains inactive, inventories are local and nonpersistent, and live GPT-5.5 operation requires valid server configuration. `not_operational` and `expert_validated: false` remain unchanged.

I left the unrelated user Markdown file untouched. The working tree also contains a modified tracked runtime SQLite database; I did not reset it because its ownership relative to existing work is unclear."

## Response:
9/2/2026, 11:11:10 PM

> **Assessing runtime SQLite concerns before merge**
>
> **Assessing runtime SQLite concerns before merge**
>
> **Verifying tracked runtime SQLite and next steps**
>
> **Verifying tracked runtime SQLite and next steps**
>
> **Assessed runtime SQLite concerns and verified tracked files**
>
> 
>
> Worked for 14s

M4.1 now appears to satisfy the intended end-to-end demonstration:

> Real ZIP upload → authentic-profile XML/PDF parsing → package-derived analysis → dossier summary → document-level evidence, graph, repair, and trace.

The separate `/baselines` workflow also preserves the product/evaluation boundary correctly.

Before merging the branch, I would resolve two final matters.

1. **Do not merge the modified runtime SQLite database.** If it is generated state, Codex should identify the exact path, confirm that it contains no required authored data, remove it from Git tracking while preserving the local copy, and add it to `.gitignore`. It should not blindly reset an unknown user change.

2. **Perform one manual live GPT-5.5 smoke test.** The automated tests demonstrate contracts and mocked/fixture behavior, but you should confirm:

   - the composite ZIP uploads successfully;
   - all three documents are discovered from XML/PDF;
   - GPT-5.5 uses the Responses endpoint;
   - the three intended decisions appear;
   - `/baselines` uses the same package hash and GPT-5.5 profile for B0, B1, and RegBridge;
   - B2 shows no model call;
   - no accuracy or reference labels appear on the arbitrary-upload comparison;
   - no secret, local absolute path, or raw sensitive text appears in logs or screenshots.

After that, merge and tag this state before enabling Qwen. The Qwen work should remain a separate model-portability milestone and experimental run so it cannot alter the completed GPT-5.5 results or M3/M4 artifacts.

The declared limitations are appropriate. In particular, “controlled authenticity-hardened profile” is the correct claim; “complete FDA eCTD validation” would still be unsupported.

## Prompt:
9/2/2026, 11:15:58 PM

Good. Now in the Implementation markdown, I see this in Case A: "Variants should change leaf titles, file names, and sibling placement while preserving or removing the actual heading conflict. The controlled prospective mapping is fixed to `3.2.S.1.1`, `3.2.S.1.2`, and `3.2.S.1.3` → `3.2.S.1`; do not create novel target mappings as synthetic variants. Include a case where `3.2.S.1` remains valid so the analyzer does not over-trigger, and an unmapped heading that must abstain rather than infer a parent." I want to understand something. I see in the fixture-controlled exaple before the M4.1, we had fixed cases (e.g, change 3.2.S.1.1). Is 3.2.S.* modification the only difference in v3.2.2 -> v4.0?  In the end-to-end, would it be able to figure out other ones?

[Attachment: IMPLEMENTATION.md]

## Response:
9/2/2026, 11:15:59 PM

No—`3.2.S.1.1–3.2.S.1.3` are not the only structural differences between v3.2.2 and v4.0. They are the deliberately bounded Case A mapping. I’ll check the current specification and rule registry alongside FDA’s complete heading-change material so I can distinguish what RegBridge can presently detect from what it merely parses and then abstains on.

## Prompt:
9/2/2026, 11:17:34 PM

Good. Now in the Implementation markdown, I see this in Case A: "Variants should change leaf titles, file names, and sibling placement while preserving or removing the actual heading conflict. The controlled prospective mapping is fixed to `3.2.S.1.1`, `3.2.S.1.2`, and `3.2.S.1.3` → `3.2.S.1`; do not create novel target mappings as synthetic variants. Include a case where `3.2.S.1` remains valid so the analyzer does not over-trigger, and an unmapped heading that must abstain rather than infer a parent." I want to understand something. I see in the fixture-controlled exaple before the M4.1, we had fixed cases (e.g, change 3.2.S.1.1). Is 3.2.S.* modification the only difference in v3.2.2 -> v4.0?  In the end-to-end, would it be able to figure out other ones? If its not, why did we constraint it to that set? I mean, in a production case, one will like to know what the reuse decisions for all possible cases (in this sub-case) when targeting v4.0, right? Like, I should know "I can keep all these", "reuse these", "discard these", etc.

[Attachment: IMPLEMENTATION(1).md]

## Response:
9/2/2026, 11:17:35 PM

The FDA change table confirms that Case A represents only one heading-change family. The broader transition also includes new and renamed headings, added subheadings, keyword changes, and Module 4/5 study-keyword changes. I’m checking the implemented branch’s rule coverage now, because parsing an unfamiliar heading and being authorized to decide its reuse are two different capabilities.

> **Searching implementation heading references**
>
>
> **Summarizing key v4 differences**
>
> **Summarizing key v4 differences**
>
> **Clarifying heading rule limitations**
>
> **Clarifying heading rule limitations**
>
> **Summarized v4 differences and clarified heading rule limitations**
>
> 
>
> **Summarizing key v4 differences**
>
> **Summarizing key v4 differences**
>
> **Clarifying heading rule limitations**
>
> **Clarifying heading rule limitations**
>
> **Summarized v4 differences and clarified heading rule limitations**
>
> 
>
> **Summarizing key v4 differences**
>
> **Summarizing key v4 differences**
>
> **Clarifying heading rule limitations**
>
> **Clarifying heading rule limitations**
>
> **Planning comprehensive heading coverage expansion**
>
> **Planning comprehensive heading coverage expansion**
>
> **Summarized v4 differences and planned expanded heading coverage**
>
> 
>
> **Searched uploaded files and extracted FDA eCTD heading changes**
>
> 
>
> **Identifying limitations in heading coverage**
>
> **Identifying limitations in heading coverage**
>
> **Planning coverage classification enhancements**
>
> **Planning coverage classification enhancements**
>
> **Identified heading coverage limitations and planned classification enhancements**
>
> 
>
> **Identifying limitations in heading coverage**
>
> **Identifying limitations in heading coverage**
>
> **Planning coverage classification enhancements**
>
> **Planning coverage classification enhancements**
>
> **Identified heading coverage limitations and planned classification enhancements**
>
> 
>
> **Identifying limitations in heading coverage**
>
> **Identifying limitations in heading coverage**
>
> **Planning coverage classification enhancements**
>
> **Planning coverage classification enhancements**
>
> **Outlining comprehensive heading transition mapping**
>
> **Outlining comprehensive heading transition mapping**
>
> **Planned enhancements for comprehensive heading coverage and transition mapping**
>
> 
>
> **Inspected rule registry, rules engine, backend service, and heading configuration**
>
> 
>
> Worked for 1m 25s

No. The `3.2.S.1.1–3.2.S.1.3 → 3.2.S.1` change is only one verified transition case—not the only difference between eCTD v3.2.2 and v4.0.

The sentence in `IMPLEMENTATION.md` means:

> Do not invent additional heading mappings merely to create benchmark variants.

It does not mean that FDA changed only those three headings.

## What the current implementation can do

The M4.1 parser can read many recognizable headings from an uploaded `index.xml`. However, parsing a heading and knowing its approved v3.2.2-to-v4.0 disposition are separate capabilities.

The branch’s rule registry explicitly permits only:

```text
3.2.S.1.1 → 3.2.S.1
3.2.S.1.2 → 3.2.S.1
3.2.S.1.3 → 3.2.S.1
```

The registry deliberately rejects any additional mapping. [Heading rule registry](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/rules/registry.py), [heading rule](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/data/rules/heading-rules.yaml).

Therefore, presently:

| Uploaded heading | Current behavior |
|---|---|
| `3.2.S.1.1–3.2.S.1.3` | Applies the verified mapping and returns `REUSE_WITH_NEW_CONTEXT` |
| `3.2.S.1` | Treats the heading as retained and continues other checks |
| Any other recognized heading | Parses it, but lacks an approved heading mapping and escalates to `HUMAN_REGULATORY_REVIEW` |

The analyzer specifically says that it will not perform a generic “nearest parent” inference. [Analysis service](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/analyzer/service.py).

So the direct answer is:

> The end-to-end system can discover other headings in the XML, but it cannot currently determine their v4.0 reuse disposition. It safely abstains because those transitions have not been encoded and adjudicated.

## Other v3.2.2-to-v4.0 changes exist

FDA’s CTOC summary identifies several other change categories, including:

- Module 1 additions and restructuring, such as new `1.12.18` and changes under `1.18`.
- New Module 2.3 subheadings for introduction, drug substance, drug product, appendices, and regional information.
- Optional keyword changes at `3.2.S`.
- A new descriptor keyword at `3.2.S.7.3`.
- Added subheadings beneath `3.2.P.2`.
- Changes to the name and keyword at `3.2.P.4`.
- New optional keywords at `3.2.P.7` and `3.2.P.8.3`.
- Changed keywords under `3.2.A`.
- Combined study identifier/title keywords and additional document types in Modules 4 and 5.

These are summarized on printed pages 36–38 of the [FDA CTOC v2.2](sandbox:/workspace/scratch/cbdce6a09de8/upload/fda-ectd-v4-ctoc-headings-v2.2.pdf).

Some are heading changes; others are keyword, hierarchy, or document-type changes. A heading number remaining available does not necessarily mean that its context-group metadata remains unchanged.

## Why RegBridge was constrained

The narrow scope was justified for the original experiment:

1. **Evidence control:** The exact mapping was verified against pinned FDA passages.
2. **No expert reviewer:** Additional interpretations could not honestly be presented as regulatory ground truth.
3. **Benchmark validity:** Synthetic variants were supposed to test one rule under changing superficial conditions—not introduce unsupported rules.
4. **Safety:** Inferring that every missing heading maps to its nearest parent could produce incorrect lifecycle decisions.
5. **Demonstration scope:** The research contribution is the graph-and-constraint architecture, evidence trace, and hybrid synthesis—not complete migration coverage.

This is why the implementation says not to create “novel target mappings as synthetic variants.” It prevents benchmark expansion through invented labels.

## Your production expectation is correct

For a production-oriented analyzer, a dossier-level report should account for every parsed document:

| Coverage/result | Meaning |
|---|---|
| Structurally unchanged | Existing heading remains available; continue metadata, lifecycle, and content checks |
| Explicitly mapped | Verified target placement exists |
| Context change required | Reuse document by identifier under a new context |
| Metadata decision required | Heading may remain, but keywords or attributes change |
| Human review required | Evidence is ambiguous or a contextual choice is needed |
| Outside encoded coverage | RegBridge has not implemented this heading/version transition |
| Technically unsupported | Parser or package profile cannot analyze the item |

It should then summarize:

```text
47 documents parsed
31 fully evaluated
8 require new context
3 require human review
5 outside current rule coverage
```

That would answer the practical question:

> Which documents can retain context, which can reuse their files under new context, which need repair, and which RegBridge cannot yet adjudicate?

“Discard” should be used cautiously. A removed heading often means that the context must change—not that the physical document must be discarded.

## What full Case A coverage would require

RegBridge would need a versioned heading-transition registry containing every relevant v3.2.2 heading:

```text
legacy heading
legacy title
target status
target heading
change category
keyword changes
document-type changes
required lifecycle treatment
supporting evidence
review status
expert validation status
```

Typical statuses would include:

```text
UNCHANGED
RENAMED_SAME_IDENTIFIER
REMOVED_WITH_EXPLICIT_MAPPING
NEW_TARGET_HEADING
KEYWORD_SCHEMA_CHANGED
DOCUMENT_TYPE_CHANGED
NO_VERIFIED_MAPPING
```

The deterministic engine could then evaluate every document against that matrix. The LLM should not invent missing mappings.

## Recommended direction

For the AAAI prototype, retain the verified three-heading rule, but make the coverage boundary unmistakable:

- Add a per-document `coverage_status`.
- Distinguish `evaluated` from `outside_demo_rule_coverage`.
- Show dossier-level evaluated/not-evaluated counts.
- Never imply that `HUMAN_REGULATORY_REVIEW` means FDA ambiguity when the real reason is missing RegBridge coverage.
- State that the uploaded demonstration dossier was constructed entirely within the encoded rule coverage.

Then treat comprehensive v3.2.2-to-v4.0 heading coverage as the next expansion milestone. That expansion can be based on the complete pinned FDA heading/change tables without altering the frozen M3 benchmark.

So, in short:

> The current end-to-end system is authentic in how it reads the dossier, but narrow in what it knows how to decide. That was intentional for experimental validity, although complete dossier-wide coverage would indeed be necessary for a production system.

## Prompt:
9/3/2026, 1:53:10 PM

I used a different agent to come up with a dossier eCTD v3.2.2 package conforming to the public standards of the ICH and FDA. Uploading the zip gets hard-rejected by Regbridge. The agent said this with regards to Regbridge not "being compatible" with real submissions:

1. FDA's own `us-regional.xml` examples declare `<!DOCTYPE ... SYSTEM "http://www.accessdata.fda.gov/...">` — an absolute URL. RegBridge's parser hard-rejects any external/absolute DOCTYPE location.
2. FDA's current regional DTD file is `us-regional-v3-3.dtd`. RegBridge's DOCTYPE allowlist only recognizes the older `us-regional-2-01.dtd` and `ich-ectd-3-2.dtd`.
3. The real ICH backbone root (`<ectd:ectd>`) carries no `dtd-version`/`version` attribute at all in the spec's own examples — RegBridge requires one and hard-fails without it.

I want to know the reason WHY you included these constraints too. Do not do modifications yet, just an explanation.

## Response:
9/3/2026, 1:53:11 PM

I’ll inspect the actual parser and the governing implementation notes on the M4.1 branch so I can distinguish deliberate security limits from mistaken assumptions about the FDA/ICH profile. I’ll only diagnose and explain; I won’t change files.

I’m also using the project-continuity workflow because these checks were introduced during the earlier “authenticity hardening” decision; that context matters to whether each constraint was intentional, conservative, or simply incorrect.

The implementation confirms the three checks are real. I’m now validating them against the official FDA/ICH artifacts, because the explanation differs sharply if they are legitimate profile restrictions versus restrictions that contradict the very submission format the demo claims to recognize.

> **Retrieved RegBridge parser constraint rationale**
>
> 
>
> **Listing Project Files and Documentation**
>
>
> **Listed project files and documentation**
>
> 
>
> **Reviewed Regbridge repository parsers, DTD references, tests, UI, and M4.1 documentation**
>
> 
>
> **Searching 11 websites**
>
>
> **Searching 12 websites**
>
>
> **Searching 12 websites**
>
>
> **Evaluating DTD version handling and validation**
>
> **Evaluating DTD version handling and validation**
>
> **Analyzing DOCTYPE and DTD allowlist inconsistencies**
>
> **Analyzing DOCTYPE and DTD allowlist inconsistencies**
>
> **Evaluated DTD version handling and allowlist inconsistencies**
>
> 
>
> **Evaluating DTD version handling and validation**
>
> **Evaluating DTD version handling and validation**
>
> **Analyzing DOCTYPE and DTD allowlist inconsistencies**
>
> **Analyzing DOCTYPE and DTD allowlist inconsistencies**
>
> **Evaluated DTD version handling and allowlist inconsistencies**
>
> 
>
> **Searching 12 websites**
>
>
> **Explaining hardening intent and side effects**
>
> **Explaining hardening intent and side effects**
>
> **Detailing DTD validation inconsistencies**
>
> **Detailing DTD validation inconsistencies**
>
> **Explained hardening intent, side effects, and DTD validation inconsistencies**
>
> 
>
> **Explaining hardening intent and side effects**
>
> **Explaining hardening intent and side effects**
>
> **Detailing DTD validation inconsistencies**
>
> **Detailing DTD validation inconsistencies**
>
> **Explained hardening intent and DTD validation inconsistencies**
>
> 
>
> **Searched 12 websites**
>
> 
>
> **Clarifying authenticity-hardening rationale and limits**
>
> **Clarifying authenticity-hardening rationale and limits**
>
> **Correcting DTD constraint explanations and test coverage**
>
> **Correcting DTD constraint explanations and test coverage**
>
> **Clarified authenticity-hardening limits and corrected DTD testing guidance**
>
> 
>
> **Clarifying authenticity-hardening rationale and limits**
>
> **Clarifying authenticity-hardening rationale and limits**
>
> **Correcting DTD constraint explanations and test coverage**
>
> **Correcting DTD constraint explanations and test coverage**
>
> **Clarified authenticity hardening and corrected DTD constraint test coverage**
>
> 
>
> **Reviewed GitHub commits for authenticity changes and demonstration UI flows**
>
> 
>
> Worked for 4m 42s

The other agent is substantially correct. These constraints came from a valid security goal, but Codex implemented that goal as an overly narrow, fixture-defined profile. They are not requirements of real FDA eCTD v3.2.2 submissions.

The crucial distinction is:

> We intended “accept known eCTD declarations without resolving them.”  
> The implementation became “accept only the declarations generated by RegBridge’s own synthetic package.”

| Constraint | Original reason | What went wrong |
|---|---|---|
| Reject absolute DOCTYPE locations | Prevent XXE, SSRF, local-file access, network dependency, and nondeterminism | Accepting a DOCTYPE identifier is not the same as resolving it. The parser can safely accept FDA’s absolute URL while disabling all external resolution. |
| Allowlist two DTD basenames | Pin the demo to known standards and reject unknown XML profiles | The list was derived from the synthetic demo package, not the current FDA profile. `us-regional-2-01.dtd` is obsolete for the general current FDA/CDER profile, which uses v3.3. |
| Require a root version attribute | Identify the input version without loading the DTD | It conflates the eCTD specification version with the DTD version and treats an omitted attribute as fatal even when official examples omit it. |

### 1. Absolute DOCTYPE rejection

The parser currently rejects a system identifier if it contains `://` or begins with `/` or `\`. See the [`_xml_record` implementation](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/parsers/profile322.py#L66-L102).

That was intended as an XML security boundary. However, it confuses two different actions:

- Recognizing and recording the literal system identifier
- Fetching or resolving the resource identified by it

FDA’s prescribed Module 1 header uses an absolute HTTPS system identifier for `us-regional-v3-3.dtd`. [FDA Module 1 specification](https://www.fda.gov/media/159382/download).

RegBridge should have been designed to accept that exact identifier as inert metadata while still forbidding:

- Network retrieval
- Filesystem resolution
- External-entity expansion
- Internal entity declarations

Therefore, the security objective was valid; rejecting the URL itself was not necessary.

### 2. The outdated regional DTD allowlist

The current code allows:

```python
{"ich-ectd-3-2.dtd", "us-regional-2-01.dtd"}
```

The FDA’s current standards page explicitly pairs eCTD v3.2.2 with **Module 1 v3.3**, and the prescribed regional DTD is `us-regional-v3-3.dtd`. [FDA eCTD v3.2.2 standards](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v322-and-regional-m1).

There is no source-based explanation in the repository for selecting only `us-regional-2-01.dtd`. The implementation evidence shows the synthetic dossier generator emits that same filename and version. See the [M4.1 dossier generator](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/scripts/generate_m4_1_dossier.py#L57-L86).

So this was effectively circular:

1. RegBridge generated a package using v2.01.
2. The parser allowlisted v2.01.
3. Tests confirmed that RegBridge could parse the package it generated.

That verifies internal consistency, but not compatibility with current public FDA examples.

`ich-ectd-3-2.dtd` is appropriate for the common Modules 2–5 backbone. The regional `2-01` entry is the problematic one for the stated current FDA/CDER profile.

### 3. Requiring `dtd-version` or `version`

The implementation accepts only:

```python
declared_version in {"3.2.2", "2.01"}
```

There are two separate problems.

First, eCTD specification version **3.2.2** uses common-backbone DTD version **3.2**. Appendix 8 declares:

```text
dtd-version CDATA #FIXED "3.2"
```

The official specification’s XML examples commonly omit the attribute from `<ectd:ectd>`, relying on the DTD’s fixed value. [ICH/FDA Modules 2–5 backbone specification](https://www.fda.gov/media/159380/download).

Second, FDA’s current regional root uses:

```xml
dtd-version="3.3"
```

not `2.01`.

The implementation therefore conflates:

- eCTD specification release: `3.2.2`
- Common-backbone DTD version: `3.2`
- FDA regional DTD version: `3.3`

Requiring some version evidence was intended to compensate for not performing DTD validation. But using only a literal root attribute—and using the wrong accepted values—made that shortcut incompatible with normal submissions.

FDA’s own validation criteria classify an omitted `dtd-version` in `index.xml` as a **medium-severity finding**, with no corrective action required unless FDA cannot process the submission. That does not support a RegBridge intake hard rejection. [FDA eCTD validation criteria](https://www.fda.gov/media/87056/download).

### Bottom line

I included the original constraints to create a secure, deterministic, offline parser for a controlled demonstration profile. I did not intend RegBridge to resolve arbitrary DTDs or claim complete FDA validation.

But the implementation overfit that profile to its own generated ZIP. In particular:

- The absolute-URL prohibition is an unnecessary security shortcut.
- The regional DTD allowlist is outdated for the stated FDA/CDER profile.
- The version logic uses incorrect values and imposes an unjustified hard-failure policy.

Consequently, “authenticity-hardened” currently means “more realistic than the original fixtures,” not “compatible with representative current FDA eCTD v3.2.2 submissions.” The test suite missed this because it did not include FDA-published example XML or an independently generated conformance package as an acceptance corpus.

## Prompt:
9/3/2026, 2:41:49 PM

Okay, let's get some things straight here. It is true that this is a demonstration, a demonstration for the AAAI 2027 conference. That doesn't mean things should be half-baked. Just because we do not have a human expert in FDA/ICH to review our documents/work doesn't mean we DO NOT HAVE ICH/FDA standard regulations and documents for application submissions! For a demo, I expect to use an eCTD dossier that conforms to FDA/ICH, at the very least, per their public standards/regulations PDFs and any other documents. Why should that not be the case? We are demoing a pain point ACTUAL organization will go through; it's only fair we at least mimic AT THE VERY LEAST how a dossier will look! THAT's the first point. It's the same for the baselines; they should be able to ingest the same dossier and come up with their judgements as per the cases/vocabularies. You are the research expert helping come up with a successful demo compliant to AAAI 2027 rules and standards; you are also an implementation expert in helping me calibrate Codex for a successful implementation as per what WE have agreed on. You'll know how to categorize the work, divide up the groups, and what to aim for. I have a general and good idea what my demo should do at AAAI 2027. For things I say that are wrong or misunderstood that don't stick to the goal, you make me aware of it instantly and vice versa. Do you understand? If there are gaps in what I said, let me know now.

## Response:
9/3/2026, 2:41:54 PM

> **Clarifying dossier conformity distinctions**
>
> **Clarifying dossier conformity distinctions**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Clarified dossier conformity distinctions and eCTD v3.2.2 nuances**
>
> 
>
> **Clarifying dossier conformity distinctions**
>
> **Clarifying dossier conformity distinctions**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Clarified dossier conformity distinctions and eCTD v3.2.2 nuances**
>
> 
>
> **Clarifying dossier conformity distinctions**
>
> **Clarifying dossier conformity distinctions**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Articulating eCTD v3.2.2 conformance nuances**
>
> **Defining dossier validation and baseline scope**
>
> **Defining dossier validation and baseline scope**
>
> **Clarified eCTD dossier conformance and validation scope**
>
> 
>
> Worked for 31s

Yes, I understand—and your correction is right. “Demonstration” limits the breadth of coverage; it does not excuse an artificial or internally invented input format.

The correct principle is:

> Synthetic regulatory content, but an authentic standards-conformant eCTD envelope.

A successful AAAI demo should model the real organizational workflow closely enough that its research contribution—not a fake input format—is what has been simplified.

## What we should require

### 1. The uploaded package must follow the public FDA/ICH profile

For the declared scope, that means a synthetic FDA/CDER submission based on:

- ICH eCTD specification v3.2.2
- ICH common backbone DTD v3.2
- FDA Module 1 specification using regional DTD v3.3
- Authentic `index.xml` and `m1/us/us-regional.xml` structure
- Correct namespaces, DOCTYPE identifiers, paths, leaf attributes, lifecycle references, and MD5 declarations
- Appropriate PDF requirements within the declared file-profile scope
- Relevant FDA validation criteria

The medical, company, and dossier content may be fictional. The packaging mechanics should not be.

### 2. Security and compatibility must be separate

RegBridge should:

- Accept officially prescribed absolute DOCTYPE identifiers.
- Record and recognize them without network retrieval.
- Use locally pinned official DTD copies for validation if DTD validation is performed.
- Disable external entity expansion, arbitrary filesystem access, and network resolution.
- Reject malicious XML based on dangerous behavior—not merely because authentic FDA syntax contains a URL.

A safe parser does not need to be incompatible with the official format.

### 3. The dossier should be independently validated

The current test was circular: RegBridge generated a ZIP matching its parser and then successfully parsed that ZIP.

The replacement acceptance gate should be:

1. Construct the synthetic package from pinned FDA/ICH specifications.
2. Validate its XML independently against pinned official DTDs.
3. Run the applicable public FDA validation checks that are within scope.
4. Test representative FDA-published XML examples.
5. Then require RegBridge to accept the independently validated package.

RegBridge must not be its own sole conformance oracle.

### 4. All systems should receive the same uploaded submission

You are also right about the baselines. The uploaded ZIP should enter one shared, deterministic ingestion layer:

```text
Authentic uploaded package
→ secure extraction
→ XML/metadata/document parsing
→ common label-free case representation
→ B0 / B1 / B2 / RegBridge
```

The systems can differ after ingestion:

- B0 receives all bounded case facts and evidence directly.
- B1 retrieves evidence before making its decision.
- B2 uses deterministic rules without semantic analysis.
- RegBridge uses graph validation, rules, semantic findings, and deterministic synthesis.

They should all use the same neutral decision and action vocabulary. Otherwise, formatting differences and invented labels would confound the comparison.

The common preprocessing must not expose:

- Reference labels
- Expected decisions
- Triggered rule IDs
- Benchmark rationales
- RegBridge’s output

Providing a shared parser and neutral output vocabulary is experimental control, not an unfair advantage.

## Important gaps to resolve

### Exact meaning of “conformant”

We should not claim unrestricted “FDA/ICH compliance.” The defensible claim should name the profile:

> A synthetic single-application FDA/CDER eCTD v3.2.2 package using ICH common-backbone DTD v3.2 and FDA Module 1 regional DTD v3.3, validated against the pinned public standards and the explicitly implemented validation subset.

That is precise and testable.

Also, FDA materials include specifications, validation criteria, technical guides, controlled terminologies, and nonbinding guidance. They should not all be called “regulations”; every rule must retain its actual bindingness.

### A conformant source package can still contain migration risks

The three demo cases must not make the source v3.2.2 package invalid merely to trigger RegBridge:

- Case A: `3.2.S.1.2` is legitimate in v3.2.2 but changes when targeting v4.0.
- Case B: `manufacturer="all"` may be structurally valid in the source but discouraged or context-sensitive for the target.
- Case C: a PDF may be structurally valid while containing stale contextual language.

That is precisely the research gap: source-format validity does not establish safe target-context reuse.

### “Submission” versus complete “dossier”

A ZIP containing one sequence is an authentic submission sequence, but it is not necessarily the complete application history.

If the demo claims to analyze cross-sequence replacement or append lifecycle, it should either:

- Upload a small multi-sequence synthetic application history with resolvable predecessors; or
- Explicitly describe the input as one submission sequence and mark prior-history reconstruction as outside scope.

We should not imply complete lifecycle analysis while supplying only isolated lifecycle attributes.

### Analysis coverage remains narrower than parsing coverage

A parser may correctly ingest many CTD headings while RegBridge has adjudicated transition rules for only three archetypes. Those are separate capabilities.

Every parsed document should therefore show one of:

- `EVALUATED_WITH_APPROVED_POLICY`
- `NO_MIGRATION_CHANGE_DETECTED`
- `OUTSIDE_ENCODED_POLICY_COVERAGE`
- `INSUFFICIENT_APPLICATION_HISTORY`
- `DOCUMENT_INSPECTION_INCOMPLETE`

Missing RegBridge coverage must not be presented as regulatory ambiguity.

## The standard I will apply going forward

For implementation guidance, I will treat these as non-negotiable:

- Authentic public-standard input structure is an acceptance gate.
- Security controls cannot reject required FDA/ICH syntax unnecessarily.
- Conformance is tested independently of RegBridge.
- Synthetic cases modify content and lifecycle conditions—not the official envelope.
- All comparison systems begin with the same upload and label-free deterministic parsing.
- Claims remain limited to the exact versions and validation subset tested.
- Current FDA forward-compatibility availability remains `not_operational`.
- Lack of expert validation limits regulatory-ground-truth claims; it does not justify ignoring official standards.
- Any shortcut affecting authenticity, experimental fairness, or the central research claim must be disclosed to you before implementation.

I should have caught that the earlier “authenticity-hardening” implementation was validated against its own generated profile rather than official examples. That was a substantive calibration failure, not merely a cosmetic limitation.

## Prompt:
9/3/2026, 4:36:41 PM

I agree with your definition of "conformant" in this context. Explain the point of "Every parsed document should therefore show one of:

- `EVALUATED_WITH_APPROVED_POLICY` 
- `NO_MIGRATION_CHANGE_DETECTED` 
- `OUTSIDE_ENCODED_POLICY_COVERAGE` 
- `INSUFFICIENT_APPLICATION_HISTORY` 
- `DOCUMENT_INSPECTION_INCOMPLETE`"

I  want to understand this

## Response:
9/3/2026, 4:36:40 PM

> **Clarifying coverage status versus decision distinctions**
>
> **Clarifying coverage status versus decision distinctions**
>
> **Clarified coverage status and decision distinctions**
>
> 
>
> **Clarifying coverage status versus decision distinctions**
>
> **Clarifying coverage status versus decision distinctions**
>
> **Defining evaluation and decision taxonomy with examples**
>
> **Defining evaluation and decision taxonomy with examples**
>
> **Clarified coverage status and defined the evaluation decision taxonomy**
>
> 
>
> Worked for 17s

These labels are meant to answer a question separate from the reuse decision:

> How much of this document was RegBridge actually capable of assessing?

A reuse decision answers, “What should happen to the document?” A coverage status answers, “Did RegBridge have the policy coverage, application history, and readable evidence required to reach that decision?”

Without this distinction, RegBridge could silently treat “I do not have a rule for this document” as “I found no problem.”

## What each status means

| Status | Meaning | Example |
|---|---|---|
| `EVALUATED_WITH_APPROVED_POLICY` | RegBridge had an author-adjudicated policy covering the detected condition and executed it. | A leaf under `3.2.S.1.2` is evaluated using the approved explicit mapping to `3.2.S.1`. |
| `NO_MIGRATION_CHANGE_DETECTED` | RegBridge evaluated the relevant supported conditions and found no target-version change requiring action. | A document already under supported heading `3.2.S.1`, with compatible metadata and clean inspection. |
| `OUTSIDE_ENCODED_POLICY_COVERAGE` | RegBridge parsed the document but has no approved transition policy for its heading or condition. | A document under `3.2.P.4.1` when the graph contains no verified v3.2.2→v4.0 policy for that heading. |
| `INSUFFICIENT_APPLICATION_HISTORY` | The decision depends on an earlier sequence or lifecycle predecessor that was not uploaded or could not be resolved. | A `replace` leaf references a document from sequence `0003`, but only sequence `0007` was uploaded. |
| `DOCUMENT_INSPECTION_INCOMPLETE` | Structural metadata was parsed, but RegBridge could not complete the necessary PDF/content inspection. | The PDF is encrypted, malformed, exceeds configured bounds, or contains text that requires OCR that was not performed. |

## Why this matters

Suppose RegBridge uploads 100 documents:

- 15 are covered by approved transition rules.
- 50 appear structurally unchanged.
- 20 are under headings RegBridge has not yet modeled.
- 10 require missing earlier sequences.
- 5 PDFs cannot be inspected.

Without coverage reporting, the interface could misleadingly say:

> 65 documents are safe to reuse; 35 require review.

But the honest report is:

> RegBridge reached supported conclusions for 65 documents. It could not fully assess the remaining 35 because of missing policy coverage, missing history, or incomplete inspection.

That distinction prevents a prototype limitation from being presented as a regulatory conclusion.

## One correction to my earlier taxonomy

`NO_MIGRATION_CHANGE_DETECTED` is not really a coverage status. It is an analysis outcome. I would therefore use two separate fields.

### 1. Assessment coverage

```text
COMPLETE
PARTIAL
OUTSIDE_POLICY_COVERAGE
INSUFFICIENT_HISTORY
INSPECTION_INCOMPLETE
```

### 2. Reuse decision

```text
REUSE_AS_LEGACY_REFERENCE
REUSE_WITH_NEW_CONTEXT
REUSE_AFTER_METADATA_REPAIR
BREAK_LIFECYCLE_AND_RESUBMIT
DO_NOT_REUSE
HUMAN_REGULATORY_REVIEW
```

Then a clean document could show:

```yaml
coverage_status: COMPLETE
decision: REUSE_AS_LEGACY_REFERENCE
finding: NO_MIGRATION_CHANGE_DETECTED
```

An unsupported heading would show:

```yaml
coverage_status: OUTSIDE_POLICY_COVERAGE
decision: HUMAN_REGULATORY_REVIEW
reason: No approved transition policy covers heading 3.2.P.4.1
```

An unreadable PDF might show:

```yaml
coverage_status: INSPECTION_INCOMPLETE
decision: HUMAN_REGULATORY_REVIEW
reason: Structural checks completed, but semantic reuse safety was not assessed
```

## Ideally, coverage should be recorded per dimension

A single document may be covered structurally but incomplete semantically. Therefore, the underlying record should be more detailed:

```yaml
assessment_coverage:
  heading_transition: complete
  metadata: complete
  lifecycle: insufficient_history
  document_content: inspection_incomplete

overall_coverage: PARTIAL
decision: HUMAN_REGULATORY_REVIEW
```

The UI can show the simple overall status, while the evidence/trace view explains each dimension.

The main purpose is not to generate more warnings. It is to make RegBridge distinguish:

- “The standards support this conclusion.”
- “No supported change was found.”
- “RegBridge does not yet cover this condition.”
- “The required evidence was unavailable.”

That distinction is essential for both an honest AAAI demonstration and eventual real-world use.

## Prompt:
9/3/2026, 4:53:25 PM

Okay, so in terms of the user using RegBridge, they upload their dossier (e.g., v3.2.2), select the target (v4.0), their metadata migration intent, and see results, right? Now, here is a question. We are assuming those using it are aware of the mass structural difference of v3.2.2 and v4.0 (in eCTD v4.0, there is no `index.xml` or `<m3-2-s-1-1-nomenclature>` tag. Instead, eCTD v4.0 uses a single, standardized XML file based on the **HL7 Regulated Product Submission (RPS)** standard.) Is it okay to make it clear that this project isn't focusing on getting a user prepared for getting a successful v4.0 submission but it's intended goal?

## Prompt:
9/3/2026, 4:56:51 PM

Okay, so in terms of the user using RegBridge, they upload their dossier (e.g., v3.2.2), select the target (v4.0), their metadata migration intent, and see results, right? Now, here is a question. We are assuming those using it are aware of the mass structural difference of v3.2.2 and v4.0 (in eCTD v4.0, there is no `index.xml` or `<m3-2-s-1-1-nomenclature>` tag. Instead, eCTD v4.0 uses a single, standardized XML file based on the **HL7 Regulated Product Submission (RPS)** standard.) Is it okay to make it clear that this project isn't focusing on getting a user prepared for getting a successful v4.0 submission but it's intended goal? Next, "reuse with new content" means WHAT?

## Response:
9/3/2026, 4:56:54 PM

Yes—the product boundary should be explicit and prominent. I’m checking the official v4 terminology so I can distinguish document reuse, Context of Use lifecycle, and actual RPS submission-package construction precisely.

> **Clarifying reuse label and user flow goals**
>
> **Clarifying reuse label and user flow goals**
>
> **Clarified reuse label and user flow goals**
>
> 
>
> **Searching www.fda.gov**
>
>
> **Defining document reuse with new context**
>
> **Defining document reuse with new context**
>
> **Clarifying reuse-with-new-context definition**
>
> **Clarifying reuse-with-new-context definition**
>
> **Defined document reuse with new context**
>
> 
>
> **Defining document reuse with new context**
>
> **Defining document reuse with new context**
>
> **Clarifying reuse-with-new-context definition**
>
> **Clarifying reuse-with-new-context definition**
>
> **Defined document reuse with new context**
>
> 
>
> **Searched 1 website**
>
> 
>
> Worked for 31s

Yes—your described workflow is correct:

1. Upload a source eCTD v3.2.2 application/sequence history.
2. Select the target jurisdiction, standards snapshot, and eCTD v4.0.
3. Declare migration intent, such as preserving existing lifecycle where technically supportable.
4. Receive document-by-document reuse decisions, risks, supporting evidence, coverage status, and required human checks.

But the project boundary should be worded carefully:

> RegBridge does not generate or certify an FDA-ready eCTD v4.0 submission. It produces an evidence-backed migration decision plan that tells a downstream publishing team which legacy documents can be reused, which require a new context, which require repair, and which require human review.

That is stronger than saying RegBridge does not “prepare” users for v4.0, because it does contribute to preparation—it just does not complete the publishing and validation process.

## What RegBridge does not do

RegBridge does not currently:

- Generate the HL7 RPS `submissionunit.xml`.
- Generate production UUIDs, OIDs, priority numbers, or complete Context of Use structures.
- Create the final v4.0 folder/package structure.
- Apply every current controlled-vocabulary package.
- Validate the complete RPS schema and FDA business-rule set.
- Transmit through FDA’s submission gateway.
- Certify submission readiness or predict FDA acceptance.

FDA’s implementation uses an HL7 RPS Release 2 message, and an individual v4.0 submission unit contains `submissionunit.xml` rather than the v3.2.2 `index.xml` backbone. [FDA Module 1 v4.0 Implementation Guide](https://www.fda.gov/media/179721/download), [ICH eCTD v4.0 Implementation Guide](https://www.fda.gov/media/91917/download).

Those functions belong to a downstream v4.0 publishing and validation system.

## What RegBridge contributes

RegBridge sits before that publishing system:

```text
v3.2.2 application history
→ RegBridge reuse-risk analysis
→ reviewed migration plan
→ v4.0 publishing system
→ complete validation and submission
```

Its output might say:

```text
Document 17

Source:
3.2.S.1.2 General Properties
Legacy leaf: leaf-017

Recommended treatment:
REUSE_WITH_NEW_CONTEXT

Target placement:
3.2.S.1 General Information

Required action:
Create a new Context of Use using the approved target heading.
Reference the existing document identifier.
Suspend the old context placement where applicable.

Coverage:
Heading transition evaluated.
Document-content inspection completed.
Human approval required before execution.
```

RegBridge recommends that treatment; it does not generate the final RPS XML that executes it.

## “Reuse with new content” versus “reuse with new context”

The correct RegBridge label is:

```text
REUSE_WITH_NEW_CONTEXT
```

It should not be called “reuse with new content.” Those mean very different things.

### Reuse with new context

This means:

- The underlying PDF/document can remain unchanged.
- The existing document identifier or supported v3.2.2 leaf reference is reused.
- Its target heading, keywords, or contextual placement changes.
- A new v4.0 Context of Use is created.
- The old context may need to be suspended.
- The document file is not automatically resubmitted as a newly authored document.

In v4.0, the document and the context in which that document appears are separate concepts. A document can therefore be referenced in a new Context of Use without changing its bytes. FDA’s guidance permits reuse of an existing document by identifier, subject to the document and its hyperlinks remaining relevant in the new context. [FDA eCTD v4.0 Technical Conformance Guide](https://www.fda.gov/media/179700/download).

### Example

Suppose v3.2.2 contains:

```text
Document: general-properties.pdf
Leaf ID: leaf-123
Heading: 3.2.S.1.2
```

RegBridge determines that the controlled target mapping is:

```text
3.2.S.1.2 → 3.2.S.1
```

The result is:

```text
Same document:
general-properties.pdf

Same reusable document identity:
leaf-123 or its supported v4 reference

New context:
3.2.S.1 General Information

New Context of Use:
Created with the required target metadata
```

The content of `general-properties.pdf` has not changed. Its regulatory placement has.

### If the document content changes

If the PDF itself must be edited—for example, to remove a stale applicant name or obsolete hyperlink—that is not simply `REUSE_WITH_NEW_CONTEXT`.

It becomes a different treatment, such as:

- Revise and submit a new document version.
- Repair metadata and reassess reuse.
- Break the relevant lifecycle relationship.
- Escalate to `HUMAN_REGULATORY_REVIEW`.

The exact decision depends on what changed and what the approved policy supports.

## Recommended audience-facing wording

The UI and demonstration should say:

> **Migration decision support—not v4.0 package generation.** RegBridge analyzes legacy documents and recommends evidence-backed reuse and repair treatments. A validated publishing system and authorized regulatory review remain required to construct and submit the final eCTD v4.0 RPS message.

And the decision label should be displayed as:

> **Reuse document in a new regulatory context**

That is much easier for an audience to understand than showing only `REUSE_WITH_NEW_CONTEXT`.

## Prompt:
9/3/2026, 6:32:19 PM

Good. The paper is already drafted, and I do not want to do too many changes to the current demo. For now, it should accept an "actual," "conformat" (as per our definition) dossier. Look at the GitHub repository really well, especially AGENTS.md and IMPLEMENTATION.md, and let me know what needs to be done with Codex for this. I have also reviewed the paper with Andrew Ng's paper reviewer tool. Attached is the paper and the reviewer's results. What changes will implementing the next job of Codex have on the paper and its review? Think through this well. I might look at further optimizing for production and expand on the limitations we have for a later paper.

[Attachment: RegBridge__Stable_and_Traceable_Regulatory_Reuse_Decisions_through_Deterministic_Synthesis__1_.pdf]

[Attachment: paper review.pdf]

## Response:
9/3/2026, 6:32:23 PM

I’ll treat this as a bounded compatibility correction, not a redesign: first identify the exact parser/profile assumptions in the current branch, then compare them with `AGENTS.md`, `IMPLEMENTATION.md`, the paper’s claims, and the reviewer’s objections. I’m using the PDF workflow for the two attached reports and the connected GitHub repository for the implementation audit; I will not modify the repository.

## Prompt:
9/3/2026, 6:33:02 PM

Good. The paper is already drafted, and I do not want to do too many changes to the current demo. For now, it should accept an "actual," "conformat" (as per our definition) dossier. Look at the GitHub repository (demonstration-ui-flow-implementation branch) really well, especially AGENTS.md and IMPLEMENTATION.md, and let me know what needs to be done with Codex for this. I have also reviewed the paper with Andrew Ng's paper reviewer tool. Attached is the paper and the reviewer's results. What changes will implementing the next job of Codex have on the paper and its review? Think through this well. I might look at further optimizing for production and expand on the limitations we have for a later paper.

## Prompt:
9/3/2026, 6:33:15 PM

Good. The paper is already drafted, and I do not want to do too many changes to the current demo. For now, it should accept an "actual," "conformat" (as per our definition) dossier. Look at the GitHub repository (demonstration-ui-flow-implementation branch) really well, especially AGENTS.md and IMPLEMENTATION.md, and let me know what needs to be done with Codex for this. I have also reviewed the paper with Andrew Ng's paper reviewer tool. Attached is the paper and the reviewer's results. What changes will implementing the next job of Codex have on the paper and its review? Think through this well. I might look at further optimizing for production and expand on the limitations we have for a later paper. @paper review.pdf @RegBridge__Stable_and_Traceable_Regulatory_Reuse_Decisions_through_Deterministic_Synthesis__1_.pdf

[Attachment: paper review.pdf]

[Attachment: RegBridge__Stable_and_Traceable_Regulatory_Reuse_Decisions_through_Deterministic_Synthesis__1_.pdf]

## Response:
9/3/2026, 6:33:18 PM

The governing documents support the stricter interpretation you chose: secure deterministic parsing is required, but complete FDA submission validation is explicitly out of scope. The immediate defect is that M4.1’s “authentic profile” was defined by its own generator instead of by an independent FDA/ICH conformance corpus. I’m tracing how far that assumption propagates through schemas, APIs, baseline serialization, tests, and demo copy before sizing the correction.

A deeper incompatibility is emerging beyond the three reported rejections: the demo generator appears to use simplified element names and namespaces, while the parser’s heading normalizer may misread authentic descriptive ICH tags. I’m validating the complete XML shape now because fixing only the DOCTYPE and version checks could make upload succeed yet still produce incorrect document headings—worse than a clean rejection.

I’ve confirmed the central issue is broader than three allowlist constants: the current M4.1 package and parser validate each other, but they do not faithfully represent the current FDA/ICH v3.2.2 envelope. I’m finishing the audit at the parser-to-API boundary so the next Codex job stays narrowly additive, preserves the frozen M3 evidence, and does not turn into a full eCTD validator.

The paper review and code point to a useful boundary: this correction materially strengthens the *demonstration’s input authenticity* and parser failure story, but it does not repair the benchmark’s small size, author-label alignment, or missing SME validation. I’m validating the exact FDA/ICH profile now so the Codex brief can say precisely what “conformant” means—and just as importantly, what it still must not claim.

The scoped correction is now clear. It should be an additive “M4.2 input-profile conformance” milestone, not a rewrite of RegBridge and not an expansion of migration-policy coverage. The non-negotiable scientific safeguard is independent validation: the new demo package cannot be declared conformant merely because the same RegBridge parser that generated/accepts it says so.

> **Planning incremental GitHub file fetching**
>
> **Planning incremental GitHub file fetching**
>
> **Planned incremental GitHub file fetching**
>
> 
>
> **Planning deep repo audit and inspection**
>
> **Planning deep repo audit and inspection**
>
> **Planned a deep repository audit and inspection**
>
> 
>
> **Implemented demonstration UI flow after reviewing contribution guidelines**
>
> 
>
> **Planning file fetching and doc updates**
>
> **Planning file fetching and doc updates**
>
> **Planned file fetching and document updates**
>
> 
>
> **Reviewed repository parser implementation and generated M4.1 dossier documentation**
>
> 
>
> **Extracting and Inspecting PDF Text**
>
>
> **Planning paper wording and demo adjustments**
>
> **Planning paper wording and demo adjustments**
>
> **Planned paper wording and demo adjustments**
>
> 
>
> **Planning paper wording and demo adjustments**
>
> **Planning paper wording and demo adjustments**
>
> **Identifying XML conformance issues**
>
> **Identifying XML conformance issues**
>
> **Planned paper wording and demo adjustments, identifying XML conformance issues**
>
> 
>
> **Extracted, converted, and reviewed PDF contents**
>
> 
>
> **Searching www.fda.gov**
>
>
> **Searching www.fda.gov**
>
>
> **Planning repository audit with GitHub tool**
>
> **Planning repository audit with GitHub tool**
>
> **Planned repository audit with GitHub tool**
>
> 
>
> **Searched 1 website**
>
> 
>
> **Reviewed M4.1 documentation, parser models, services, schemas, workspaces, scripts, data, and tests**
>
> 
>
> **Listing uploaded PDF files**
>
>
> **Planning Codex implementation prompt**
>
> **Planning Codex implementation prompt**
>
> **Planned Codex implementation prompt**
>
> 
>
> **Listed uploaded PDFs and reviewed their text contents**
>
> 
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Searching 2 websites**
>
>
> **Searched 2 websites**
>
> 
>
> **Implemented and reviewed demonstration UI flow with repository and testing standards**
>
> 
>
> **Searching Upload Documentation Keywords**
>
>
> **Searched upload documentation keywords and reviewed implementation sections**
>
> 
>
> **Reviewed repository commits, UI flow branch, parser implementation, and standards snapshot contents**
>
> 
>
> **Searching www.fda.gov**
>
>
> **Planning detailed answer with cautious citation advice**
>
> **Planning detailed answer with cautious citation advice**
>
> **Designing profile updates and DTD handling**
>
> **Designing profile updates and DTD handling**
>
> **Planned detailed answer with citation guidance and DTD profile updates**
>
> 
>
> **Planning detailed answer with cautious citation advice**
>
> **Planning detailed answer with cautious citation advice**
>
> **Designing profile updates and DTD handling**
>
> **Designing profile updates and DTD handling**
>
> **Planned a detailed answer with citation guidance and profile DTD updates**
>
> 
>
> **Planning detailed answer with cautious citation advice**
>
> **Planning detailed answer with cautious citation advice**
>
> **Designing profile updates and DTD handling**
>
> **Designing profile updates and DTD handling**
>
> **Refining DTD validation and package parsing logic**
>
> **Refining DTD validation and package parsing logic**
>
> **Planned profile updates and refined DTD package validation logic**
>
> 
>
> **Planning detailed answer with cautious citation advice**
>
> **Planning detailed answer with cautious citation advice**
>
> **Designing profile updates and DTD handling**
>
> **Designing profile updates and DTD handling**
>
> **Refining DTD validation and package parsing logic**
>
> **Refining DTD validation and package parsing logic**
>
> **Implementing policy coverage tagging for headings**
>
> **Implementing policy coverage tagging for headings**
>
> **Planned profile updates, DTD validation, and policy coverage tagging**
>
> 
>
> **Planning detailed answer with cautious citation advice**
>
> **Planning detailed answer with cautious citation advice**
>
> **Designing profile updates and DTD handling**
>
> **Designing profile updates and DTD handling**
>
> **Refining DTD validation and package parsing logic**
>
> **Refining DTD validation and package parsing logic**
>
> **Implementing policy coverage tagging for headings**
>
> **Implementing policy coverage tagging for headings**
>
> **Planned profile, DTD, package parsing, and policy tagging updates**
>
> 
>
> **Searched 1 website**
>
> 
>
> **Planning parser and UI enhancements**
>
> **Planning parser and UI enhancements**
>
> **Refining dossier upload and documentation**
>
> **Refining dossier upload and documentation**
>
> **Planned parser UI enhancements and refined dossier upload documentation**
>
> 
>
> **Planning parser and UI enhancements**
>
> **Planning parser and UI enhancements**
>
> **Refining dossier upload and documentation**
>
> **Refining dossier upload and documentation**
>
> **Outlining review response and documentation updates**
>
> **Outlining review response and documentation updates**
>
> **Planned parser, UI, upload, and documentation enhancements**
>
> 
>
> **Planning parser and UI enhancements**
>
> **Planning parser and UI enhancements**
>
> **Refining dossier upload and documentation**
>
> **Refining dossier upload and documentation**
>
> **Outlining review response and documentation updates**
>
> **Outlining review response and documentation updates**
>
> **Planned parser UI enhancements and documentation updates**
>
> 
>
> **Planning parser and UI enhancements**
>
> **Planning parser and UI enhancements**
>
> **Refining dossier upload and documentation**
>
> **Refining dossier upload and documentation**
>
> **Outlining review response and documentation updates**
>
> **Outlining review response and documentation updates**
>
> **Designing separate input profile manifests**
>
> **Designing separate input profile manifests**
>
> **Planned parser, UI, dossier, review, and manifest enhancements**
>
> 
>
> **Planning parser and UI enhancements**
>
> **Planning parser and UI enhancements**
>
> **Refining dossier upload and documentation**
>
> **Refining dossier upload and documentation**
>
> **Outlining review response and documentation updates**
>
> **Outlining review response and documentation updates**
>
> **Designing separate input profile manifests**
>
> **Designing separate input profile manifests**
>
> **Planning local DTD validation with resolvers**
>
> **Planning local DTD validation with resolvers**
>
> **Planned parser, documentation, profile manifests, and local DTD validation enhancements**
>
> 
>
> **Analyzed Profile 322 parser implementation and logic**
>
> 
>
> **Structuring detailed Codex prompt and audit table**
>
> **Structuring detailed Codex prompt and audit table**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Structured Codex prompt and summarized XML fixes and work scope**
>
> 
>
> **Structuring detailed Codex prompt and audit table**
>
> **Structuring detailed Codex prompt and audit table**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Structured a Codex prompt and summarized required XML fixes**
>
> 
>
> **Structuring detailed Codex prompt and audit table**
>
> **Structuring detailed Codex prompt and audit table**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Summarizing required XML fixes and Codex work scope**
>
> **Detailing Codex prompt instructions and evaluation boundaries**
>
> **Detailing Codex prompt instructions and evaluation boundaries**
>
> **Structured Codex prompt, audit table, XML fixes, and evaluation scope**
>
> 
>
> Worked for 7m 53s

Yes—this should be the next Codex job, but as a narrow additive milestone: **M4.2 — Public-Standards eCTD v3.2.2 Input Compatibility**.

It should correct the dossier envelope and parser without changing the three migration policies, frozen benchmark, Phase 2 results, or core UI flow.

## What the repository audit found

The current M4.1 workflow is architecturally sound: both Analyzer and Baselines use the same parsed `ApplicationInventory`, and the comparison service runs B0/B1/B2/RegBridge from package-derived, label-free facts. That part should stay.

The problem is that the parser and generated package currently agree with each other rather than with the public FDA/ICH profile.

| Current implementation | Why it is incompatible | Required correction |
|---|---|---|
| Rejects absolute DOCTYPE system identifiers | FDA’s Module 1 example uses an absolute FDA URL | Recognize exact approved URLs but map them to pinned local DTDs; never fetch them |
| Allows regional DTD `2.01` | FDA removed 2.01 from the supported catalog in 2022; current regional DTD is 3.3 | Add v3.3 and stop presenting 2.01 as the current authentic profile |
| Requires root `dtd-version` | ICH examples can omit it; FDA classifies omission as a medium validation finding, not an automatic unreadable-package condition | Infer the profile version from recognized DOCTYPE/root/namespace and return a warning when the attribute is absent |
| Generates `<ectd xmlns="urn:ich-org:ectd">` | The public specification uses `<ectd:ectd>` and `http://www.ich.org/ectd` | Generate the authentic root and namespace |
| Generates abbreviated elements such as `<m3-2-s-1-2>` | The standard element is `m3-2-s-1-2-structure` | Generate and parse the actual descriptive element names |
| Places `manufacturer` on a leaf | The ICH DTD places `substance` and `manufacturer` on `m3-2-s-drug-substance` | Move and parse the metadata from the correct ancestor |
| Omits the `index.xml` leaf referencing `m1/us/us-regional.xml` | FDA’s Module 1 specification calls for that reference | Add it and classify it as a backbone relationship, not an analyzable PDF |
| Treats every non-delete leaf as a PDF | The Module 1 XML reference would consequently be rejected | Separate backbone XML leaves from dossier-document candidates |
| Rejects `../0001/index.xml#leaf-id` as traversal | This is an authentic `modified-file` lifecycle reference | Parse it as a lifecycle URI; do not treat it as a ZIP extraction path |
| Supports sequence roots only at depths 0 or 2 | A normal `0000/index.xml` wrapper has depth 1 | Support root, sequence-only, and application/sequence layouts |
| Reads `applicant-name`, not authentic `company-name` | FDA Module 1 represents the applicant under `company-name` | Parse the actual regional structure |
| Tests only the internally generated package | Generator and parser can share the same mistake | Add an independent DTD validator and a separately produced acceptance package |

The current behavior is visible in [profile322.py](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/parsers/profile322.py), [ectd322.py](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/parsers/ectd322.py), and [generate_m4_1_dossier.py](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/scripts/generate_m4_1_dossier.py).

FDA’s current standards catalog identifies eCTD backbone specification 3.2.2, ICH DTD 3.2, Module 1 specification 2.6, and US regional DTD 3.3. It also records removal of regional DTD 2.01. [FDA eCTD v3.2.2 standards catalog](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/ectd-submission-standards-ectd-v322-and-regional-m1)

The official Module 1 specification supplies the absolute DTD identifier, `fda-regional:fda-regional` root, v3.3 declaration, and the requirement to reference `us-regional.xml` from `index.xml`. [FDA Module 1 specification](https://www.fda.gov/media/159382/download)

The ICH backbone specification shows the actual namespace, descriptive Module 3 tags, metadata placement, and authentic cross-sequence `modified-file` syntax. [FDA-hosted ICH eCTD v3.2.2 backbone specification](https://www.fda.gov/media/159380/download)

## Scope Codex should implement

The job should produce a **synthetic, independently DTD-validated, single-sequence FDA/CDER eCTD v3.2.2 package**. It should not claim that RegBridge is a complete FDA submission validator.

The boundary should be:

- Authentic public-standard XML envelope and directory structure.
- Correct ICH DTD 3.2 and FDA regional DTD 3.3 structures.
- Correct namespaces, lifecycle references, checksums and document paths.
- Synthetic PDFs containing the three demonstration signals.
- Safe, offline parsing and local DTD validation.
- PDF-only semantic inspection remains acceptable as a declared product subset.
- No complete FDA validation-criteria implementation.
- No multi-sequence lifecycle reconstruction.
- No v4 RPS package generation.
- No expansion to every v3.2.2→v4.0 mapping.

A valid but unsupported document must not receive a default “safe to reuse” conclusion. It should appear as `OUTSIDE_ENCODED_POLICY_COVERAGE`. Missing prior sequences should appear as `INSUFFICIENT_APPLICATION_HISTORY`; incomplete PDF inspection should remain explicit. This separates format acceptance from policy coverage.

## Preservation rules

Codex should not modify:

- The 30-case benchmark or digest.
- Phase 1/Phase 2 results.
- Frozen prompts or evaluation configurations.
- The M4 presentation snapshot.
- Existing M4.1 package bytes or manifest.
- Reported evaluation numbers.

Create a new profile and package, for example:

```text
fda-ectd-322-public-profile-v2
data/input-profiles/fda-ectd-322-public-v2/
data/demo-dossiers/m4-2/
```

Do not add the input-profile standards to the frozen `fda-cder-demo-v1` evidence snapshot. Give them a separate manifest because they establish input compatibility, not migration-decision evidence.

## Prompt for Codex

```text
Implement an additive milestone:

M4.2 — Public-Standards eCTD v3.2.2 Input Compatibility

Work on branch demonstration-ui-flow-implementation. Read AGENTS.md and
IMPLEMENTATION.md completely before changing anything. Inspect the existing
M4.1 parser, package generator, product APIs, Analyzer, Baselines flow, tests,
and protected-artifact manifests.

Goal

Make RegBridge accept and safely parse a synthetic FDA/CDER eCTD v3.2.2
single-sequence package whose envelope conforms to the pinned public ICH/FDA
technical standards. Preserve the existing three migration-policy archetypes
and UI flow.

This is input-profile compatibility, not complete FDA submission validation,
submission-readiness assessment, or eCTD v4.0 generation.

Governance and immutable boundaries

- Treat this as additive M4.2 work.
- Do not modify the frozen M3 benchmark, labels, families, prompts, evaluation
  configurations, Phase 1/Phase 2 artifacts, M4 presentation snapshot, existing
  numerical claims, or existing M4.1 package bytes.
- Preserve:
  - FDA/CDER-only scope
  - prospective_forward_compatibility framing
  - current availability: not_operational
  - expert_validated: false
- Record pre/post SHA-256 values for all protected artifacts.
- Do not alter the migration decisions or author-adjudicated rules.
- Do not expand the explicit Case A mapping beyond:
  3.2.S.1.1, 3.2.S.1.2, and 3.2.S.1.3 → 3.2.S.1.

Documentation first

1. Add docs/milestones/M4.2.md and update AGENTS.md and IMPLEMENTATION.md.
2. Correct the ambiguous security instruction “disable XML DTDs” to:
   recognize approved DOCTYPE declarations while disabling network retrieval,
   untrusted filesystem resolution, entity expansion, and archive-supplied DTD
   execution.
3. Define the supported input profile exactly:
   - FDA/CDER
   - eCTD v3.2.2 backbone specification
   - ICH eCTD DTD v3.2
   - FDA Module 1 specification v2.6
   - US regional DTD v3.3
   - one selected sequence, optionally under an application wrapper
   - supported semantic-analysis documents: bounded PDFs
4. State explicitly that this is not full FDA validation.

Pinned input-profile assets

Create a separate, additive input-profile manifest rather than changing the
frozen regulatory evidence snapshot. Record official URL, retrieval date,
version, local path, SHA-256, and intended use for:

- ICH/FDA eCTD backbone specification v3.2.2
- ICH eCTD DTD v3.2
- FDA Module 1 specification v2.6
- US regional DTD v3.3
- any DTD dependencies required for offline validation
- selected applicable FDA validation criteria used only to define parser
  warnings or supported-profile failures

Do not silently retrieve these assets at runtime.

Safe XML and DTD behavior

Implement an exact mapping from approved DOCTYPE system identifiers to trusted,
pinned local DTD files.

- Accept recognized official absolute HTTP/HTTPS identifiers and recognized
  standard relative identifiers.
- Never fetch a DOCTYPE, stylesheet, schema, entity, or other resource from the
  network.
- Never use a DTD supplied inside the uploaded ZIP as trusted validation code.
- Reject internal subsets, entity declarations, unknown DTD identifiers,
  conflicting root/namespace/DTD combinations, and any attempted external
  resource outside the exact local catalog.
- Use a locked-down parser and custom local resolver.
- Prove with tests that no outbound request occurs.

Parser corrections

- Accept authentic <ectd:ectd> and namespace http://www.ich.org/ectd.
- Accept authentic <fda-regional:fda-regional>, namespace
  http://www.ich.org/fda, and US regional DTD 3.3.
- Do not require an explicit index.xml dtd-version attribute when the approved
  DTD/root/namespace identifies the version. Record the omission as a warning
  and record how the version was inferred.
- Parse authentic descriptive element names such as:
  m3-2-s-1-1-nomenclature
  m3-2-s-1-2-structure
  m3-2-s-1-3-general-properties
  to 3.2.S.1.1, 3.2.S.1.2, and 3.2.S.1.3.
- Ensure descriptive suffixes do not become fake heading segments.
- Recognize standard v3.2.2 headings structurally without creating new v4
  migration mappings.
- Parse substance/manufacturer from m3-2-s-drug-substance and support the
  authentic keyword attribute names.
- Parse FDA regional company-name and relevant application/submission fields.
- Recognize the index.xml leaf referencing m1/us/us-regional.xml as a backbone
  relationship. Do not treat it as a dossier PDF.
- Separate backbone XML, regional XML, STF, support files, analyzable dossier
  documents, and unsupported members.
- Accept sequence roots at archive root, 0000/, and application/0000/, while
  continuing to reject ambiguous multiple roots.
- Parse authentic modified-file values such as
  ../0001/index.xml#leaf-id as lifecycle references. Do not feed them to the
  archive-member path validator. If prior history is absent, record
  INSUFFICIENT_APPLICATION_HISTORY rather than hard-rejecting the package.
- Continue to verify declared MD5 compatibility checksums separately from
  SHA-256 provenance.

Coverage behavior

Parsing a structurally accepted document does not imply that RegBridge has a
migration rule for it.

For each parsed dossier document expose one of:

- EVALUATED_WITH_APPROVED_POLICY
- NO_MIGRATION_CHANGE_DETECTED, only for an explicitly encoded clean-negative
  policy condition
- OUTSIDE_ENCODED_POLICY_COVERAGE
- INSUFFICIENT_APPLICATION_HISTORY
- DOCUMENT_INSPECTION_INCOMPLETE

Do not assign unconditional legacy reuse merely because a document parsed
successfully. Analyzer and Baselines must consume the same inventory and the
same coverage record.

Authentic demonstration package

Do not overwrite data/demo-dossiers/m4-1. Add a reproducible M4.2 package using:

- an authentic application/sequence or sequence-only wrapper;
- DTD-valid ICH index.xml;
- DTD-valid FDA v3.3 m1/us/us-regional.xml;
- the required index.xml reference to us-regional.xml;
- correct root elements, namespaces, attributes, paths and MD5 values;
- three synthetic PDFs carrying the existing Case A, B and C signals;
- manufacturer="all" on the correct standard ancestor element;
- no expected decisions, benchmark IDs, fixture IDs, hidden labels or
  adjudication rationale.

Validate the generated XML independently against the pinned DTDs through the
local resolver. The RegBridge parser must not be the sole conformance oracle.

Also locate and test the separately generated user acceptance ZIP if it exists
in the workspace. Do not tailor the parser to its arbitrary spellings: any
accepted behavior must follow from the pinned standards/profile. If it is
absent, report the missing path rather than fabricating it.

Product and UI

Keep the current Analyzer and Baselines page structure.

- Analyzer continues to show only RegBridge results.
- Baselines continues to run B0/B1/B2/RegBridge against the same parsed upload.
- Point the demo preset/documentation to the new M4.2 package.
- Add compact profile information:
  profile ID/version, detected DTD identities, validation performed/result,
  sequence root, warning count and policy-coverage count.
- Display unsupported/out-of-coverage documents without presenting them as
  safe reuse decisions.
- Do not add benchmark metrics or system rankings to arbitrary-upload pages.

Tests and verification

Add independent tests for:

1. The new package passes both pinned DTD validations.
2. The separately generated acceptance package parses successfully when it
   satisfies the declared profile.
3. Official absolute FDA DOCTYPE identifiers are accepted without network I/O.
4. ICH relative DOCTYPE identifiers are safely mapped to pinned local files.
5. Missing index dtd-version is accepted with a warning/inferred version.
6. US regional DTD 3.3 is accepted; unsupported or conflicting versions fail
   with a precise profile error.
7. Authentic roots and namespaces are enforced.
8. The index reference to us-regional.xml is not treated as a PDF.
9. Authentic descriptive Module 3 tags produce the correct CTD headings.
10. Manufacturer metadata is inherited from the correct ancestor.
11. company-name is parsed from Module 1.
12. Authentic modified-file references are recorded without being mistaken for
    ZIP traversal.
13. A one-level sequence wrapper is accepted.
14. XXE, internal subsets, hostile archive DTDs, unknown absolute identifiers,
    path escape, archive bombs and ambiguous roots still fail closed.
15. Documents outside encoded migration-policy coverage do not receive
    unconditional reuse decisions.
16. Analyzer and all four comparison systems receive the same package-derived
    inventory and no label/fixture leakage occurs.
17. Two generation/parse runs reproduce package, inventory and result digests.
18. All pre-existing tests pass and protected M3/M4 hashes remain unchanged.

Add make m4-2-verify and scripts/m4-2-verify.ps1. Run the full verifier twice.

Final report

Report:

- exact files changed;
- the new profile and package identifiers;
- pinned standards and SHA-256 digests;
- generated package SHA-256;
- independent DTD-validation results;
- user acceptance-package result;
- parser/profile warnings;
- two-run reproducibility digests;
- backend/frontend/E2E test counts;
- protected-artifact verification;
- remaining limitations.

Do not modify the paper during this task. Provide a concise paper-impact note
for the author.
```

## Effect on the paper

Only small, localized changes are warranted in the [current draft](sandbox:/workspace/scratch/cbdce6a09de8/upload/RegBridge__Stable_and_Traceable_Regulatory_Reuse_Decisions_through_Deterministic_Synthesis__1_.pdf).

| Paper location | Change |
|---|---|
| Problem and Demonstration Goal | Replace “select a controlled case” with uploading an independently DTD-validated synthetic v3.2.2 sequence and inspecting the injected conditions |
| System Contribution | Specify ICH DTD 3.2/FDA regional DTD 3.3 input support and offline non-resolving validation |
| Limitations | Add single-sequence, PDF-analysis subset; no complete FDA validation and no multi-sequence reconstruction |
| Reproducibility | Record the new profile/package digest and demo-release commit |
| References | Add the FDA-hosted v3.2.2 backbone and Module 1 specifications |
| Results | No change |
| Abstract | No necessary change |
| Evaluation claims | No change |

Keep two reproducibility identities:

- `04ce54…` remains the Phase 2 evaluation commit.
- The eventual M4.2 commit becomes the demo-release commit.

Do not replace the former with the latter as though the experiment had been rerun.

## Effect on the reviewer’s assessment

The implementation directly improves two criticisms in the [review report](sandbox:/workspace/scratch/cbdce6a09de8/upload/paper review.pdf):

- “noisy parsing is not demonstrated”;
- parser-failure and document-corruption handling are insufficiently described.

It also improves the Demonstration Track case substantially: the audience sees a recognizable dossier enter the system, rather than choosing a fixture that happens to contain equivalent facts.

It does **not** resolve:

- the 12-case sample size;
- author/rule-label alignment;
- absence of SME validation;
- only three represented decisions;
- missing validator/retrieval ablations;
- action-space mismatch;
- limited related-work positioning;
- real-world generalization.

Therefore, this should not be presented as overturning the reviewer’s research-validity concerns. Its value is different:

> It turns RegBridge from a controlled decision-engine demonstration with a simplified input wrapper into a controlled decision-engine demonstration operating on a publicly specified, independently validated eCTD v3.2.2 envelope.

That is a meaningful improvement for an AAAI demonstration submission while leaving the later production-oriented paper—broader heading coverage, full histories, external validation, larger data and additional regulators—cleanly separated.

Use the phrase **“synthetic, independently DTD-validated FDA/CDER eCTD v3.2.2 single-sequence package”**, not “real FDA submission,” “FDA-compliant dossier,” or “submission-ready dossier.”

## Prompt:
9/4/2026, 2:24:26 PM

It got implemented and Codex said this: 

"Implemented M4.2 completely on `demonstration-ui-flow-implementation`. The final implementation passed the full verifier twice.

## Outcome

- Profile: `fda-cder-ectd-322-public-standards-profile-v1`
- Version: `1.0.0`
- Package: `regbridge-m4-2-public-standards-synthetic-v1`
- Package SHA-256: `4d236d51694b1c15d37ad92b9d0074b97a15075cde86cb96c393b9f87ce3e6e4`
- Sequence root: `synthetic-application/0000`
- Coverage: 3 × `EVALUATED_WITH_APPROVED_POLICY`
- Warning: `index-dtd-version-inferred`
- `prospective_forward_compatibility`, `not_operational`, and `expert_validated: false` remain unchanged.
- The paper was not modified.

The parser now uses an exact local DTD catalog, accepts authentic ICH/FDA roots and namespaces, infers omitted index versions, understands descriptive Module 3 tags and regional metadata, handles historical lifecycle references safely, separates STF/support/unsupported members, and prevents out-of-coverage documents from receiving permissive reuse decisions.

## Pinned standards

All were retrieved on 2026-09-03 and recorded in the [input-profile manifest]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/manifest.yaml).

- [ICH eCTD specification v3.2.2](https://admin.ich.org/sites/default/files/inline-files/eCTD_Specification_v3_2_2_0.pdf): `d8273833eac401ff3c094d782863b078110e33a7f358438d3f7a0dad277fc2b0`
- [ICH eCTD DTD v3.2](https://admin.ich.org/sites/default/files/inline-files/ich-ectd-3-2_dtd_0.zip): `c094aa2bded99564ade8ac78ae1540f95e518461b8eebe9a3063f67a165c2731`
- [FDA Module 1 specification v2.6](https://www.fda.gov/media/159382/download?attachment=): `1adcbc40ad55adc63b3ae0c6ab6428721ccf6c8f3f64a4a1be58b1ee276b87f2`
- [FDA US regional DTD v3.3](https://www.accessdata.fda.gov/static/eCTD/us-regional-v3-3.dtd): `d45139785dd6aa7eb3a60a23854ec2ea7d5d17c7c87b9ca12ab268baafc1dbec`
- [FDA eCTD validation criteria v4.6](https://www.fda.gov/media/87056/download?attachment=): `e5cc369a03840164ef97371d92504124ba013517f69e54487c7dfe9e5f3c46b6`

The two DTDs are self-contained; no additional DTD dependencies were required.

## Validation and reproducibility

Both generated backbones passed independent validation:

- `index.xml` → `ich-ectd-dtd-v3-2`: passed
- `m1/us/us-regional.xml` → `fda-us-regional-dtd-v3-3`: passed

Two-run deterministic digests, identical across both full verifier executions:

- Package: `4d236d51694b1c15d37ad92b9d0074b97a15075cde86cb96c393b9f87ce3e6e4`
- Inventory: `91cee37243b2612f20f48b487744a86c1a2905075f6f8615eb520990e98c93b1`
- Analysis result: `b0b4fad6c5497e0cb99c53618dbde4326dfd294b4eb754d11c30b260d8ec08ab`

The separately generated acceptance ZIP was found and tested unchanged:

- SHA-256: `ce88d218e993cd3a11f561455b97de607f18ef513292ba0b6aed4d39405f2857`
- Result: `rejected_nonconforming`
- Precise cause: its archive-supplied `ich-ectd-3-2.dtd` conflicts with the pinned official catalog asset.

No arbitrary spelling exceptions were introduced.

## Verification counts

Each final verifier run completed successfully:

- Backend: 223 passed
- Dedicated M4.2 integration suite: 21 passed
- Frontend: 7 passed across 5 test files
- E2E/accessibility: 4 passed across 1280px and 1440px viewports
- Ruff, mypy, schema drift, ESLint, TypeScript, and production build: passed
- Build: 1,769 modules transformed

The PowerShell verifier was run twice. The `make m4-2-verify` target was added, but GNU Make is not installed on this Windows host, so the equivalent [PowerShell verifier]\(C:/Users/david/OneDrive/Documents/regbridge/scripts/m4-2-verify.ps1) was invoked directly.

## Protected artifacts

Every recorded pre/post digest matched:

| Protected artifactPre/post SHA-256 |                                                                    |
| ---------------------------------- | ------------------------------------------------------------------ |
| `data/benchmark`                   | `9590c82dcc5106fa6217212760a8f3f40caf4f75e1dbf4096906776214152718` |
| `data/evaluation`                  | `817a04846cda6f912235a2460965b749ce974fdb6e6a70c2ff9cf32d5360ca79` |
| `results/validation`               | `7cf1c2f7e0c474b88e61e0ceae304ae8ab0e73ffcd2a17004adc76de9a929a2d` |
| `results/live`                     | `b6e845894e5f0b220a5fc64468c6ec7bd78ea8c425604a132f6d763dfcca1d92` |
| `paper/tables`                     | `5ced3f8cba468232ab645c41b1a2e2e791dc8c285eac6e30bde6b142adf0e417` |
| `data/presentation/m4`             | `f3fdced35c50617658fbbddc5036e6ebb878907d3e07aacf37a8479e52c2a065` |
| `paper/figures/m4`                 | `09a053bb3c73a6b46ace47467dc27aa2db4e714f7bb0aa33325248f421c16cd7` |
| M4.1 ZIP                           | `81d77881a1ab90bcbcbad38b836f4a829852b75e68906c0b23171aa85609e597` |
| M4.1 generation manifest           | `936869ec33f5682d98cca40a4fee0f7ec3cd96b3bd66745e732587d8d6782fc0` |
| M4.1 protected manifest            | `5661dd76b38b23879651c59e82bd3521204a3fb95a9711ec2f39fe48680502a0` |

See the [M4.2 protected-artifact manifest]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2/protected-artifacts.json).

## Exact files changed

Governance and documentation:

- [AGENTS.md]\(C:/Users/david/OneDrive/Documents/regbridge/AGENTS.md)
- [IMPLEMENTATION.md]\(C:/Users/david/OneDrive/Documents/regbridge/IMPLEMENTATION.md)
- [README.md]\(C:/Users/david/OneDrive/Documents/regbridge/README.md)
- [Makefile]\(C:/Users/david/OneDrive/Documents/regbridge/Makefile)
- [M4.2.md]\(C:/Users/david/OneDrive/Documents/regbridge/docs/milestones/M4.2.md)
- [DEMO\_M4\_2.md]\(C:/Users/david/OneDrive/Documents/regbridge/docs/DEMO\_M4\_2.md)

Backend:

- [service.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/analyzer/service.py)
- [routes.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/api/routes.py)
- [models.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/parsers/models.py)
- [profile322.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/parsers/profile322.py)
- [public322.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/parsers/public322.py)
- [comparison.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/product/comparison.py)
- [product models.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/product/models.py)
- [product services.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/product/services.py)
- [verify\_m42.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/product/verify\_m42.py)
- [pyproject.toml]\(C:/Users/david/OneDrive/Documents/regbridge/backend/pyproject.toml)
- [requirements.lock]\(C:/Users/david/OneDrive/Documents/regbridge/backend/requirements.lock)
- [test\_m4\_2\_public\_profile.py]\(C:/Users/david/OneDrive/Documents/regbridge/backend/tests/integration/test\_m4\_2\_public\_profile.py)

Frontend and schemas:

- [m4.spec.ts]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/e2e/m4.spec.ts)
- [client.ts]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/src/api/client.ts)
- [contracts.ts]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/src/api/contracts.ts)
- [BaselinesWorkspace.tsx]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/src/pages/BaselinesWorkspace.tsx)
- [DossierWorkspace.tsx]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/src/pages/DossierWorkspace.tsx)
- [M41Workspace.test.tsx]\(C:/Users/david/OneDrive/Documents/regbridge/frontend/src/test/M41Workspace.test.tsx)
- [application-inventory.schema.json]\(C:/Users/david/OneDrive/Documents/regbridge/schemas/application-inventory.schema.json)
- [openapi.json]\(C:/Users/david/OneDrive/Documents/regbridge/schemas/openapi.json)

Data, assets, and scripts:

- [generation-manifest.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/demo-dossiers/m4-2/generation-manifest.json)
- [regbridge-m4-2-public-standards.zip]\(C:/Users/david/OneDrive/Documents/regbridge/data/demo-dossiers/m4-2/regbridge-m4-2-public-standards.zip)
- [input-profile manifest]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/manifest.yaml)
- [ectd-spec-v3-2-2.pdf]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/assets/ectd-spec-v3-2-2.pdf)
- [ich-ectd-3-2.dtd]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/assets/ich-ectd-3-2.dtd)
- [fda-module-1-spec-v2-6.pdf]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/assets/fda-module-1-spec-v2-6.pdf)
- [us-regional-v3-3.dtd]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/assets/us-regional-v3-3.dtd)
- [fda-ectd-validation-criteria-v4-6.pdf]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/assets/fda-ectd-validation-criteria-v4-6.pdf)
- [protected-artifacts.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2/protected-artifacts.json)
- [generate\_m4\_2\_dossier.py]\(C:/Users/david/OneDrive/Documents/regbridge/scripts/generate\_m4\_2\_dossier.py)
- [m4-2-verify.ps1]\(C:/Users/david/OneDrive/Documents/regbridge/scripts/m4-2-verify.ps1)

## Remaining limitations and paper impact

This remains bounded input-profile compatibility, not full FDA validation, submission-readiness assessment, multi-sequence application reconstruction, production conversion, or eCTD v4.0 generation. Prior-sequence references without uploaded history remain `INSUFFICIENT_APPLICATION_HISTORY`; STF files are safely inventoried but not executed or semantically analyzed; semantic analysis remains limited to bounded PDFs.

Paper-impact note: the author can describe M4.2 as adding pinned-public-standard, offline-DTD-validated eCTD v3.2.2 input compatibility and explicit migration-policy coverage reporting. It should not change frozen benchmark numbers or imply FDA validation, expert validation, or operational forward compatibility."

## Response:
9/4/2026, 2:24:46 PM

This is a strong implementation report, but I would not sign off on M4.2 from the summary alone because one result directly touches the milestone’s purpose: the independently generated acceptance package was still rejected. I’m checking whether that rejection reflects a genuinely invalid XML/DTD package or an unnecessarily strict byte-hash policy for an archive-supplied DTD.

> **Assessing acceptance ZIP conformance**
>
> **Assessing acceptance ZIP conformance**
>
> **Evaluating DTD mismatch impact on acceptance**
>
> **Evaluating DTD mismatch impact on acceptance**
>
> **Assessed acceptance ZIP conformance and DTD mismatch impact**
>
> 
>
> **Assessing acceptance ZIP conformance**
>
> **Assessing acceptance ZIP conformance**
>
> **Evaluating DTD mismatch impact on acceptance**
>
> **Evaluating DTD mismatch impact on acceptance**
>
> **Assessed ZIP conformance and DTD mismatch impact on acceptance**
>
> 
>
> **Identifying missing push of local branch**
>
> **Identifying missing push of local branch**
>
> **Planning investigation of DTD conflict standards**
>
> **Planning investigation of DTD conflict standards**
>
> **Identified missing branch push and planned DTD conflict investigation**
>
> 
>
> **Reviewed parsers, UI flows, milestone documentation, standards, and integration tests**
>
> 
>
> **Searching 5 websites**
>
>
> **Identifying unpushed GitHub branch and advising push**
>
> **Identifying unpushed GitHub branch and advising push**
>
> **Planning detailed DTD conflict comparison and classification**
>
> **Planning detailed DTD conflict comparison and classification**
>
> **Identified unpushed branch and planned DTD conflict classification**
>
> 
>
> **Searched 5 websites**
>
> 
>
> Worked for 59s

This is mostly excellent, but I would mark M4.2 as **implemented with one acceptance issue still requiring adjudication**, not fully closed.

## What succeeded

The important objectives were met:

- Authentic ICH/FDA roots, namespaces and descriptive Module 3 elements.
- Pinned local DTD catalog with no network resolution.
- Independent DTD validation of the generated package.
- Correct handling of omitted backbone `dtd-version`.
- Explicit policy-coverage reporting.
- No modification of frozen M3/M4 artifacts.
- Same package-derived inventory for Analyzer and Baselines.
- The paper and experimental results remained untouched.

This is sufficient to demonstrate an authentic public-standard envelope rather than the simplified M4.1 wrapper.

## The unresolved issue

The separately generated acceptance package was rejected because its bundled `ich-ectd-3-2.dtd` differed from the pinned official DTD.

That rejection is correct only if one of these is true:

- Its XML fails validation against the pinned official DTD.
- The bundled DTD is genuinely modified in a substantive way.
- The bundled DTD attempts entity loading or introduces another security concern.
- An explicitly pinned public criterion requires exact DTD bytes.

A different SHA-256 alone does not prove substantive nonconformance. Harmless differences such as CRLF versus LF line endings, encoding markers or comments can change a digest without changing the DTD grammar.

The secure and scientifically defensible behavior should be:

1. Never execute or trust the archive-supplied DTD.
2. Validate the XML using RegBridge’s pinned local official DTD.
3. Compare the bundled DTD separately.
4. If the XML passes but the bundled DTD differs harmlessly, accept the package with a warning such as:

```text
ARCHIVE_DTD_DIFFERS_FROM_PINNED_COPY
Archive DTD was ignored; XML was validated using the pinned official DTD.
```

5. Hard-reject only if the XML fails the pinned DTD or the bundled DTD creates a demonstrated security/profile violation.

FDA’s validation criteria distinguish unsupported DTD versions and invalid XML, but the implementation report does not establish that an arbitrary byte mismatch is itself an FDA hard-rejection criterion. [FDA validation criteria](https://www.fda.gov/media/87056/download)

## Follow-up message for Codex

Send this before declaring final M4.2 closure:

> M4.2 is provisionally accepted, but the separately generated acceptance ZIP requires one final adjudication.
>
> Determine exactly why its bundled `ich-ectd-3-2.dtd` differs from the pinned official asset:
>
> 1. Record both SHA-256 digests.
> 2. Compare raw bytes and normalized text using consistent UTF-8 decoding and LF line endings.
> 3. Report the first substantive differences, excluding newline, BOM and trailing-whitespace changes.
> 4. Ignore the archive-supplied DTD and independently validate its `index.xml` against RegBridge’s pinned official ICH DTD.
> 5. Independently validate `us-regional.xml` against the pinned FDA regional DTD.
>
> Apply this policy:
>
> - If either XML fails validation against the pinned official DTD, retain `rejected_nonconforming` and report the exact validation errors.
> - If both XML files pass and the only issue is a non-identical bundled DTD, do not classify the complete dossier as nonconforming solely from the digest mismatch unless an exact official source requires byte identity.
> - In that case, accept the package using the pinned local DTD and emit `ARCHIVE_DTD_DIFFERS_FROM_PINNED_COPY`, stating that the archive DTD was ignored.
> - If the bundled DTD contains dangerous external entities or other hostile constructs, hard-reject it as a security violation.
>
> Add tests for byte-identical, line-ending-only, comment-only, substantively modified and hostile bundled DTD variants. Do not alter the frozen benchmark, Phase 2 outputs or migration policies.

## GitHub status

The remote `demonstration-ui-flow-implementation` branch currently still points to commit `3982b8c1ad2bb0a90da6ccac06d3a9a7db5fc171`. The reported M4.2 files—including `public322.py`, `M4.2.md` and the new integration test—are not yet present remotely.

So the implementation appears complete locally, but it must be committed and pushed before the repository or paper can cite it.

## Paper effect

Do not update the paper yet. First:

- Resolve the acceptance-package classification.
- Push M4.2.
- Record the final demo-release commit.
- Confirm the verifier once from the committed tree.

Then the paper needs only the small changes previously identified. The strongest defensible sentence will be:

> The demonstration accepts a synthetic, independently DTD-validated FDA/CDER eCTD v3.2.2 single-sequence package through a pinned, offline public-standards input profile.

Do not say it “accepts real submissions generally.” The current evidence supports one bounded public-standard profile, not arbitrary FDA dossiers or complete submission validation.

## Prompt:
9/4/2026, 2:26:52 PM

I just pushed the commit, it should be seen by you now

## Response:
9/4/2026, 2:26:54 PM

I’ll verify the pushed branch head and inspect the actual M4.2 parser, acceptance-package logic, tests, and milestone documentation. The main thing I’m checking is whether the reported `rejected_nonconforming` result is based on pinned-DTD validation or merely a byte-digest mismatch.

> **Inspecting public322 DTD and tests**
>
> **Inspecting public322 DTD and tests**
>
> **Inspected public322 DTD and tests**
>
> 
>
> **Evaluating GitHub base64 fetch and decoding**
>
> **Evaluating GitHub base64 fetch and decoding**
>
> **Confirming parser DTD rejection and validation limits**
>
> **Confirming parser DTD rejection and validation limits**
>
> **Evaluated GitHub decoding and confirmed parser DTD validation limits**
>
> 
>
> **Evaluating GitHub base64 fetch and decoding**
>
> **Evaluating GitHub base64 fetch and decoding**
>
> **Confirming parser DTD rejection and validation limits**
>
> **Confirming parser DTD rejection and validation limits**
>
> **Evaluated GitHub decoding and confirmed parser DTD validation limits**
>
> 
>
> **Reviewed demonstration flow, M4.2 verification, profile tests, dossier generation, and eCTD standards**
>
> 
>
> Worked for 52s

I can see the pushed implementation now. The branch head is:

`254f4e64326c891e4e2bf78eb3de0903a3962796`

The M4.2 files are present, and most of the implementation is strong. The exact local resolver, authentic namespaces, DTD validation, heading parsing, lifecycle handling and policy-coverage gate are implemented as reported.

However, my earlier concern is confirmed in the actual code.

## Remaining issue

In [public322.py](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/parsers/public322.py), RegBridge checks every archive DTD’s raw SHA-256 against the pinned DTD and rejects the package before validating its XML:

```python
if pinned is not None and _sha256(archive_dtd) != pinned.sha256:
    raise EctdSecurityError(
        f"archive-supplied DTD conflicts with pinned catalog asset: {archive_dtd.name}"
    )
```

Meanwhile, [test_m4_2_public_profile.py](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/tests/integration/test_m4_2_public_profile.py) passes whether the independent package is accepted or rejected with one of several expected messages. Therefore, it is a compatibility diagnostic—not a true acceptance test.

The verifier similarly records `rejected_nonconforming` for any parser error without proving that the XML itself fails the official pinned DTD.

## Verdict

M4.2 successfully establishes:

> RegBridge can parse and analyze its independently DTD-validated, public-standard-structured demonstration package.

It has not yet established:

> RegBridge accepts a separately generated conformant package.

That second statement is important because it rules out generator–parser co-adaptation.

## Recommended final correction

Ask Codex to perform one short M4.2.1 task:

1. Compare the independent package’s DTD with the pinned DTD after normalizing BOM, line endings and trailing whitespace.
2. Validate its `index.xml` against the pinned official DTD while ignoring the archive DTD.
3. If validation fails, preserve the rejection and report exact DTD validation errors.
4. If validation passes and the archive DTD is non-hostile, accept the package but warn:

```text
ARCHIVE_DTD_DIFFERS_FROM_PINNED_COPY
Archive-supplied DTD was ignored; XML was validated using the pinned official DTD.
```

5. Continue hard-rejecting entity declarations, internal subsets, dangerous external references and XML that fails the pinned DTD.
6. Change the independent-package test so its expected result is explicit—accepted or rejected for a precisely documented standards violation—not “either outcome passes.”

This correction does not affect the paper results, migration policies or frozen artifacts. After it, M4.2 can be considered fully closed and the paper can credibly describe compatibility with both the reproducible demo package and a separately generated standards-based package.

## Prompt:
9/4/2026, 2:29:32 PM

So I can send that follow-up message you sent in the earlier message?

## Response:
9/4/2026, 2:29:33 PM

Yes—send the earlier follow-up message. It remains accurate after inspecting the pushed code.

One wording improvement: begin with this to prevent Codex from unnecessarily redesigning M4.2:

> M4.2 is accepted for the generated demonstration package. Before final closure, implement this narrowly scoped M4.2.1 independent-package adjudication. Do not change migration policies, frozen artifacts, benchmark results, or the existing product flow.

Then include the full instructions beginning:

> Determine exactly why its bundled `ich-ectd-3-2.dtd` differs from the pinned official asset…

The key requirement is that Codex must first establish whether the difference is merely byte-level or substantively changes the DTD. It should not automatically weaken the rejection, nor continue treating every hash difference as proof that the dossier XML is nonconforming.

## Prompt:
9/4/2026, 2:57:36 PM

Done: "Implemented M4.2.1 on `demonstration-ui-flow-implementation`.

### Adjudication result

The independent acceptance package remains `rejected_nonconforming`.

- Package SHA-256: `ce88d218e993cd3a11f561455b97de607f18ef513292ba0b6aed4d39405f2857`
- Bundled ICH DTD SHA-256: `f28d7c22d0ebccff6176058926ed7b956744c20942929676bcc1345cf6104134`
- Pinned official ICH DTD SHA-256: `c094aa2bded99564ade8ac78ae1540f95e518461b8eebe9a3063f67a165c2731`
- Pinned FDA regional DTD SHA-256: `d45139785dd6aa7eb3a60a23854ec2ea7d5d17c7c87b9ca12ab268baafc1dbec`

The bundled DTD is a non-hostile, 149-byte comment stub; the pinned DTD is 31,400 bytes. Raw bytes, normalized UTF-8/LF text, and comment-stripped semantic text all differ. The first substantive missing content includes the `%att` entity declaration, `ectd:ectd` element declaration, its attribute list, and fixed eCTD namespace declaration.

The archive DTD was ignored and never executed.

Both independent validations failed because the submitted XML declares:

`http://www.w3.org/1999/xlink`

while the pinned ICH and FDA DTDs require the fixed value:

`http://www.w3c.org/1999/xlink`

For both XML files, libxml reported:

- namespace does not match the DTD;
- attribute differs from its default;
- attribute does not equal the required fixed value.

FDA eCTD Validation Criteria v4.6 criterion 1130 requires required UTIL-file checksums to match. Therefore this profile has an exact byte-identity requirement. The implementation still supports and tests `ARCHIVE_DTD_DIFFERS_FROM_PINNED_COPY` for profiles without such a requirement.

The complete machine-readable result is in [independent-package-adjudication.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2-1/independent-package-adjudication.json).

### Verification

The full M4.2 verifier passed twice:

- Backend: 229 passed
- Dedicated M4.2/M4.2.1 tests: 27 passed
- Frontend: 7 passed
- E2E: 4 passed
- Lint, typecheck, build, Ruff and mypy: passed
- Protected M3/M4 artifacts: every recorded pre/post SHA-256 matched
- `git diff --check`: passed

Reproducibility remained stable:

- Package: `4d236d51694b1c15d37ad92b9d0074b97a15075cde86cb96c393b9f87ce3e6e4`
- Inventory: `91cee37243b2612f20f48b487744a86c1a2905075f6f8615eb520990e98c93b1`
- Result: `b0b4fad6c5497e0cb99c53618dbde4326dfd294b4eb754d11c30b260d8ec08ab`
- Adjudication record: `81657b91b8213b1a97e677e3e630fef88298f77a8069e4864d8c6f8f216b77e6`

### Files changed

- [AGENTS.md (line 234)]\(C:/Users/david/OneDrive/Documents/regbridge/AGENTS.md:234)
- [IMPLEMENTATION.md (line 1034)]\(C:/Users/david/OneDrive/Documents/regbridge/IMPLEMENTATION.md:1034)
- [public322.py (line 283)]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/parsers/public322.py:283)
- [verify\_m42.py (line 82)]\(C:/Users/david/OneDrive/Documents/regbridge/backend/app/product/verify\_m42.py:82)
- [test\_m4\_2\_public\_profile.py (line 174)]\(C:/Users/david/OneDrive/Documents/regbridge/backend/tests/integration/test\_m4\_2\_public\_profile.py:174)
- [manifest.yaml (line 32)]\(C:/Users/david/OneDrive/Documents/regbridge/data/input-profiles/fda-cder-ectd-322-public-standards-v1/manifest.yaml:32)
- [M4.2.1.md (line 1)]\(C:/Users/david/OneDrive/Documents/regbridge/docs/milestones/M4.2.1.md:1)
- [independent-package-adjudication.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2-1/independent-package-adjudication.json)
- [protected-artifacts.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2-1/protected-artifacts.json)

No migration policies, benchmark results, Phase 2 outputs, product flow, or paper files were changed.

Paper-impact note: if this package is discussed later, describe it as independently rejected due to fixed-namespace validation failures and a nonofficial bundled DTD—not as evidence that arbitrary bundled DTD digest differences always invalidate a dossier."

## Response:
9/4/2026, 2:57:42 PM

The implementation outcome is mostly the right one, but two claims in that report deserve a careful sanity check before you treat M4.2.1 as closed: the unusual `w3c.org` fixed namespace and the inference from FDA criterion 1130 to byte-identical bundled DTDs. I’m checking those against the pinned official materials and the branch, because either claim could materially change how the rejection should be described. I’m using the continuity workflow to preserve the exact M4.2/M4.2.1 boundary we already agreed on.

> **Verifying xlink URI discrepancy**
>
> **Verifying xlink URI discrepancy**
>
> **Verified xlink URI discrepancy**
>
> 
>
> **Inspected profile tests, parser implementation, milestone documentation, standards, and adjudication data**
>
> 
>
> **Searching www.fda.gov**
>
>
> **Searching www.fda.gov**
>
>
> **Verifying DTD checksum enforcement**
>
> **Verifying DTD checksum enforcement**
>
> **Clarifying rejection severity and terminology**
>
> **Clarifying rejection severity and terminology**
>
> **Verified DTD checksum enforcement and clarified rejection severity terminology**
>
> 
>
> **Verifying DTD checksum enforcement**
>
> **Verifying DTD checksum enforcement**
>
> **Clarifying rejection severity and terminology**
>
> **Clarifying rejection severity and terminology**
>
> **Verified DTD checksum enforcement and clarified rejection severity terminology**
>
> 
>
> **Searched 1 website**
>
> 
>
> Worked for 1m 31s

M4.2.1 can be considered complete. The adjudication is now technically defensible.

The surprising namespace result is correct: FDA’s published Module 1 specification and examples use the fixed value `http://www.w3c.org/1999/xlink`, not the conventional W3C namespace `http://www.w3.org/1999/xlink`. Therefore, the independent package genuinely fails validation against the pinned DTDs. [FDA Module 1 specification v2.6](https://www.fda.gov/media/159382/download)

The implementation also now makes the right distinctions:

- The archive’s 149-byte DTD stub was treated as untrusted data and never executed.
- The XML was independently validated against the pinned official DTDs.
- The package failed because its XML violates fixed DTD declarations—not merely because its bundled DTD had a different hash.
- The comparison machinery can distinguish byte-only, comment-only, substantive, and hostile differences.
- The acceptance test now requires the precise expected outcome.
- Frozen experiments and migration policies remain untouched.

One wording boundary should be preserved: FDA criterion 1130 is classified as **Low severity** and says no corrective action is necessary for the submitted sequence, although procedures should prevent altered required files. Therefore, do not describe the DTD checksum issue by itself as meaning “FDA would reject the submission as not received.” Describe it as:

> The package does not satisfy RegBridge’s strict pinned-public-standards input profile; independently, both XML backbones also fail validation against their pinned official DTDs.

Criterion 1130 supports exact identity for the applicable required UTIL asset—not a universal claim about every archive-supplied DTD. [FDA eCTD Validation Criteria v4.6, criterion 1130](https://www.fda.gov/media/87056/download?attachment=)

No substantive paper revision is needed. The paper should emphasize the successfully accepted, independently DTD-validated M4.2 demonstration package. The rejected third-party package is implementation validation evidence, not a central research result. If mentioned at all, one sentence is enough:

> Uploaded XML is validated offline against digest-pinned official DTDs, while archive-supplied DTDs are treated as untrusted data and never executed.

You can now close M4.2/M4.2.1 and move to the local-model experiment.

## Prompt:
9/4/2026, 7:57:39 PM

![8257ed68-8b56-4069-a564-e2f52eca86a7.png](https://chatgpt.com/backend-api/estuary/content?id=file_000000005e1c81f5b575ab5e1814e2fa&fn=8257ed68-8b56-4069-a564-e2f52eca86a7.png&cd=attachment&ts=496913&p=fs&cid=1&sig=c349fcd66ff2d42b5c07787bb68e999383ea95fd44ca6c83315bf0a0b2b839aa&v=0)

![b79129bd-3451-4886-85c0-9ba12ea38cad.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000024881f5bf1f603fab2b111a&fn=b79129bd-3451-4886-85c0-9ba12ea38cad.png&cd=attachment&ts=496913&p=fs&cid=1&sig=e4dde7796493d106f1c7f6bdc89456e4949360f51743e06cca6de779900b479e&v=0)

Decided to parse and analyze the demo present regbridge-m4-2-public-standards.zip  

And here are the results; interesting. Upon opening **Synthetic molecular structure**  and **Synthetic lifecycle metadata context**, the GPT 5.5 model call failed, so I can see it resorted to **HUMAN\_REGULATORY\_REVIEW**  for both. However, the evidence is showing a complete map. Is this a bug to look at? Make it make sense to me let's see.

## Response:
9/4/2026, 7:57:42 PM

The graph and the fallback can both be technically valid, but the screen may still be misleading. I’m checking three separate contracts: whether a model failure is supposed to override a hard structural rule, what “Failed: 0” actually counts, and whether the displayed graph includes the failure path that produced `HUMAN_REGULATORY_REVIEW`. I’m using the continuity workflow because the answer depends on the M2 decision precedence we previously fixed, not just the screenshot.

I found the key distinction: this is not one problem but two. The conservative fallback is defensible for some cases, yet the product currently collapses a valid model abstention into the label `failed`, while the graph displays deterministic evidence without displaying the uncertainty that actually caused the human-review outcome. I’m checking the previously approved precedence language now, because Case A may also be losing a valid hard structural conclusion.

> **Planning repository inspection for bug analysis**
>
> **Planning repository inspection for bug analysis**
>
> **Analyzing model call failures and human review logic**
>
> **Analyzing model call failures and human review logic**
>
> **Analyzed repository for model call failures and review logic**
>
> 
>
> **Planning repository inspection for bug analysis**
>
> **Planning repository inspection for bug analysis**
>
> **Analyzing model call failures and human review logic**
>
> **Analyzing model call failures and human review logic**
>
> **Analyzed repository model call failures and human review logic**
>
> 
>
> **Analyzing live mode error handling**
>
> **Analyzing live mode error handling**
>
> **Analyzed live mode error handling**
>
> 
>
> **Analyzing model status inconsistencies**
>
> **Analyzing model status inconsistencies**
>
> **Identifying configuration-induced modeling bug**
>
> **Identifying configuration-induced modeling bug**
>
> **Analyzed configuration-induced model status inconsistencies**
>
> 
>
> **Analyzing model status inconsistencies**
>
> **Analyzing model status inconsistencies**
>
> **Identifying configuration-induced modeling bug**
>
> **Identifying configuration-induced modeling bug**
>
> **Identified a configuration-induced modeling bug causing status inconsistencies**
>
> 
>
> **Analyzing model status inconsistencies**
>
> **Analyzing model status inconsistencies**
>
> **Identifying configuration-induced modeling bug**
>
> **Identifying configuration-induced modeling bug**
>
> **Assessing graph explanation and decision precedence issues**
>
> **Assessing graph explanation and decision precedence issues**
>
> **Analyzed modeling inconsistencies, configuration bugs, and graph decision precedence issues**
>
> 
>
> **Analyzing model status inconsistencies**
>
> **Analyzing model status inconsistencies**
>
> **Identifying configuration-induced modeling bug**
>
> **Identifying configuration-induced modeling bug**
>
> **Assessing graph explanation and decision precedence issues**
>
> **Assessing graph explanation and decision precedence issues**
>
> **Diagnosing decision synthesis and status labeling bugs**
>
> **Diagnosing decision synthesis and status labeling bugs**
>
> **Diagnosed model status, configuration, explanation, and decision labeling bugs**
>
> 
>
> **Investigated package failures, validation handling, graph services, and model implementations**
>
> 
>
> **Clarifying result failure criteria**
>
> **Clarifying result failure criteria**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identified result failure criteria and decision UI graph bugs**
>
> 
>
> **Clarifying result failure criteria**
>
> **Clarifying result failure criteria**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identified result failure criteria and decision UI graph bugs**
>
> 
>
> **Clarifying result failure criteria**
>
> **Clarifying result failure criteria**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Analyzed failure criteria, decision handling bugs, and live-mode abstention semantics**
>
> 
>
> **Clarifying result failure criteria**
>
> **Clarifying result failure criteria**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Recommending preserving deterministic rule despite abstention**
>
> **Recommending preserving deterministic rule despite abstention**
>
> **Analyzed failure criteria, decision bugs, abstention, and deterministic rule preservation**
>
> 
>
> **Clarifying result failure criteria**
>
> **Clarifying result failure criteria**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Identifying bugs in decision handling and UI graph**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Analyzing model abstention versus failure in live mode**
>
> **Recommending preserving deterministic rule despite abstention**
>
> **Recommending preserving deterministic rule despite abstention**
>
> **Outlining product-flow issue with status distinctions**
>
> **Outlining product-flow issue with status distinctions**
>
> **Clarified failure criteria and recommended preserving deterministic decisions amid abstention**
>
> 
>
> **Searched lifecycle, regulatory, and semantic signal references**
>
> 
>
> Worked for 2m 39s

Yes—there is a real issue to fix, but it is not that the evidence map is wrong. Three different concepts are being collapsed together: model abstention, analysis failure, and final decision synthesis.

## What happened

The screen shows:

- `3 Analyzed`
- `3 Human approval`
- `0 Failed`
- Per-document model status apparently shown as `failed`
- Final decisions of `HUMAN_REGULATORY_REVIEW`

Those facts mean the overall analysis pipeline did not fail. RegBridge successfully parsed the documents, ran its deterministic rules, built the graph, synthesized results, and published three `DossierLeafResult` objects.

The `Failed: 0` card counts only terminal leaf failures where RegBridge could not produce a result at all. It does not count a nested semantic-model abstention or failure inside an otherwise completed result.

## Why “failed” may not really mean failed

There is a status-mapping problem in [`services.py`](https://github.com/chirix33/regbridge/blob/demonstration-ui-flow-implementation/backend/app/product/services.py).

The underlying model run can have statuses such as:

- `completed`
- `abstained`
- `failed`
- `not_applicable`

But the product record converts everything except `completed` and `not_applicable` into:

```text
failed
```

Therefore, a perfectly valid GPT-5.5 response saying “I cannot determine this from the supplied evidence” is displayed as a model failure.

That is a bug in telemetry and presentation. `abstained` and `failed` must remain separate.

The API/UI should expose something closer to:

| Status | Meaning |
|---|---|
| `completed` | Valid semantic inspection returned |
| `abstained` | Model completed normally but declined to make a finding |
| `failed` | Provider, transport, schema, or validation failure |
| `not_applicable` | No model inspection was needed |

The UI should also display the redacted cause or abstention reason. It currently only shows model, adapter, status, and latency.

## Why the evidence map is still complete

The graph is built from several independent components:

- Parsed artifact
- Parsed heading
- Parsed keywords
- Dossier evidence occurrences
- Author-adjudicated rules
- Official evidence spans
- Model findings, if any
- Synthesized decision and action

The heading and metadata portions are deterministic. They do not disappear merely because GPT-5.5 abstains.

For the molecular-structure document, RegBridge already knows from XML and approved evidence that:

```text
3.2.S.1.2 → 3.2.S.1
```

That mapping remains factual even if semantic PDF inspection does not complete.

Also, the graph builder currently adds the entire approved Case A mapping neighborhood—`3.2.S.1.1`, `.1.2`, and `.1.3`—when an M1 rule is triggered. It is therefore showing the policy neighborhood, not solely the exact execution path for that document.

That explains the apparent contradiction:

```text
Deterministic mapping exists
        +
Semantic inspection incomplete
        =
Current synthesis returns human review
```

## The graph nevertheless has an explanation gap

The heading “Why this conclusion is connected” is currently too strong.

The graph shows the structural rule and its evidence, but it does not show the model abstention or incomplete semantic inspection that actually caused `HUMAN_REGULATORY_REVIEW`. There is no uncertainty or analysis-limitation node connected to the decision.

Consequently, the graph visually appears to justify a structural mapping while the decision shown is human review.

For traceability, it should include something like:

```text
SEMANTIC_INSPECTION
    status: abstained
        ↓ LEAVES_UNRESOLVED
DOCUMENT_INSPECTION_INCOMPLETE
        ↓ TRIGGERS_DECISION
HUMAN_REGULATORY_REVIEW
```

Alternatively, rename the graph section to “Evidence and policy neighborhood,” but adding the actual uncertainty path would be better.

## Is each decision correct?

### Synthetic molecular structure — likely a synthesis bug

This document has a source-supported hard structural mapping. The approved Case A outcome is:

```text
REUSE_WITH_NEW_CONTEXT
```

A missing semantic inspection should not erase that known structural requirement. A more faithful result would be:

```text
Decision: REUSE_WITH_NEW_CONTEXT
Human approval: required
Document inspection: incomplete
Unresolved uncertainty: GPT-5.5 abstained or failed
```

The implementation contract says a semantic signal cannot override a hard rule. Although abstention is the absence of a signal, using it to replace the hard result with `HUMAN_REGULATORY_REVIEW` still hides the mechanically established action.

This should be corrected.

### Synthetic lifecycle metadata context — human review can be correct

For exact `manufacturer="all"` with preserve-existing-lifecycle intent, the deterministic evidence can establish conditional technical eligibility. But the approved policy depends on completing the required content/relevance inspection.

If GPT-5.5 abstained or failed, then:

```text
HUMAN_REGULATORY_REVIEW
```

is a defensible conservative result.

The graph should explain:

> Exact keyword preservation is structurally supported, but semantic inspection did not complete; therefore unconditional legacy reuse was not approved.

### Synthetic applicant responsibility statement — human review is expected

This is the semantic Case C document. If GPT-5.5 detected the applicant mismatch—or could not safely adjudicate it—human review is the intended result.

## What should be fixed before recording the demonstration

This is a small but important M4.2 product correction:

1. Preserve `abstained` separately from `failed`.
2. Show the model’s abstention/failure cause.
3. Add model-completion counts separately from pipeline-failure counts.
4. Add the incomplete-inspection path to the explanation graph.
5. For Case A, retain `REUSE_WITH_NEW_CONTEXT` when the hard heading rule fires; attach semantic incompleteness as uncertainty and require human approval.
6. Keep Case B/C conservative when semantic inspection is genuinely necessary.
7. Add tests for completed, abstained, invalid-output, and transport-failure behavior across all three archetypes.

So your instinct was right: the complete evidence map is not itself a bug, but the current screen does not accurately communicate how that evidence, the model status, and the final decision relate. The Case A synthesis behavior is the substantive issue; the `failed` label and graph explanation are presentation/traceability bugs. These are worth fixing before the final demo because deterministic, traceable synthesis is the paper’s central claim.

## Prompt:
9/4/2026, 8:05:59 PM

Okay, word it properly for Codex to perform the fix. Think properly

## Response:
9/4/2026, 8:06:00 PM

I’ll frame this as a narrow M4.2.2 correction, not a redesign. The prompt will force Codex to diagnose the exact observed statuses first, preserve the frozen experiments, and distinguish four things that must never be conflated: valid model abstention, provider failure, deterministic policy conclusions, and human-review requirements. I’m using the drafting workflow because this is a complete implementation instruction you will paste directly into Codex.

> **Planning detailed diagnostic prompt**
>
> **Planning detailed diagnostic prompt**
>
> **Defining model status semantics and diagnostics**
>
> **Defining model status semantics and diagnostics**
>
> **Defined model status semantics and planned diagnostic prompts**
>
> 
>
> **Planning detailed diagnostic prompt**
>
> **Planning detailed diagnostic prompt**
>
> **Defining model status semantics and diagnostics**
>
> **Defining model status semantics and diagnostics**
>
> **Planned diagnostic prompt and defined model status semantics**
>
> 
>
> **Planning detailed diagnostic prompt**
>
> **Planning detailed diagnostic prompt**
>
> **Defining model status semantics and diagnostics**
>
> **Defining model status semantics and diagnostics**
>
> **Refining decision and repair action semantics**
>
> **Refining decision and repair action semantics**
>
> **Defined model diagnostics, status semantics, and repair actions**
>
> 
>
> **Planning detailed diagnostic prompt**
>
> **Planning detailed diagnostic prompt**
>
> **Defining model status semantics and diagnostics**
>
> **Defining model status semantics and diagnostics**
>
> **Refining decision and repair action semantics**
>
> **Refining decision and repair action semantics**
>
> **Specifying graph nodes for semantic inspection status**
>
> **Specifying graph nodes for semantic inspection status**
>
> **Defined diagnostic prompt semantics, repair actions, and inspection status nodes**
>
> 
>
> **Planning detailed diagnostic prompt**
>
> **Planning detailed diagnostic prompt**
>
> **Defining model status semantics and diagnostics**
>
> **Defining model status semantics and diagnostics**
>
> **Refining decision and repair action semantics**
>
> **Refining decision and repair action semantics**
>
> **Specifying graph nodes for semantic inspection status**
>
> **Specifying graph nodes for semantic inspection status**
>
> **Refining UI, tests, and prompt for semantic status trace**
>
> **Refining UI, tests, and prompt for semantic status trace**
>
> **Defined semantic diagnostic statuses, decisions, repairs, graph nodes, UI, tests, and prompts**
>
> 
>
> **Designing repair action codes**
>
> **Designing repair action codes**
>
> **Extending model status and telemetry fields**
>
> **Extending model status and telemetry fields**
>
> **Designed repair action codes and extended model status telemetry fields**
>
> 
>
> **Designing repair action codes**
>
> **Designing repair action codes**
>
> **Extending model status and telemetry fields**
>
> **Extending model status and telemetry fields**
>
> **Designed repair action codes and extended model status telemetry fields**
>
> 
>
> **Designing repair action codes**
>
> **Designing repair action codes**
>
> **Extending model status and telemetry fields**
>
> **Extending model status and telemetry fields**
>
> **Fixing live mode availability and graph limitations**
>
> **Fixing live mode availability and graph limitations**
>
> **Designed repair codes, extended telemetry fields, and fixed live mode limitations**
>
> 
>
> Worked for 1m 19s

Use this as the Codex implementation prompt:

**standard: **

Implement a narrowly scoped **M4.2.2 — Semantic Status, Synthesis Precedence, and Decision-Trace Correction** on the `demonstration-ui-flow-implementation` branch.

Read `AGENTS.md` and `IMPLEMENTATION.md` completely before changing anything. Inspect the current M4.2/M4.2.1 implementation and preserve all existing governance boundaries.

Do not modify:

- Frozen M3 benchmark data, labels, splits, evaluation results, or manifests.
- Phase 1 or Phase 2 outputs.
- M4 presentation snapshots or protected experimental artifacts.
- Author-adjudicated migration rules or official evidence spans.
- `not_operational`.
- `expert_validated: false`.
- The paper.
- The accepted M4.2 dossier or its reproducibility digests, except if a newly introduced runtime-only presentation field necessarily changes a newly generated M4.2.2 result digest. Do not rewrite historical artifacts.

## Problem to diagnose first

When `regbridge-m4-2-public-standards.zip` was analyzed, all three documents produced published analysis results and the package summary showed:

- 3 analyzed
- 3 requiring human approval
- 0 failed

However, the per-document model record appeared as `failed` for at least:

- `Synthetic molecular structure`
- `Synthetic lifecycle metadata context`

Both documents received `HUMAN_REGULATORY_REVIEW`, while their graph panels still displayed complete deterministic headings, rules, and evidence.

Before implementing, reproduce or inspect this behavior and record the exact values of:

- `analysis.model_run.status`
- `analysis.model_run.validation_error`
- `DossierLeafResult.model.status`
- `DossierLeafResult.model.failure`
- the semantic-inspection trace step
- `run.failures`
- the server `llm_mode`
- the selected model’s actual adapter and execution mode

Determine whether each observed record represents:

1. a valid structured model abstention;
2. an actual provider/transport failure;
3. an invalid structured output;
4. a configuration-mode inconsistency; or
5. another cause.

Do not assume that the UI label `failed` proves that the provider call failed.

## Confirmed implementation gaps

### 1. Abstention is incorrectly collapsed into failure

The underlying model run supports a valid `abstained` status, but the product execution record currently maps every status other than `completed` and `not_applicable` to `failed`.

Preserve these statuses distinctly:

- `completed`
- `abstained`
- `failed`
- `not_applicable`

A valid structured abstention is a completed provider interaction with no decision-support finding. It is not a provider or pipeline failure.

Update backend models, schemas, OpenAPI, frontend contracts, summaries, and UI rendering accordingly.

### 2. Execution mode must be unambiguous

Ensure model availability, model construction, analyzer behavior, and UI disclosures use one consistent execution-mode source.

Required behavior:

- `live`: GPT-5.5 is available only when the required live configuration is complete, and the Responses adapter is actually used.
- `fixture`: the internal deterministic fixture model is used and must be visibly identified as fixture mode; the interface must not imply that a live GPT-5.5 call occurred.
- `disabled`: a live model-dependent analysis must not silently construct or call the Responses adapter merely because credentials happen to exist.

Display the actual execution mode and adapter in the result. Do not expose credentials, raw provider payloads, or sensitive error text.

### 3. Provider failures must not become regulatory decisions

Maintain the already approved failure policy:

- Retry only retryable transport/provider-API failures, with the existing bounded maximum.
- After retry exhaustion, record a terminal leaf failure.
- Schema, citation, graph, persistence, and other nonretryable contract failures halt that leaf immediately.
- Do not translate an actual execution failure into `HUMAN_REGULATORY_REVIEW`.
- `HUMAN_REGULATORY_REVIEW` represents domain uncertainty or a valid model abstention where semantic completion is an eligibility condition—not infrastructure failure.

A terminally failed leaf must appear in `run.failures`, increment the pipeline-failure count, and must not be published as a successful decision result.

### 4. Hard deterministic Case A conclusions must not be erased by semantic abstention

The approved Case A mapping is a hard, mechanically derived conclusion:

- `3.2.S.1.1` → `3.2.S.1`
- `3.2.S.1.2` → `3.2.S.1`
- `3.2.S.1.3` → `3.2.S.1`

When one of these exact rules fires, a valid model abstention or incomplete semantic inspection must not replace the hard structural decision with a generic human-review decision.

For the M4.2 molecular-structure document, the expected abstention behavior is:

- Decision: `REUSE_WITH_NEW_CONTEXT`
- Repair: preserve the existing mandatory `CREATE_NEW_CONTEXT_GROUP_AND_SUSPEND_LEGACY_CONTENT` action.
- Human approval: required.
- Semantic/document inspection: explicitly marked incomplete or abstained.
- Unresolved uncertainty: preserve the bounded abstention reason.
- Do not describe the document as semantically cleared.
- Do not produce unconditional reuse.

The hard structural action and the incomplete content inspection are two simultaneous facts. Represent both instead of discarding the established action.

A supported semantic risk may qualify the result and require a bounded human content check, but a `semantic_signal` must not erase or reverse the hard structural mapping.

### 5. Preserve conservative Case B and Case C behavior

For exact `manufacturer="all"` under preserve-existing-lifecycle intent:

- A completed clean semantic inspection may permit the controlled `REUSE_AS_LEGACY_REFERENCE` result while retaining the manufacturer advisory.
- A valid semantic abstention means the eligibility gate is incomplete and should produce `HUMAN_REGULATORY_REVIEW`.
- Use a bounded action meaning “complete document inspection”; do not claim that stale content was detected when the model merely abstained.

For Case C:

- A supported stale or applicant-mismatch finding produces `HUMAN_REGULATORY_REVIEW` with the existing bounded verification action.
- A valid model abstention also produces `HUMAN_REGULATORY_REVIEW`, but its action and explanation must say that inspection is incomplete—not that stale content was positively detected.
- A completed clean inspection may permit the appropriate controlled legacy-reuse result when no deterministic guard blocks it.

Add an action such as `COMPLETE_DOCUMENT_INSPECTION` if the existing action vocabulary cannot accurately express an incomplete inspection. Do not reuse `HUMAN_VERIFY_STALE_CONTENT` for an abstention unless stale content was actually found.

## Summary and UI corrections

Separate these counts and concepts in the dossier summary:

- Successfully analyzed results
- Human approval required
- Model abstentions
- Pipeline/leaf failures

Retain `failed_count` for API compatibility if necessary, but label it clearly as `Pipeline failures` in the UI.

For each document, display:

- Model profile
- Actual adapter
- Execution mode
- Status: completed, abstained, failed, or not applicable
- Bounded abstention reason or redacted failure category
- Attempt count
- Whether the final result used a deterministic hard rule, semantic finding, or abstention gate

A user must be able to understand why “model abstained” can coexist with “analysis completed.”

## Graph and explanation correction

The existing graph can display deterministic regulatory evidence even when semantic inspection is incomplete. That evidence is valid, but the current graph does not display the uncertainty that caused or qualified the final decision.

Extend the typed graph contract with an explicit non-regulatory analysis-status representation. Use a node such as:

- `ANALYSIS_LIMITATION` or `INSPECTION_STATUS`

It must be clearly distinct from:

- regulatory evidence;
- dossier evidence;
- a model finding; and
- an author-adjudicated rule.

For an abstention, the node should contain bounded properties such as:

- component: semantic inspection
- status: abstained
- reason category
- prompt version/request digest where safe

Connect it to the synthesized decision using semantically accurate edges:

- If abstention causes `HUMAN_REGULATORY_REVIEW`, it may `TRIGGER` or `LEAVE_UNRESOLVED` the decision.
- If a hard Case A decision remains in force, the limitation must `QUALIFY` the decision rather than appear to trigger or override it.

Do not create a `MODEL_FINDING` when the model abstained. Abstention is not a substantive finding and must not cite dossier evidence as though it discovered a risk.

Also make the displayed graph an execution-relevant explanation path. For a document under `3.2.S.1.2`, do not display unrelated `3.2.S.1.1` and `3.2.S.1.3` mapping nodes as though they participated in that document’s conclusion. Either:

- include only the active source heading, target heading, triggered rule, cited evidence, decision, repair, and limitation; or
- clearly separate inactive registry context from the active decision path.

The preferred implementation is the minimal active path.

After this correction, the title `Why this conclusion is connected` must be literally true: the graph must include every material reason that determined or qualified the final result.

## Required tests

Add deterministic unit, integration, schema, frontend, and E2E tests covering at least:

### Status tests

- Completed model output remains `completed`.
- Valid structured abstention remains `abstained`.
- `not_applicable` remains distinct.
- Invalid output becomes a terminal leaf failure, not human review.
- Retryable transport failure retries only to the approved limit and then becomes a terminal leaf failure.
- No provider or pipeline failure is converted into a regulatory decision.

### Case A tests

For an exact removed-heading mapping:

- Completed clean inspection → `REUSE_WITH_NEW_CONTEXT`.
- Valid model abstention → still `REUSE_WITH_NEW_CONTEXT`, mandatory structural repair retained, human approval required, inspection marked incomplete.
- Graph contains the active heading mapping and limitation.
- A `3.2.S.1.2` result does not include inactive `.1.1` or `.1.3` mappings in its active explanation path.

### Case B tests

For exact `manufacturer="all"` with preserve intent:

- Completed clean inspection → controlled `REUSE_AS_LEGACY_REFERENCE` with advisory retained.
- Valid abstention → `HUMAN_REGULATORY_REVIEW` plus `COMPLETE_DOCUMENT_INSPECTION`.
- The result must not claim that stale content was detected.
- Metadata occurrence, normalized keyword, rule, evidence, limitation, and decision paths validate under the graph contract.

### Case C tests

- Supported applicant mismatch → `HUMAN_REGULATORY_REVIEW` with the supported semantic finding and cited occurrence.
- Valid abstention → `HUMAN_REGULATORY_REVIEW` plus incomplete-inspection action, with no fabricated finding.
- Completed clean inspection → appropriate controlled reuse when no deterministic guard blocks it.

### Summary/UI tests

For a run containing one completed result, one abstention-derived result, and one terminal failure, assert exact counts for:

- analyzed results;
- human approval;
- model abstentions;
- pipeline failures.

Verify that the UI does not display an abstention as a failed model call.

Run accessibility checks at the existing 1280×720 and 1440×900 viewports.

## Verification and deliverables

Create:

- `docs/milestones/M4.2.2.md`
- a redacted machine-readable diagnostic/adjudication record under `data/product/m4-2-2/`
- a protected-artifact pre/post digest manifest
- a dedicated M4.2.2 verification command
- updated `AGENTS.md` and `IMPLEMENTATION.md` language where necessary
- updated OpenAPI/schema snapshots and frontend contracts
- tests proving the behaviors above

Run the new verifier and the complete existing M4.2 verifier twice.

Verify that:

- the accepted M4.2 package still parses;
- its clean fixture-mode path still produces the intended three archetype outcomes;
- the model-abstention path produces the corrected outcomes;
- all protected historical artifacts retain identical hashes;
- FDA availability remains `not_operational`;
- all regulatory rules remain `expert_validated: false`;
- no benchmark result or paper claim changes.

Do not require a paid live-model call for automated acceptance. Use deterministic scripted model doubles for status and failure-path tests. If an already authorized live smoke test is performed, apply a strict bounded call/token budget and report it separately from experimental results.

At completion, report:

1. the diagnosed cause of the observed screen;
2. whether the calls truly failed or validly abstained;
3. exact before/after behavior for all three M4.2 documents;
4. schema and graph-contract changes;
5. tests and commands executed;
6. protected-artifact hashes;
7. remaining limitations;
8. any effect on the paper—expected to be none unless a substantive scientific assumption changes.

## Prompt:
9/5/2026, 3:26:01 PM

![08e1153e-4752-4756-953c-9d23e5ce50bc.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000371881f59b29882df1df41b8&fn=08e1153e-4752-4756-953c-9d23e5ce50bc.png&cd=attachment&ts=496913&p=fs&cid=1&sig=b1d5da3fdb60567b347128c093f4057146815c354b2f16017f7ab90ca12be28f&v=0)

![211f7554-045f-4ae7-a9d5-47615eb2fe6c.png](https://chatgpt.com/backend-api/estuary/content?id=file_0000000041c881f5b70e28f87824123a&fn=211f7554-045f-4ae7-a9d5-47615eb2fe6c.png&cd=attachment&ts=496913&p=fs&cid=1&sig=8d4f3c29a3afb5a3317710b55b37b2336f4c6afa20ab3e3494f8dd3c51da4ee1&v=0)

![4cf3e88c-63d7-4503-991f-6fa537a388b8.png](https://chatgpt.com/backend-api/estuary/content?id=file_00000000a44881f5b98a8aee42675afe&fn=4cf3e88c-63d7-4503-991f-6fa537a388b8.png&cd=attachment&ts=496913&p=fs&cid=1&sig=adaccadeae0305dd329abd8817ecff5007e72335a62fda6974fc8bae4d84631b&v=0)

Codex worked on it and I committed it to GitHub, and tested it. The attached pictures are the resulsts of the analysis. Codex's output: "Implemented M4.2.2 on `demonstration-ui-flow-implementation`. The final verification state is green.

## Diagnosis

The observed records were valid structured abstentions, not provider or transport failures:

- `analysis.model_run.status`: `abstained`
- `analysis.model_run.validation_error`: `null`
- old `DossierLeafResult.model.status`: incorrectly mapped to `failed`
- old `DossierLeafResult.model.failure`: `null`
- semantic trace: `Semantic inspection abstained; 0 validated findings.`
- `run.failures`: `[]`
- server mode: `live`
- selected model: `gpt-5.5`
- actual configured adapter: Responses
- execution mode: live

The product projection previously converted every status except `completed` and `not_applicable` to `failed`. It also allowed abstention to erase Case A’s hard structural conclusion and incorrectly used `HUMAN_VERIFY_STALE_CONTENT` when no stale-content finding existed.

No live call was made during this adjudication, and historical raw provider payloads were not retained. However, the Responses adapter emits `abstained` only after a completed provider response passes structured-output validation. Provider, transport, and invalid-output conditions raise terminal errors instead.

The complete redacted diagnosis is in [diagnostic-adjudication.json (line 24)]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2-2/diagnostic-adjudication.json:24).

## Corrected behavior

| DocumentClean fixture inspectionValid abstention |                                                                                                   |                                                                                                                    |
| ------------------------------------------------ | ------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------ |
| Synthetic molecular structure                    | `REUSE_WITH_NEW_CONTEXT`; structural repair retained                                              | Still `REUSE_WITH_NEW_CONTEXT`; structural repair retained; human approval required; limitation qualifies decision |
| Synthetic lifecycle metadata context             | Controlled `REUSE_AS_LEGACY_REFERENCE`; manufacturer advisory retained                            | `HUMAN_REGULATORY_REVIEW` + `COMPLETE_DOCUMENT_INSPECTION`; no stale-content claim                                 |
| Synthetic applicant responsibility statement     | `HUMAN_REGULATORY_REVIEW` + existing verification action because fixture finds applicant mismatch | `HUMAN_REGULATORY_REVIEW` + `COMPLETE_DOCUMENT_INSPECTION`; no fabricated model finding                            |

Provider/pipeline failures now terminate the leaf, appear in `run.failures`, increment pipeline failures, and publish no regulatory decision.

## Contract changes

- Preserved `completed`, `abstained`, `failed`, and `not_applicable` distinctly.
- Added actual adapter and execution mode to profiles and execution records.
- `live`, `fixture`, and `disabled` now use one consistent construction source.
- Added separate summary counts for successfully analyzed results, human approval, model abstentions, and pipeline failures.
- Retained `failed_count` as the pipeline-failure compatibility alias.
- Added runtime-only `COMPLETE_DOCUMENT_INSPECTION` without changing the frozen M3 action vocabulary.
- Added product graph contract v3:
  - `ANALYSIS_LIMITATION`
  - `QUALIFIES_DECISION`
  - `LEAVES_UNRESOLVED`
- Abstentions create no `MODEL_FINDING`.
- Case A graphs contain only the active heading mapping.

See [M4.2.2.md (line 42)]\(C:/Users/david/OneDrive/Documents/regbridge/docs/milestones/M4.2.2.md:42).

## Verification

Final results:

- Backend: 239 passed.
- Ruff: passed.
- Mypy: 102 source files, no issues.
- Schema/OpenAPI drift check: passed.
- Frontend: 13 passed across 7 files.
- Frontend lint/typecheck/build: passed.
- E2E/accessibility: 4 passed at 1280×720 and 1440×900.
- Dedicated `scripts/m4-2-2-verify.ps1`: passed.
- Complete `scripts/m4-2-verify.ps1`: passed twice.
- No final failures or skipped checks.

Two-run digests:

- Clean fixture result: `20cca46988cd5edeaee4c0fed0b115839c03c75582d9db921361df969da71e0a`
- Abstention result: `551b2bf5d108a5644f4ab67eb99308e43a2b1972be65816944e3576c15c582d4`
- M4.2 runtime result: `734520f0afe27f7180b65ac2d6954e20e19d88b05ea9640afdd014d39a89c88e`
- Inventory: `91cee37243b2612f20f48b487744a86c1a2905075f6f8615eb520990e98c93b1`
- Accepted package: `4d236d51694b1c15d37ad92b9d0074b97a15075cde86cb96c393b9f87ce3e6e4`

Transient E2E failures occurred because Playwright initially reused stale localhost servers and because two new selectors were overly broad. Fresh fixture-mode servers and corrected selectors resolved them. A frontend expectation was also updated after the final summary wording was made explicit.

## Protected artifacts

Every recorded pre/post digest matched. Notable protected hashes include:

- M3 benchmark: `9590c82dcc5106fa6217212760a8f3f40caf4f75e1dbf4096906776214152718`
- Evaluation data: `817a04846cda6f912235a2460965b749ce974fdb6e6a70c2ff9cf32d5360ca79`
- Live results: `b6e845894e5f0b220a5fc64468c6ec7bd78ea8c425604a132f6d763dfcca1d92`
- Validation results: `7cf1c2f7e0c474b88e61e0ceae304ae8ab0e73ffcd2a17004adc76de9a929a2d`
- M4 presentation data: `f3fdced35c50617658fbbddc5036e6ebb878907d3e07aacf37a8479e52c2a065`
- M4 figures: `09a053bb3c73a6b46ace47467dc27aa2db4e714f7bb0aa33325248f421c16cd7`
- Paper tables: `5ced3f8cba468232ab645c41b1a2e2e791dc8c285eac6e30bde6b142adf0e417`
- Rules: `0fb935b70eb9624befe87f766dcf0f4c1357c47bed32f39efa8160dddac17ae9`
- Standards: `b4c9709614eb21633ab7a59ce988a1b823a94a7a3978ef21c4705ebb2f6d21d4`

The new protected manifest is [protected-artifacts.json]\(C:/Users/david/OneDrive/Documents/regbridge/data/product/m4-2-2/protected-artifacts.json) with SHA-256 `619cb2dfd7750b16bb4e27ff7f5ad9b22d6c996a7a4562a75f76cf7e8a419bda`.

`not_operational` and `expert_validated: false` remain unchanged.

## Exact files changed

34 files:

- Documentation/build: `AGENTS.md`, `IMPLEMENTATION.md`, `Makefile`, `docs/milestones/M4.2.2.md`, `scripts/m4-2-2-verify.ps1`
- Backend: `backend/app/analyzer/repairs.py`, `backend/app/analyzer/service.py`, `backend/app/baselines/runner.py`, `backend/app/domain/enums.py`, `backend/app/domain/models.py`, `backend/app/domain/vocabulary.py`, `backend/app/evaluation/phase1_b2.py`, `backend/app/graph/builder.py`, `backend/app/graph/models.py`, `backend/app/product/comparison.py`, `backend/app/product/models.py`, `backend/app/product/models_registry.py`, `backend/app/product/services.py`, `backend/app/product/verify_m422.py`
- Backend tests: `backend/tests/integration/test_m4_2_2_semantic_status.py`, `backend/tests/unit/test_m1_analysis.py`
- Frontend: `frontend/e2e/m4.spec.ts`, `frontend/src/api/contracts.ts`, `frontend/src/components/GraphNeighborhood.tsx`, `frontend/src/pages/DossierWorkspace.tsx`, `frontend/src/test/M41Workspace.test.tsx`, `frontend/src/test/M422Workspace.test.tsx`
- Schemas: `schemas/analysis-response.schema.json`, `schemas/analysis-result.schema.json`, `schemas/graph-neighborhood.schema.json`, `schemas/graph-response.schema.json`, `schemas/openapi.json`
- Records: `data/product/m4-2-2/diagnostic-adjudication.json`, `data/product/m4-2-2/protected-artifacts.json`

## Remaining limitations and paper impact

No live paid smoke test was performed. Semantic inspection remains bounded by extracted document evidence and is not complete FDA validation or submission-readiness assessment. The separately generated M4.2.1 acceptance package remains rejected for its previously recorded pinned-DTD namespace errors.

The paper was not modified. No scientific assumption, benchmark result, numerical claim, or migration policy changed, so expected paper impact is none."

## Response:
9/5/2026, 3:26:04 PM

I’m checking the three screenshots against the exact M4.2.2 behavior we intended—especially whether abstention is now separated from failure and whether each archetype applies the right precedence. I’m using the continuity workflow because this is a verification of the policy boundary we just established, not a fresh design decision.

> **Inspecting model abstention reasoning**
>
> **Inspecting model abstention reasoning**
>
> **Evaluating semantic risk handling and terminology**
>
> **Evaluating semantic risk handling and terminology**
>
> **Evaluated model abstention reasoning and semantic risk terminology**
>
> 
>
> **Inspecting model abstention reasoning**
>
> **Inspecting model abstention reasoning**
>
> **Evaluating semantic risk handling and terminology**
>
> **Evaluating semantic risk handling and terminology**
>
> **Evaluated abstention reasoning and semantic risk terminology**
>
> 
>
> **Explaining table rules and confirming correctness**
>
> **Explaining table rules and confirming correctness**
>
> **Refining case rationales and preparing closure**
>
> **Refining case rationales and preparing closure**
>
> **Explained table rules, refined rationales, and prepared closure**
>
> 
>
> **Explaining table rules and confirming correctness**
>
> **Explaining table rules and confirming correctness**
>
> **Refining case rationales and preparing closure**
>
> **Refining case rationales and preparing closure**
>
> **Explained table rules, refined rationales, and prepared closure**
>
> 
>
> Worked for 43s

This now behaves correctly, and the three results form a surprisingly strong demonstration story.

| Document | Model behavior | RegBridge behavior | Why |
|---|---|---|---|
| Molecular structure | Valid abstention | `REUSE_WITH_NEW_CONTEXT` | The hard structural mapping remains valid independently of semantic inspection. Abstention qualifies the result but cannot erase it. |
| Lifecycle metadata | Valid abstention | `HUMAN_REGULATORY_REVIEW` | Legacy reuse depends on completing the semantic eligibility check, so RegBridge refuses unconditional reuse. |
| Applicant statement | Completed finding | `HUMAN_REGULATORY_REVIEW` | GPT-5.5 found and cited an applicant-name mismatch requiring verification. |

The most important distinction is now clear:

> The provider completed all three calls. Two calls returned valid abstentions; none were execution failures.

That explains why the package can show zero pipeline failures while two model records say `abstained`.

### Why Case A is correct

The heading mapping is deterministic and author-adjudicated:

```text
3.2.S.1.2 → 3.2.S.1
```

GPT-5.5’s abstention concerns semantic document inspection, not whether the heading changed. RegBridge therefore preserves:

- `REUSE_WITH_NEW_CONTEXT`
- Blocking severity
- New context-group creation
- Suspension of the legacy context
- Human approval
- An explicit warning that semantic clearance was not obtained

This is exactly the proper relationship between hard rules and model uncertainty.

### Why Case B is different

For `manufacturer="all"`, the evidence shows:

- The general manufacturer value is discouraged, not prohibited.
- Exact keywords can be retained when preserving lifecycle.
- Eligibility still depends on completing the bounded content/context inspection.

Because the model abstained, RegBridge cannot safely complete the last condition. Therefore:

```text
HUMAN_REGULATORY_REVIEW
→ COMPLETE_DOCUMENT_INSPECTION
```

is correct. Importantly, it no longer falsely claims that stale content was detected.

### Why Case C is correct

GPT-5.5 produced a substantive, occurrence-cited finding:

```text
Legacy Applicant Corporation
≠
RegBridge Synthetic Therapeutics LLC
```

That is a supported semantic risk—not an abstention—so human review and `HUMAN_VERIFY_STALE_CONTENT` are appropriate.

## Research significance

This live example communicates RegBridge’s architectural contribution better than three uniformly successful calls would:

1. A model abstention does not erase a hard deterministic conclusion.
2. The same abstention blocks reuse when semantic completion is an eligibility condition.
3. A supported semantic finding produces a traceable escalation.

That is deterministic, context-sensitive synthesis over nondeterministic model behavior.

M4.2.2 can be closed. The only optional UI polish I see is making the Case C headline more specific:

> A supported responsible-applicant mismatch requires human review.

The current generic “stale or ambiguous evidence” wording is correct but less compelling than the actual finding beneath it.

The benchmark numbers should remain unchanged. If the paper does not already express this behavior, one system-design sentence would be worthwhile:

> RegBridge represents structured model abstention as an auditable state rather than an execution failure: hard structural rules remain operative, while decisions whose eligibility depends on semantic inspection are escalated for human review.



---
Powered by [ChatGPT Exporter](https://www.chatgptexporter.com)